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ABSTRACT OF DISSERTATION 
 
THE ROLE OF INNATE IMMUNITY AND ANGIOGENESIS IN OSTEOSARCOMA 
GROWTH AND METASTASIS 
 
 Osteosarcoma is the most common primary bone tumor in dogs and humans.  
Novel therapeutics are required since a number of patients will succumb to metastatic 
disease.  Currently, it is known that a neoplastic mass contains more than transformed 
cells, but requires the presence of immune cells to create a supportive environment, and 
endothelial cells to form blood vessels to deliver oxygen and nutrients.  Not only do these 
cells play a role in primary tumor growth, but they create an atmosphere conducive to 
invasion and metastasis, the primary cause of death for osteosarcoma patients.  Therefore, 
better understanding of how immune and endothelial cells support metastatic growth is 
crucial for better understanding osteosarcoama. 
 Utilizing murine tumor models, we have been able to explore the observation that 
patients with post-surgical infections have increased time to metastasis and increased 
survival.  We have determined that this effect is mediated by NK cells and monocytes, 
which inhibit tumor growth through restriction of angiogenesis.  We have also 
investigated the role of an anti-inflammatory therapeutic, tepoxalin, which leads to tumor 
growth inhibition.  These observations explain the paradox of inflammation, where the 
type and timing of inflammation may inhibit or promote an anti-tumor effect. 
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 Due to the importance of angiogenesis and metastasis in osteosarcoma, we sought 
to develop new models and techniques to assess these processes.  Fine needle aspiration 
coupled with flow cytometry accurately measures angiogenesis in cutaneous tumors, 
thereby allowing for repeated assessment of angiogenesis in a minimally invasive 
manner.  We have also developed a novel post-surgical model of luciferase transfected 
murine osteosarcoma that grows orthotopically and spontaneously metastasizes, allowing 
us to non-invasively investigate the development of metastases.  These tools will allow 
for investigation into novel anti-angiogenic and anti-metastatic compounds. 
 Novel prognostic markers are required to better determine the outcome of cancer 
patients.  We have determined that monocyte and lymphocyte counts from a pre-
treatment complete blood count are prognostic for disease free interval in dogs with 
osteosarcoma.  These data describe the interactions between immune infiltrate and 
metastasis.  The combination of the studies presented herein provides evidence for the 
interactions between the immune system and angiogenesis in the process of metastasis.   
 
Joseph L. Sottnik 
Graduate Degree Program in Cell and Molecular Biology 
Colorado State University 
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 Osteosarcoma (OSA) is the most common primary bone tumor in humans and 
dogs [1, 2].  OSA affects approximately 1,000 human patients and approximately 8,000 
canine patients every year [2-4].  Tumor metastasis is the most common cause of death 
from OSA [5-8].  OSA typically metastasizes to the lung, brain, and other bone sites [2, 
5-8].  There is no specific etiology of disease, although theories range from ionizing 
radiation to mutations in the p53 and Rb genes [9-12].  There are numerous subtypes of 
OSA, such as osteoblastic, chondroblastic, and fibroblastic, which characterize the 
predominant matrix and cells present within the tumor [13].  The 5-year survival in 
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humans is approximately 60% with surgery and adjuvant chemotherapy [14].  However, 
in the dog, long term survival is only 20% with comparable treatment [5]. 
The primary modalities of treatment for OSA are surgery and chemotherapy.  
Radiation therapy, by external beam radiation, is sometimes used for the treatment of 
OSA in conjunction with surgery; however, the efficacy of this combination is still 
controversial across species [15-19].  Surgery is required to remove the primary tumor 
and to attempt to inhibit dissemination of disease and decrease pain.   
 The first method developed for treatment of appendicular disease was 
amputation.  It was later described that a limb-sparing surgery, which involves removal 
of the tumor-bearing bone and replacement using a cortical allograft, could be used to 
successfully remove the primary tumor and allow the patient to retain function of the 
limb [20].  Techniques such as rotationplasty (eg. Van Nes Rotation) have also been 
developed to allow patients to retain limb function and remove the primary tumor [21].  
However, 10-20% of patients presenting with OSA have clinical metastases at diagnosis, 
with a much greater number of animals having occult micro-metastatic disease [7, 8].  
Therefore, systemic chemotherapy is required to treat this disease.  The standard of care 
for OSA is currently amputation of the tumor bearing limb and adjuvant chemotherapy, 
typically consisting of doxorubicin and carboplatin in dogs.  In humans, the standard of 
care is typically removal of the primary tumor and chemotherapy with cisplatin, 
methotrexate, and doxorubicin [22].  The introduction of liposomal muramyl tripeptide 
phosphatidyl ethanolamine (L-MTP-PE; discussed below) as an immunotherapeutic has 




Canine OSA as a Translational Model of Human OSA 
 The dog is a superlative model for human OSA due to numerous similarities in 
the diseases [2].  The recent elucidation of the canine genome and the subsequent 
realization of the greater degree of homology to that of the human genome than that of 
the mouse has also fostered interest in the use of the canine model [2, 31-33].  Indeed, 
dogs share a common environment with humans and have a relatively long period of 
disease progression when compared to rodent models [2, 13].  Furthermore, the biology 
of canine OSA is similar to that of humans in that it metastasizes to similar organs, 
spontaneously occurs, and has similar pathology to the human condition [2, 4, 5, 34].  
The large number of canine patients that develop spontaneous disease is also beneficial 
because it allows for large numbers of animals to be studied in a relatively short period of 
time.  Due to these factors, a number of individuals and consortia, specifically the 
Comparative Oncology Trials Consortium (COTC) have pooled their resources to 
determine methods to better integrate canine cancer patients into human clinical trials and 
drug development [2]. 
 It has been suggested that canine cancer patients can be used to help translate pre-
clinical research.  Normal beagle dog studies are already a staple of the drug development 
process, but further integration of pet dogs with spontaneous disease into the drug 
development pipeline could help bolster these studies [2].  This work has been 
exemplified in the process of moving L-MTP-PE from dogs into humans, and shows the 
interplay of how the dog may be integrated into human clinical trials [23-30, 35].  
Therefore, it is plausible that dogs with spontaneous disease may be integrated to better 
define pharmacokinetic and pharmacodynamic endpoints before movement of novel 
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therapeutics into the human setting.  It is also believed that modulation of shared cancer 
biomarkers between species may be used to better understand the mechanisms of disease 
and efficacy of these novel compounds [2, 5].  Lastly, the ability to study the efficacy of 
novel compounds in a condensed time frame allows for decreased screening time, and 
thus less time to approve compounds for human use as long as due diligence is performed 
in human testing.  Therefore, integration of the dog model is a welcome and efficacious 
step juxtaposing rodent/laboratory pre-clinical models and human clinical trials. 
 
Orthotopic Cancer Models in Mice 
 There have been numerous murine tumor models developed for the study of OSA 
[36-47].  The use of syngeneic and immunocompetent mouse tumor models bridges 
numerous mouse strains, thereby yielding flexibility to investigators interested in testing 
hypotheses involving genetically modified mice.  For example, the DLM8 (C3H) and 
K7M2 (BALB/c) models are the most widely used [43, 48, 49].  Interestingly, there does 
not appear to be a model of murine OSA that grows in C57BL/6 mice, although 
descriptions of spontaneous tumors in this strain exist [50, 51].  Furthermore, there have 
been a number of human and canine xenograft models that have been created to allow for 
the study of OSA as it pertains directly to these species, allowing for the investigation of 
novel therapeutics when the endpoints are specific to the xenogeneic tumor cells [36, 38, 
40, 41, 45, 47].  Human examples include the SAOS-2 and KRIB cell lines, whereas 
Abrams is a canine OSA cell line often used. 
 Murine OSA models can further be described by those that are implanted 
orthotopically, in the bone, the tissue of origin [36, 38, 40, 42, 43, 45-47].  Orthotopic 
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tumors are superior to tumor models grown in subcutaneous tissues because they preserve 
the natural environment in which tumors arise, and better recapitulate the progression of 
disease [52-54].  For example, it has previously been described that tumors implanted 
orthotopically and heterotopically grow and metastasize differently, and it is plausible 
that changes in the tissue micro-environment account for this difference [42, 44, 55-57].  
Furthermore, syngeneic tumor models are superior to models utilizing nude mice in that 
they retain a more natural interaction between the tumor cells and host [49, 58].  
Recently, a transgenic model of spontaneous murine OSA has been created through 
engineered mutations of the p53 and Rb genes in a conditional knock-out [59, 60].  
Syngeneic tumor models allow for natural interactions in cytokines released from the 
tumor and host animal to interact. However, the interaction of human tumor cells and 
murine stromal cells not interact properly unless they are highly conserved, thereby 
altering tumor growth.  Furthermore, these data would suggest that spontaneous tumors 
developing in dogs, and syngenic tumor models in mice, are the most valuable models [1, 
49, 56, 58].  Therefore, novel mouse models that are being defined, which better mimic 
the clinical subtext of cancer patients, are important in helping to understand the basis of 












 The term metastasis is used to describe a process as much as it describes the 
presence of disseminated disease.  Delay or prevention of metastatic disease is used as a 
measure of therapeutic success, and metastasis is typically the reason patients succumb to 
cancer as a disease.  The need to better understand the metastatic cascade and the 
inhibition of this process is thought to be one of the requirements in cancer therapy.  This 
is of considerable importance in OSA because it is believed that while only 10-20% of 
patients have clinically detectable metastatic disease at the time of diagnosis, the number 
of patients with occult micrometastatic disease that is not evident at the time of diagnosis 
is considerably higher [7, 8].  Strikingly, 30-40% of human patients with OSA will die 
from these metastases despite best available care [6-8].  Therefore, it is of great 
importance to understand the process of metastasis in order to more effectively develop 
interventions to inhibit metastatic disease and increase survival for patients with OSA and 
other types of cancer. 
 
Metastatic Initiation 
 Tumor cells metastasize as they grow and invade, and acquire mechanisms by 
which to invade surrounding tissues.  This process is of such importance that it is 
considered a ‘hallmark of cancer’ [61].  Tumor cells and their supportive stromal 
components release a number of matrix metalloproteinases (MMP) in order to break 
down the extracellular matrix and allow tumors to invade into this environment [62].  
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This process, coupled with the increased motility of the malignant cells, provides one of 
the first steps in the metastatic cascade allowing tumor cells to begin to metastasize.  
Considerable research has been performed to help describe those tumors that are likely to 
metastasize, as well as the factors responsible for this phenotype.  Ezrin, a cytoskeletal 
linker protein, is one of the primary players in OSA metastasis [42, 63, 64].  Ezrin is 
involved in the reorganization of the cytoskeleton and cell adhesion molecules allowing 
cells to become more invasive and potentiating metastasis [63, 65].  Exacerbated tumor 
growth and metastasis require angiogenesis, blood vessel growth.  The presence of blood 
vessels and lymphatics in a tumor provides a mechanism to deliver oxygen and nutrients 
and transport waste away from a tumor, but they also allow for tumor cells to move into 
these vessels and disseminate systemically [57, 66].  Tumor invasion and migration into 
vasculature are required for the dissemination of malignant tumors, and are perceived as 
the early steps leading to systemic metastases. 
  
Routes of Metastasis 
 The two primary routes of metastasis are lymphatic and hematogenous.  
Lymphatic metastasis occurs when tumor cells extravasate from the tumor environment, 
enter lymphatic vessels, and migrate to a draining lymph node [67, 68].  Lymphatic 
vessels are an important part of tumor growth as they are a constituent of normal tissues, 
thereby allowing some tumors to colonize draining lymph nodes during the metastatic 
process.  A primary example of this process is breast cancer, in which a finding of tumor 
cells in draining lymph nodes is a known negative prognostic factor [68-70].  The 
metastasis to lymph nodes is of such importance in breast cancer that a number of these 
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nodes are removed as a precautionary measure when a mastectomy is performed to 
remove possible micrometastatic disease which may be present in these tissues.  Lymph 
node metastasis also opens the possibility of systemic dissemination of disease due to 
drainage of lymphatics into venous circulation allowing for systemic circulation of tumor 
cells in the blood.  However, the route of metastasis from a given tumor is described by 
the method the tumors cells exit from the primary tumor, and not the route in which they 
enter distant tissues [71].  
 The other primary route of metastasis is hematogenous metastasis since tumor 
cells are able to directly enter the systemic circulation of blood vessels.  One of the 
primary examples of hematogenous metastasis has been well described by in vivo mouse 
models of pancreatic cancer.  Dr. Isiah Fidler has described this process through the 
implantation of orthotopic models in which tumor cells are injected into the pancreas or 
colon and subsequently, and spontaneously, metastasize to the liver [72-75].  The tumor 
cells are established as a primary tumor in the pancreas before undergoing the metastatic 
process and reaching the liver, where they form new metastatic nodules.   
 The hematogenous route of metastasis can also be studied by challenging mice 
with tumor cells by intravenous injection, leading to seeding of cells in the lung and 
disease formation [76].  However, these models do not replicate the entire metastatic 
process as previously described, for they do not account for intravasation to the 
vasculature and escape from the primary tumor environment.  These models typically use 
a large number of tumor cells, and do not form metastases by extravasation from the 
vasculature, but may create focal disease by embolizing in the vessel, and growing, 
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before invading into the lung parenchyma.  However, these models are useful in that they 
allow for the study of tumor formation in a site of typical of metastasis, such as the lung. 
 
Metastatic Clonality 
 There have been a number of questions concerning the clonality of individual 
metastases and their relationship to the primary tumor.  Since changes in the tumor 
microenvironment can greatly alter the expression of genes within tumor and stromal 
cells, these questions have increased in complexity [42, 52-54].  It was previously 
believed that a single cell could circulate systemically before coming to rest in a distant 
tissue, and then create metastatic foci [77].  However, the primary tumor itself is 
composed of a mosaic of tumor cells, with each of these subpopulations having a varied 
gene expression all its own [78].  This may explain in part some of the variability in the 
genetic makeup of metastases [78-80].  Furthermore, this process is likely beneficial to 
the tumor, in that it provides numerous mechanisms by which to disseminate and sustain 
growth of positively selected cells [78, 80].  This evolutionary selection process for 
clones which are able to intravasate into the circulation, extravasate, and survive in a 
distant tissue, may be one of the reasons metastases are more aggressive than their 
primary tumor counterparts.  Indeed, it is likely that selection of those cells that can 
survive and grow in hostile foreign environments propagates the aggressiveness of 
tumors.  Metastatic cells have already been selected for to evade immune recognition and 
organize a variety of cellular players to promote their own survival [78, 81].  However, it 
has been argued that metastatic clones are able to adapt to their environment [80].  Thus, 
it is thought that a clonal population of cells is released from the primary tumor, and 
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those that can adapt to their new environments develop into metastases while those that 
cannot are selected against.  The underlying argument is that the cells best able to adapt 
to their environment may have been selected for by the process of metastasis [82].  
Therefore, it is a difficult question to discern the establishment and mechanisms 
associated with the clonality of metastasis, even though it is an integral question to 
metastasis biology. 
 
Pre-Metastatic Niche and Metastatic Development 
 The pre-metastatic niche is a term developed to describe a location in a distant 
tissue that is susceptible to metastatic development, and may be required to precede the 
seeding of tumor cells in this environment.  The seed-and-soil hypothesis was first 
postulated by Paget in 1889 to describe the site (the soil) for proper growth of the tumor 
cells (the seed) [83].  There are numerous explanations and arguments for and against this 
hypothesis, and this subject is still extensively argued [57, 78, 84-86].  However, the cells 
that make-up this pre-metastatic niche are thought to derive from the bone marrow, and 
act in locations of previous damage that tumor cells may exploit in order to grow in 
distant tissues [57, 84-86].  For example, Harold Dvorak has previously described tumors 
as “wounds that will not heal” [87].  The location of a microscopic injury that is being 
repaired by leukocytes may create an immunosuppressed and pro-angiogenic 
environment which may benefit the implantation and early growth of metastatic clones.  
The presence of inflammatory cells in the pre-metastatic niche assists with the 
aggregation of tumor cells into a large and developed primary tumor, thus enabling 
promotion of tumor seeding and growth [88]. 
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 It is believed that a subset of hematopoietic stem cells (HSC) that are bone 
marrow derived play a role in this process by homing to areas of repair and regeneration 
to create a supportive environment for tissue repair [84].  Tumor cells exploit these 
niches, which provide protection from the foreign tissue environment [84].  It will be 
discussed later how leukocytes play a large part in tumor formation and growth, and it is 
plausible that HSC play a similar role in preparing an environment for tumor generation 
in distant tissues.  The expression of cytokines such as VEGF, bFGF, and Angiopoietin-1 
play a role in aiding tumor growth, and thus likely play a role in enabling metastasis [57].  
The cytokines expressed in the pre-metastatic niche may even allow for homing or 
direction of tumor cells to these sites as cells in these locations express these cytokines to 
elicit their repair/regenerative functions.  Once in these locations, tumor cells are nurtured 
by these cells, and allowed to grow in a less hostile environment than the rest of the 
tissue.  Since tumor cells may have been selected in the primary tissue, this step is 
important because it provides a barrier against more hostile surrounding environments, 
and allows the primordial metastasis to develop, until it is of reasonable size to promote 
its own growth and conduct changes in the tumor microenvironment [78, 80].  Once these 
changes occur, a metastasis develops, and this new tumor can plausibly spur its own 
metastases.  Furthermore, the selection and adaptation to a new environment may make 
for more aggressive progeny since numerous anti-tumor obstacles were overcome in the 









 Hypoxia inducible factor-1α (HIF-1α) is a transcription factor and is one of the 
primary means by which cells respond to hypoxia, or a decrease in tissue pO2.  HIF-1α is 
continually expressed and rapidly turned over in cells, making it a prime regulator of 
rapidly changing oxygen conditions.  In the presence of oxygen, HIF-1α is ubiqutinated 
by the Von-Hippel Lindau (VHL) tumor suppressor protein, which leads to the 
degradation of HIF-1α and its inability to act as a transcription factor [89].  In the 
presence of oxygen, VHL is hydroxylated leading to formation of the active binding site, 
thereby allowing for ubiquitination of HIF-1α [90].  Under hypoxic conditions, this 
hydroxylation does not occur, and thus the ubiquitin ligase function of VHL is not 
present [89, 90].  Stabilization of HIF-1α allows it to translocate to the nucleus and bind 
to hypoxia response elements (HRE) leading to the activation and production of 
numerous hypoxia-related genes [91-99].  It has been shown that HIF-1α is at least 
partially responsible for activating genes such as mTOR, VEGF, c-myc, and p53 which 
lead to a phenotype conducive to living in the hypoxic environment [96-99].  Therefore, 
HIF-1α is an important mediator in the regulation of cellular metabolism and signaling, 
and plays a crucial role in how cells interact with their environment. 
 
Hypoxic Adaptation of Tumor Cells 
 Hypoxia is an important process in tumor growth because it acts to alter the 
cellular metabolism of tumor and stromal cells [100].  Tumor cells require nutrients and 
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oxygen to survive like any other cell in the body.  In fact, tumors are not able to grow 
more than a few millimeters in size without a sufficient blood supply [101, 102].  
Without the delivery of oxygen to these cells, they institute a number of molecular and 
cellular changes in order to survive.  In the presence of hypoxia, a metabolic shift occurs 
away from oxygen dependent processes, such as oxidative phosphorylation, and toward 
processes that do not require free oxygen, such as glycolysis [103].  It is believed that 
hypoxia plays a role in helping to maintain the Warburg effect, which was first described 
by Dr. Otto Warburg in 1956 to describe the metabolic changes that tumor cells must 
undergo to survive in hypoxic and stressful environments [104].  Hypoxia, like 
metastasis, is believed to be of such importance that it was also denoted as one of the 
“hallmarks of cancer” [61]. 
Hypoxia leads to a number of cellular changes that can induce more aggressive 
changes in tumor cells.  For example, it has been shown that hypoxia can not only alter 
angiogenesis but alter the translation of specific proteins dependent upon the presence of 
5’ mRNA cap [105].  This observation suggests that a switch occurs in tumor cells 
promoting a mechanism that allows for the synthesis of a greater number of mRNA’s and 
removes a key regulatory mediator in translation.  Another group has recently shown that 
VHL plays a much larger role than simply regulating HIF-1α concentrations by also 
modulating microtubule formation [106].  Recently, it has also been shown that hypoxia 
may be a contributing factor to the cancer stem cell phenotype, a population of cells 
believed to be involved in chemotherapy resistance and metastasis [107, 108].  Therefore, 




Modulation of the Microenvironment 
 Tumors are composed of a variety of stromal components, including immune 
cells, endothelial cells, fibroblasts, and tumor cells, all of which may be impacted by the 
hypoxic environment present in tumors.  For example, it has been suggested that an 
oxygen gradient may be a chemoattractant leading to enhanced monocyte migration 
[109].  It has been shown that tumor associated macrophages (TAM) preferentially 
accumulate in hypoxic regions of tumors, likely due to a phenotype which promotes 
repair of hypoxic wounds [110, 111].  Once in this environment, monocytes/TAM alter 
their gene expression in response to the hypoxic environment, making them more suited 
to survive [111, 112].  These changes are partially responsible for the promotion of pro-
angiogenic factors released from TAM [113, 114].  In this environment, TAM also 
release a number of anti-inflammatory molecules, such as TGF-β and IL-10 [111, 115].  
However, new work suggests that hypoxia can also lead to increased IFN-γ production, 
which may promote an anti-tumor phenotype, suggesting that there are a number of 
factors impacting TAM function in the hypoxic environment [116].  The presence of the 
hypoxic environment also leads to an upregulation of NF-κB, leading to increased 
survival of TAM [111, 117].   
 These changes manifest themselves at the cellular level, as they promote tumor 
angiogenesis and invasion into surrounding tissues, thereby increasing tumor 
aggressiveness [118, 119].  It is not only TAM that alter their phenotype in response to 
hypoxia; these changes also occur in neutrophils [120] and T cells [121, 122].  Thus, it is 
very apparent that the presence of hypoxia modulates the tumor microenvironment in 
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A Brief History and Overview 
 Angiogenesis is the process of blood vessel growth, and is of such importance to 
tumors that it has been described as a “hallmark of cancer” [61].  The process of 
angiogenesis as it pertains to tumors was first described by Dr. Rudolf Virchow in the 
late 1800’s when he observed that tumors were highly vascularized [123].  Dr. Judah 
Folkman later elaborated upon these observations to describe the presence of pro-
angiogenic factors [101, 102].  Folkman described how angiogenesis was required for 
tumor growth and that tumors could not grow larger than two millimeters without 
recruiting blood vessels.  Angiogenesis is required in that it allows for the supply of 
nutrients and oxygen to tumors and removes waste and metabolic by-products from cells.  
Angiogenesis is a global term that encompasses a number of processes that are involved 
in blood vessel growth.  For example, the term angiogenesis specifically applies to the 
branching of new blood vessels from a common progenitor which then invade and supply 
blood to a specific tissue [61].  Conversely, the process of vasculogenesis requires 
precursors, typically circulating in the blood, to move into tissues and create new vessels 
[124, 125].  Further divisions of the types of angiogenesis have also been termed to 
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explain specific phenotype that correspond to blood vessel growth, such as sprouting 
angiogenesis and intussusceptive angiogenesis [126]. 
Tumors themselves have also evolved new mechanisms to create blood supplies 
in order to increase oxygenation of tissues, such as vascular mimicry in which tumor cells 
create patent openings that lead to established conduits without endothelial cells, 
allowing blood to pass through as if they were actual vessels [127, 128].  The process of 
vessel co-option occurs when tumor cells grow along established vessels in an attempt to 
disseminate [126].  Tumors themselves have developed a number of mechanisms to ‘flip 
the angiogenic switch,’ and thus it is easy to discern the importance of angiogenesis in 
tumor growth [129-133].  Nevertheless, tumor endothelial cells may be more nefarious 
than simply supplying the tumor with oxygen and nutrients, and may also play a role in 
immune suppression [134]. 
 
Angiogenic Cytokines 
 One of the primary molecules mediating angiogenesis is vascular endothelial 
growth factor (VEGF).  VEGF was first described in 1983 by Senger and Dvorak who 
named it vascular permeability factor (VPF) [135].  VPF was implicated in making 
vasculature leaky to promote increased movement of leukocytes from the blood into 
peripheral tissues.  It was not until later that VPF was also implicated as a growth factor 
for endothelial cells, and was renamed VEGF once it was determined that the two 
molecules were the same [136]. 
VEGF-A was the first isoform of VEGF described, and subsequent isoforms were 
consecutively lettered to differentiate them (e.g. VEGF-A, VEGF-B, VEGF-C) [137].  
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VEGF signals through three VEGF receptors (VEGFR1, VEGFR2, and VEGFR3), each 
of which has a specific tissue distribution and function [137-140].  For example, 
VEGFR1 is expressed on endothelial cells and monocytes/macrophages and is 
responsible for cellular motility and extravasation [139], whereas VEGFR2 is expressed 
on the same cells and induces mitotic changes and vessel permeability [138], while 
VEGFR3 is primarily involved in lymphoangiogenesis [140].  Lymphoangiogenesis is 
the process of new lymphatic vessel development from pre-existing lymph vessels in a 
similar matter to that of blood vessel growth [141].  Each of these receptors is a receptor 
tyrosine kinase that acts through various pathways to elicit the above noted actions [142].  
Activation of VEGFR is important in maintaining the vascular endothelium and 
promoting vessel invasion.  Tumors and stromal cells can secrete high concentrations of 
VEGF which may act as a chemoattractant for cells expressing VEGFR, and VEGFR2 
more specifically.  However, the interplay of these receptors is also important, as 
alternatively spliced forms of VEGFR2 may be stimulatory for vascular growth and 
inhibitory of lymphatic growth [143].  
The signaling and effects of VEGF remain difficult to discern and at times 
contradictory due to the variety of roles VEGF can play given various environments, 
isoforms, and receptors activated.  For example, VEGF has been shown to be necessary 
for maintenance of vasculature due to autocrine signaling [144].  However, it has recently 
been postulated that VEGF may also serve as an antagonist to vascular growth under 
certain microenvironmental pressures and its absence may actually increase 
tumorigenesis if removed from myeloid cells [145, 146].  Therefore, the role that VEGF 
plays in maintaining and initiating angiogenesis has yet to be fully defined, although its 
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importance in angiogenesis cannot be dismissed.  Furthermore, increased circulating 
levels of VEGF have been found to be a negative prognostic factor in human and canine 
OSA [147-150].   
It has also been shown that interleukin-8 (IL-8) is a powerful initiator of 
angiogenesis [151-153].  IL-8 signals through CXCR1/2, which also responds to various 
other CXC-type chemokines, and feeds into to common pathways involved with VEGFR 
signaling [154-156].  Furthermore, activation of these pathways, primarily PI3-K and 
AKT, lead to signals that also promote cell survival, proliferation, and invasion [153].  It 
is also believed that the induction of neutrophil and monocyte/macrophage chemotaxis 
leads to the promotion of a pro-angiogenic phenotype in these target cells by degrading 
the extracellular matrix and stimulating blood vessel invasion [153, 157].  The ability of 
IL-8 to promote angiogenesis, chemotherapy resistance, and tumor cell survival make it a 
potent modulator of tumor development and dissemination. 
  
Circulating Endothelial Cells 
 Circulating endothelial cells (CEC) are a generic term used to describe any cell in 
circulation that may give rise to new vasculature.  These cells were first described in 
1997 by Asahara et al. who showed that CEC could be isolated from the blood and 
induced to form vascular endothelium when provided with the proper growth factors 
[124, 158].  Since this time, much work has been done to better characterize these cells, 
their function, and role in vascular growth in a number of diseases [159-167] including 
cancer [168-174].  CEC are currently defined as cells that shed from mature vasculature 
in the body and circulate before initiating branching and new vessel formation elsewhere 
19 
 
in the body.  It is further believed that tumors themselves can induce shedding of CEC to 
promote vascularization in other parts of the tumor.  However, it is also thought that there 
may be a common bone marrow progenitor cell (e.g. a circulating endothelial progenitor 
[CEP]), which is released from the bone marrow to circulate and initiate angiogenesis at 
distant sites.  It is believed that CEP play a greater role in development, but it has also 
been suggested that tumors may elicit responses that lead to increased CEP release from 
the bone marrow to stimulate angiogenesis.  CEP can also be elicited by vascular 
disrupting agents used in cancer therapy, possibly acting as a mechanism to initiate 
angiogenesis after ablation with these therapies [175]. 
 Due to the division of CEC and CEP in circulation, much work has been afforded 
to characterizing these cells for their potential to act as a biomarker for diseases such as 
cancer.  It has only recently been suggested that a standardized method of characterizing 
CEC for analysis in humans is required [176].  Mancuso et al. have suggested that cells 
that are DNA+CD45-CD31+CD146+ may be identified as CEC in humans.  It is 
imperative that CD45- cells are selected since those cells that are CD45+ may also express 
these markers, such as monocytes and neutrophils.  Since some of these markers (e.g. 
CD146) are also present on platelets, a stain for DNA is required to identify CEC.  
Previously, a number of different markers, including CD133, CD34, CD117, and 
VEGFR2/Flk-1 were suggested to define CEC in humans and mice [170, 177, 178].  
However, a number of these markers are general hematopoietic stem cell (HSC) markers, 
and may thus not truly be labeling CEC unless used in coordination endothelium specific 
markers such as CD31 [170].  It has been further suggested that CEC and CEP can be 
distinguished by their differential expression of these markers, such as the presence of 
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CD133 (human) or CD117 (mice) on CEP and lack of these markers on CEC [179, 180].  
However, others have shown that the presence of these markers may define a subset of 
CEC rather than truly identifying CEP [170]. 
 It has previously been suggested that CEC may act as a pharmacodynamic 
surrogate suggestive of changes in systemic angiogenesis.  Indeed, it has been shown that 
cancer patients have increased CEC [172].  For this reason, many have been interested in 
tracking CEC over time to determine whether changes in CEC can be used as a marker 
for changes in tumor angiogenesis and a measure of therapeutic efficacy.  The use of 
CEC as a biomarker has been best described by specific anti-angiogenic compounds such 
as VEGFR inhibitors and “metronomic” chemotherapy, the practice of giving small doses 
of cytotoxic drugs more frequently to decrease toxicity while maintaining a positive 
therapeutic index [173, 181-184].  The ability to monitor angiogenesis using a blood test 
would be valuable in the clinic and drug development sectors as it could provide insight 
into changes in angiogenesis and possibly tumor inhibition or progression. 
 
Measuring Angiogenesis 
 There are numerous methods used to evaluate changes in angiogenesis using in 
vitro and in vivo based assays [185].  In vitro assays are typically based on using primary 
or immortalized endothelial cell (EC) lines that are conducive to cell culture principles 
and thus may not be representative of EC in vivo.  However, HUVEC (human umbilical 
vein endothelial cells) are non-immortalized cells that can be used in these types of 
experiments and were first isolated in 1973 [186].  Assays concerning the relative growth 
and migratory capacity of EC lines have been in the forefront of study [185, 187].  
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Further studies have also been performed to recapitulate the in vivo scenario by allowing 
EC to differentiate and form tubes to better understand the mechanisms of vessel 
formation in an isolated system [185, 188-190].  Even though these systems are 
beneficial to understanding the properties of EC in defined systems, they lack the 
complexity of the microenvironment and growth factors which are present in animal 
models. 
 The ability to use in vivo models to study angiogenesis has allowed for a more 
relevant context into the study of angiogenesis as a biologic process.  One of the simplest 
models is the chick chorioallantoic membrane (CAM) assay.  Since the embryo is 
immunotolerant, tumor cells can be introduced into the system to study the invasion of 
EC into the tumor in a simple model system [191].  However, this is system only allows 
for short term analysis of angiogenesis, and thus may be more beneficial for screening 
anti-angiogenic compounds rather than understanding changes occurring over time [185].  
Another model system involves the use of the cornea as a measurement for changes in 
vessel growth [192, 193].  The cornea can be damaged or tumor tissue/cells implanted 
into the tissue and observation of blood vessels into the area assessed [194-196].  This 
technique has been used to describe changes that occur in the presence of tumor cells and 
various cytokines and growth factors. The chamber assay is another assay in which 
angiogenesis can be studied by placing a skin fold from a mouse in a frame which can be 
illuminated and vessels observed [197].  The advantage of this model is that it can be 
used for longer periods of time than the methods previously described, and can be used to 
describe vessel formation into a region that can be easily monitored [185].  This model 
has the advantage that it does not initiate angiogenesis on its own, and thus changes in 
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angiogenesis are due to the tumor cells implanted or cytokines/growth factors placed into 
the frame [198].  The other advantage is that it allows for repeated analysis of a single 
animal over time [198].  As good as these models are they do not take into account the 
variable microenvironment present in tumors, and the changes that may be associated 
with orthotopic tumor sites. 
 The description of vasculature in the tumor microenvironment is an important 
aspect for understanding the role of angiogenesis in tumor biology.  For many years, 
subcutaneous tumor models have been the preferred method of studying tumors in mice 
due to their easily accessible location; however, non-invasive techniques to study 
angiogenesis are typically time and cost prohibitive [199-201].  The primary problem 
with this system is that it does not allow for repeated measurements of angiogenesis 
within the tumor unless expensive methodologies such as ultrasound, CT, or angiography 
are utilized [185].  Furthermore, characterization of the amount of angiogenesis requires 
sacrifice of the animal and subsequent immunohistochemical analysis by immunostaining 
with CD31 and manual determination of micro-vessel density (MVD) [202, 203].  Large 
biopsies are required in dogs and humans with subsequent staining using CD31 or 
CD146, respectively [185, 204].  However, it is likely that vessels are not evenly 
distributed throughout a tumor, and thus a method of “hot-spot” analysis may be 
performed in which fields with only dense vasculature are counted in order to select for 
the most angiogenic regions of a tumor [202].  This method may not be representative of 
the overall tumor burden, and is therefore subject to bias.  Lastly, the interaction between 
human/canine tumor xengorafts and the stromal components of the host nude mouse may 
alter vascular modeling and maintenance [49, 52-54, 58].  It is plausible that the 
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cytokines/growth factors between the species may not interact properly with their 
xenograft counterpart, which may lead to artifacts not present in syngeneic studies.  The 
ability to properly characterize angiogenesis in mouse models is critical, as novel 
therapeutics seek to target angiogenesis as a means to inhibit tumor growth. 
 
Anti-Angiogenic Therapeutics 
 The development of compounds that are approved as anti-angiogenic compounds 
for cancer has only occurred recently with the acceptance of Avastin® (bevacizumab).  
Avastin is a humanized monoclonal antibody targeted against VEGF-A.  Avastin was 
first approved for metastatic colon and non-small cell lung cancer along with standard of 
care therapy in each of these diseases [205-207].  However, Avastin was recently (2008) 
approved for use against metastatic breast cancer even though it failed to significantly 
prolong survival and only moderately decreased the rate of tumor growth [208].  
Additional studies are investigating the efficacy of Avastin in glioblastoma, renal cell 
carcinoma, and other tumors [209-213].  The ability to inhibit angiogenesis while 
concurrently inhibiting tumor growth with more conventional cytotoxic compounds 
suggests that inhibition of tumor growth by a variety of mechanisms may increase 
survival in patients with various tumor types. 
 There have been numerous ideas on the best way to inhibit angiogenesis.  There 
has been interest in directly inhibiting the receptor for VEGF as an anti-angiogenic 
strategy.  One of these compounds is ZD6474, which acts as a VEGFR2 and EGFR 
inhibitor [214-216].  It is thought that the inhibition of multiple pathways involved in 
angiogenesis and tumor progression may be a better approach to anti-tumor therapy than 
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selective inhibition of a single pathway.  However, a recent opposing view is that this 
pan-receptor form of inhibition may lead to myelosuppression due to the indirect 
inhibition of development pathways, particularly c-kit and Flt-3 [217].  It has also been 
suggested that metronomic chemotherapy, the practice of giving small doses of cytotoxic 
therapy continuously, may inhibit angiogenesis by the inhibition of CEC [170, 173, 218].  
The primary compound investigated in this paradigm has been cyclophosphamide, with 
an inhibition of CEC and decreased tumor vasculature reported [173, 219].  The promise 
of novel anti-angiogenic compounds suggests that angiogenesis may be a potential 
mechanism to inhibit tumor growth. 
 The first anti-angiogenic compound approved for therapy in dogs was Palladia® 
(toceranib).  Palladia is a tyrosine kinase inhibitor (TKI) that specifically targets c-kit, but 
has also been found to inhibit PDGFR and VEGFR [220-223].  Palladia is currently 
approved as a therapeutic for mast cell tumors in dogs and is under evaluation for 
efficacy against other tumor types in combination with standard cytotoxic chemotherapy.  
A number of other TKIs have been used in canine cancer treatment, although exploitation 
of these compounds as a possible therapeutic has only recently begun to be explored 
[224].  Thus, it is easy to see how anti-angiogenic therapies may play a role in helping to 
control tumor growth and synergize with other therapeutics to increase efficacy and 







Inflammation and Cancer 
 
A Brief History and Overview 
 The observation that tumors contained large leukocytic infiltrates was first made 
by Dr. Rudolf Virchow in 1863 [225, 226].  Since then, the importance of inflammation 
in tumors has waxed and waned through scientific literature for much of the past century.  
It has now become accepted that inflammation plays an important role in cancer initiation 
and progression [227].  Dvorak stated that “tumors are wounds that do not heal,” thus 
leading to a chronic inflammatory response in the presence of a tumor [87].  The presence 
of infectious agents, both bacterial and viral, has been implicated in creating and 
sustaining chronic low-level inflammation that perpetuates oncologic changes in cells; 
these studies will be discussed later in this chapter.  Inflammation is a double-edged 
sword in biology because it allows the immune system to coordinate an attack against 
foreign pathogens, yet if not kept in check, the process of inflammation itself can cause 
damage to cells that cannot be repaired, thus leading to other problems.  Chronic 
inflammatory diseases are of great concern to human health, and thus may be viewed in a 
much wider context than that of cancer. 
  
Inflammatory Mediators 
 The mediators of inflammation are not only immune cells, but the inflammatory 
factors produced by normal cells in response to damage and/or foreign pathogens.  
Inflammatory cytokines, such as the interferons, interleukins 1, 2, 8, 12, 18, and tumor 
necrosis factor-α (TNF-α) may be released by resident cells in response to stresses [228-
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234].  The release of these inflammatory mediators trigger a cascade of other cytokines 
and processes that promote the invasion of immune cells into target areas [235].  For 
example, IL-8 and CCL2 promote the infiltration of neutrophils and monocytes, 
respectively [153, 236-238].   Soluble immune mediators act as signals between and 
among cells to coordinate activities that remove pathogens and repair damage caused by 
various types of injury.  The production of prostaglandins and leukotrienes coordinate the 
inflammatory environment, and recruit cells that remove foreign material, clean up the 
debris, and repair the site of damage [239].  If these systems are not inter-related and 
balanced, auto-immunity may develop as a consequence of the inflammatory cascade.  
Therefore, the importance of inflammation extends beyond that of the cancer phenotype, 
and persists as a foundation of human health when properly controlled and implemented. 
 
Cycloxygenase 
 The cyclooxygenase (COX) family is a group of enzymes primarily responsible 
for the formation of a number of inflammatory mediators, primarily prostaglandins and 
their derivatives.  The COX pathways convert arachadonic acid to prostaglandins [240].  
The primary COX enzymes involved are COX-1 and COX-2 [241].  The distribution of 
these enzymes varies across tissues, but primarily resides in blood vessels, stomach, and 
kidneys.  COX-1 is considered to be constitutively active in most normal tissues; 
whereas, COX-2 is a more inducible form of the enzyme that is expressed in areas of 
high inflammation by mediators such as macrophages [242].  Increased prostaglandin 
concentrations do more than regulate inflammation, they also lead to changes in vascular 
smooth muscle tension, platelet aggregation, hormone control, control cell growth, and 
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regulate calcium movement (an important signaling factor) [243-248].  It has also been 
suggested that COX-2 expression may be prognostic in dogs with OSA, and inhibition of 
COX-2 may lead to decreased pain in these patients [249, 250].  Indeed, it is easy to see 




 Other important mediators of inflammatory signals are the lipoxygenase (LOX) 
enzymes.  These are a family of iron containing enzymes that mediate the formation of 
leukotrienes from arachadonic acid [239].  Leukotrienes derived their names from the 
large expression within from leukocytes [251].  The primary mediator of leukotriene 
synthesis is 5-lipoxygenase (5-LOX) [239].  Leukotrienes act as important inflammatory 
mediators, and have been best studied in the field of asthma [252, 253].  Leukotrienes are 
also important chemoattractants for neutrophils [254].  Leukotrienes have been 
implicated in increasing vascular permeability, and thus may play a role in increased 
leukocyte migration into areas of inflammation. 
 
NSAID Inhibitors of Inflammation 
 Numerous compounds have been developed for the treatment and inhibition of 
inflammation.  One of the most popular classes of these compounds is the non-steroidal 
anti-inflammatory drugs (NSAIDs).  These drugs act primarily by inhibiting the function 
of the COX/LOX enzymes.  Inhibition of the production of anti-inflammatory mediators 
has been used for the treatment of both acute and chronic inflammation.  However, 
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NSAIDs constitute a broad class of drugs that differentially inhibits COX-1 and COX-2 
[255, 256].   For example, aspirin is a salicylate that irreversibly binds to COX-1 and 
modulates the activity of COX-2 [257].  However, newer compounds such as rofecoxib 
were created to specifically inhibit COX-2, although these drugs have met with some 
unanticipated side-effects requiring their withdrawal from the commercial market [258].  
Compounds such as indomethacin, nordihydroguaiaretic acid (NDGA), and piroxicam 
differentially inhibit COX-1 and COX-2, leading to a variety of effects and uses based on 
these differences [255, 256, 259-261]. 
 Inhibition of LOX pathways is slightly different since leukotrienes retain their 
fatty-acid characteristics, and thus inhibition of leukotrienes are typically independent of 
COX inhibition.  However, the compound tepoxalin, a dual COX-1/COX-2 inhibitor that 
also inhibits 5-LOX, inhibits the production of both prostaglandins and leukotrienes, 
providing a broader inhibition of inflammation [262].  Targeting of multiple pathways 
may be a better strategy in cancer therapy because it decreases the possibility that tumor 
cells will evade the effects of the compound.  The primary toxicity associated with 
NSAID therapy is gastrointestinal in nature, and decreasing this toxicity is important if 
NSAIDs will be used for long periods of time, as is necessary for them to be most 
effective [263-267]. 
 
Importance of COX/LOX in Cancer 
 Increased expression of COX-2 has been studied in a variety of tumors, and has 
been found to have prognostic value in various tumor types including OSA [249, 268-
271].  Therefore, a number of investigations have been performed to better classify the 
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expression and possible inhibition of COX-2 in cancer and its related processes.  
Logically, tissues normally expressing COX-2 are preferential targets for this type of 
treatment since tumors arising from these tissues typically over express these enzymes.  It 
has also been shown that long-term treatment with an NSAID may decrease the risk of 
specific tumor types due to the anti-inflammatory properties, such as colon cancer [272].  
It has recently been shown that inhibition of COX-2 may lead to inhibition of breast 
cancer formation in a murine model [273].  Inhibition of COX/LOX can influence 
various processes such as the inhibition of metastasis, reduction in bone pain and tumor 
growth, and inhibition of tumor formation and promotion in a colon tumor model [250, 
274-276].  In veterinary medicine, piroxicam has been studied as a therapeutic for 
bladder cancer in dogs [277, 278].  It is easy to see the importance that inflammation 
plays in tumor growth and promotion, and the possibilities that are present through the 
modulation and of inflammatory mediators. 
 
 
Infection and Cancer 
 
A Brief History and Overview 
It has long been established that inflammation is a plausible cause of cancer 
progression.  One of the most well documented examples is that of Helicobacter pylori, a 
bacterial pathogen present in the stomach [279-282].  Chronic infection with this 
pathogen leads to low levels of inflammation in the stomach wall, and may subsequently 
give rise to gastric carcinoma and mucosa-associated lymphoid tissue lymphoma [279-
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285].  It has also been shown that removal of the inflammatory stimuli can lead to tumor 
regression.  Another example is osteomyelitis, or infection of the bone [13, 286].  Studies 
speculate that the chronic low level infection associated with osteomyelitis may lead to 
carcinogenic changes possibly leading to tumor formation.  Recently, prostate cancer was 
implicated as having a possible infectious etiology.  However, it is not just bacterial 
pathogens that can lead to tumor formation, for there is a wide body of literature that has 
shown that a number of viruses can incite pro-oncologic changes in target cells [287-
290].  In this case, virally infected cells are re-programmed by the virus to survive in the 
presence of an immune assault, and continue to replicate.  These factors lend themselves 
to a pro-tumor environment, in which few other changes are necessary for the 
development of a tumor. 
The antithesis of the above information was proposed in the 1893 when Dr. 
William Coley observed that a head-and-neck cancer patient developed an infection that 
subsequently lead to tumor regression [291].  This observation, and anecdotal evidence 
collected over the next decade (including a passage by Paget suggesting infection may 
play a role in tumor regression), suggested that infection could lead to tumor growth 
inhibition [292, 293].  Coley went as far as to prepare a mixture of live bacteria which he 
injected into the tumors of patients with inoperable disease, with mixed success [294, 
295].  A number of Coley’s patients succumbed to the effects of acute infection; 
however, there are also reports of miraculous cures [292].  Interestingly, Coley’s 
inspiration may have been derived from the death of patients with metastatic bone tumors 
(including OSA), and he believed that his unique form of immunotherapy may be 
especially potent against this type of tumor [295].  Nevertheless, Coley never published 
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the recipe to his so called “Coley’s toxin,” although it is believed he never stopped 
altering the recipe.  Due to these observations and experiments, Coley is thought of as the 
father of immunotherapy in a time when germ theory was being postulated [296]. 
 
Modern Mechanisms of Coley’s Toxin 
 Exploration into the mechanisms behind Coley’s toxin rapidly fell out of favor 
due to the mixed results of his experiments and contradictions in experimental setup 
[295].  It was not until the 1990’s and discovery of toll-like receptors (TLRs) did the 
scientific community began to approach Coley’s work again.  It was thought that 
targeting of TLRs could activate the immune system in a similar manner to that of the 
infectious agents used by Coley, but in a safer manner.  Numerous individuals and 
companies formulated mixtures and compounds to simulate the response of Coley’s 
infectious agents [294].  Soluble agents of infection have also been studied, and treatment 
of bladder cancer with BCG has become an effective therapeutic for some patients [297-
299].  Murine models investigating a number of infectious agents as anti-tumor 
therapeutics have also been created, although many of these are more focused on the 
mechanisms of growth inhibition than the use of pathogens as clinical agents [227, 300-
303]. 
 One of the greatest advancements in recapitulating Coley’s toxin while decreasing 
the toxicity of the compound is liposomal muramyl tripeptide (L-MTP-PE).  This 
compound increases monocyte accumulation in the tumor as one of the mechanisms of 
tumor and metastasis inhibition [304].  It is thought that activation of monocytes homing 
to the tumor and tumor associated macrophages become activated in the presence of L-
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MTP-PE thus leading to tumoricidal properties and an increased inflammatory response 
against the tumor [305-307].  It has also been shown that combination of L-MTP-PE with 
conventional chemotherapy may be an efficacious therapy for OSA [308].  Furthermore, 
this therapy has found a home in treating OSA, in humans and dogs [23-30, 35].  Another 
mechanism of exploiting the effects of Coley’s toxin without treating patients with 
infectious pathogens utilizes CpG pathogens.  CpG islands are unique to bacterial DNA, 
and administration of these molecules has been shown to activate the immune system 
non-specifically and may act as a potent adjuvant in cancer vaccines [309-311].  Clinical 
trials have also been performed with these molecules to some success [312-314].  
Therefore, it is plausible that the type and timing of inflammation can direct tumor 
growth promotion or inhibition.  It is interesting in that Coley first explored the use of 
immunotherapy in bone tumors, and this is one of the most successful venues for this 
type of therapy. 
 
Pathogens as Delivery Systems in Cancer 
Due to the unique ability of specific bacteria, such as Salmonella species, to 
migrate towards areas of hypoxia, it has been suggested that these pathogens act as a 
vehicle for anti-tumor compounds [315, 316].  Thus, individuals have engineered a 
variety of therapeutics into these pathogens to exploit these effects, such as IL-2, CCL21, 
Fas Ligand (FasL), IL-18, TRAIL, and endostatin [315-326].  However, it is likely, that 
initiating an immune response to bacteria present in a tumor will lead to indirect killing 
of tumor cells and thus decreased tumor growth.  For example, Salmonella migration to a 
tumor incites an immune response against the bacteria.  Subsequent infiltration of 
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neutrophils and monocytes into the tumor microenvironment leads to lysis of the bacteria 
and indirect killing of the tumor cells due to the release of cytotoxic compounds from 
both of these cell types.  However, this role has also been attributed to some viruses, and 
may be a mechanism of delivering normal genes to tumor cells to correct tumor 
promoting mutations [327, 328].  There has been interest in mechanisms to exploit the 
observations originally made by Coley, and make these therapeutics more efficacious 
with fewer toxicities. 
 
 
Innate Immunity/Myeloid Cells 
 
Monocytes 
 Monocytes, or mononuclear cells, are bone marrow derived leukocytes that play a 
role in guarding against foreign pathogens and initiating repair mechanisms for damaged 
tissues.  This wide variety of roles has made monocytes of great interest to tumor 
biology, since they are the pre-cursor cell to both macrophages and dendritic cells (DC).  
Monocytes are harbored in bone marrow and are released due to systemic changes in the 
concentration of MCP-1 (monocyte chemoattractant protein-1; CCL2) and attracted into 
tissues by MCP-1, CSF (colony stimulating factor), IL-17, Galectin-1, RANTES/CCL5,  
and other danger signals such as the chemokines CX(3)CL1 and CXCL16 [329-337].  
However, there are believed to be multiple types of monocytes in circulation, which can 
be recruited to tissues dependent on signals sent from these tissues to perform a number 
of jobs [338-340].  Once monocytes migrate out of the blood and into peripheral tissues, 
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they rapidly undergo phenotypic changes to become macrophages or DC.  Therefore, the 
interesting aspects of these cells involve the small differences which persist while they 
are in circulation, and what these changes mean for these cells once they extravasate from 
the blood into peripheral tissues. 
The introduction of flow cytometry and identification of specific markers tied to 
their cellular phenotype has greatly enhanced the characterization of circulating 
leukocytes.  Typical surface markers present on murine monocytes are Ly6G-
CD11b+CD115+Ly6C+/- [340-342].  Ly6C differentiates monocytes from neutrophils 
despite the expression of very similar markers (eg. Ly6G) on these two cell types [342].  
The differential size of these two cells type also enhances their identification by flow 
cytometry.  Interestingly, the ability to use Ly6C (monocyte/macrophage differentiation 
antigen) in the analysis allows for characterization of two distinct subsets of monocytes 
that cannot be differentiated by cellular morphology, but do have phenotypic differences 
[339, 340].  However, it is not well understood how expression of Ly6C is regulated, and 
how cells coming out of the bone marrow are led to express this marker or not [340, 343].  
However, it is well established that the lack of Ly6C (steady state monocyte) or presence 




 Inflammatory monocytes are characterized as Ly6C+, which helps differentiate 
them as having a pro-inflammatory bias in response to inflammation.  It has been shown 
that Ly6C+ monocytes are more activated and differentiate into activated macrophages 
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once undergoing extravasation at target tissues [340].  Furthermore, it has been shown 
that Ly6C+ cells preferentially differentiate into DC once they extravasate.  DC are 
professional phagocytic cells which phagocytize debris and transport it to a lymph node 
to help prime an adaptive immune response.  DC induction is critical in the clearance of 
pathogens because they help coordinate innate and adaptive immune responses and 
provide an inflammatory environment [345]. 
 It is believed that the circulation of high numbers of inflammatory monocytes 
allows for rapid migration of a large number of cells into damaged tissues in response to 
inflammatory signals.  In order to contain, damage, and sequester possible pathogens, 
large numbers of activated cells are required.  However, Ly6C+ monocytes also have a 
shorter half-life, and are thus present as a rapidly deployable defense in response to 
inflammatory stimuli [339, 340].   
 Tumors employ mechanisms to dampen the inflammatory properties of Ly6C+ 
monocytes since inflammatory monocytes are potentially harmful to tumor development.  
It has been shown that the bone marrow can down-regulate Ly6C+ expression on 
monocytes due to a variety of stimuli, and it is plausible that a similar mechanism may be 
present in tumors that nullify the inflammatory properties of these cells and turn them 
into more tumor supportive monocytes [346]. 
 
Steady State Monocytes 
 Steady state monocytes are characterized as being Ly6G-CD11b+CD115+Ly6C- 
cells when characterized by flow cytometry [340].  These cells have also been referred to 
as resident monocytes, since they may be found attached to the luminal side of blood 
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vessels and remain in a partially inactivated state until stimulated by inflammatory 
mediators [339, 347].  Not as much is known about the role of Ly6C- monocytes, but in a 
mouse model of cardiac damage, it was shown that after the inflammatory period and 
migration of Ly6C+ monocytes into the area of damage, there was an influx of Ly6C- 
monocytes [348].  Other models have shown that Ly6C- monocytes may be sequestered 
in the bone marrow, and upon receiving inflammatory stimuli, quickly become activated 
and potentially increase Ly6C+ expression [343, 346].  Once present, these steady state 
monocytes took over the role of repairing the damage done by the inflammatory process.  
These changes were characterized by the release of anti-inflammatory compounds and 
increased expression of VEGF, a potent stimulator of angiogenesis [348].  Therefore, it 
stands to reason that a similar process may be occurring in tumor tissues, in which 
inflammatory mediators are released that recruit these less inflammatory cells to quell the 
process and begin to repair the affected tissues and support tumor growth. 
 
Macrophages 
 Macrophages are derived from monocytes which have recently extravasated from 
the circulation upon movement into the extracellular environment.  The context of this 
environment is thought to impact how these cells change phenotypically, and the 
response and interactions which they have with their local environment.  Macrophages 
have classically been subdivided into two groups: the classically activated macrophage 
(M1) that is inflammatory and acts against foreign pathogens, and the reparative 
macrophage involved in repairing damaged tissues (M2) [235].  These two types of 
macrophage have been defined in numerous models, including cancer, but are best 
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described in a variety of infectious disease models where their phenotypes are more 
sharply contrasting and straightforward [349].  In tumors, the phenotypic designation of 
these cells is not as straightforward, and there exists a continuum upon which different 
“flavors” of these cells reside [349].  It is no longer thought that there are simply two 
types of macrophages, or that there are inflammatory and anti-inflammatory cells.  
Current studies show that a mixture of factors in the tumor micro-environment can create 
a variety of phenotypes for these cells that cannot be easily defined.  However, for 
simplicity, many people still refer to macrophages as M1 or M2 to describe their overall 
functions, sometimes further characterizing them into more precise groups by defining 
M2a, M2b, and M2c phenotypes to describe large differences in the non-inflammatory 
population of cells [350]. 
 
Inflammatory macrophages (M1) 
 Inflammatory macrophages are thought to be derived from inflammatory 
monocytes and have an anti-tumor role [340].  M1 macrophages are also called classical 
macrophages in that they were first reported as scavengers of bacterial pathogens, and 
play a role in controlling infections [340].  The cytotoxic role of these cells is not 
reserved only for pathogens, but it is thought that macrophages could also inhibit tumor 
cell growth [351, 352].  It is now believed that macrophages produce an environment 
inhibitory to tumor growth by promoting inflammatory responses that place various 
stresses on tumor cells [350].  Furthermore, the presence of an inflammatory process is 
stimulatory to other immune cells and effectors, and thus leads to an anti-tumor 
phenotype.  Although, this process may be beneficial in inhibiting growth of established 
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tumors, it may also lead to tumor promotion.  It has been well studied that macrophages 
may promote certain types of cancer if this inflammatory response is prolonged, leading 
to the accumulation of mutations in cells and resulting in their transformation [353-356].  
It is thought that production of ROS and RNS may lead to mutation accumulation in cells 
leading to transformation and increased invasion [354, 355, 357].  Thus, the duality of 
this process is likely tumor type and environment specific.  M1 macrophages are typically 
inflammatory and promote this phenotype through the production of IL-1β, IFN-γ and 
TNF-α [358-360].  The production of these cytokines also promotes a TH1 type response, 
thereby helping to activate T cells against the tumor [349].   
 By altering the tumor microenvironment, it is possible to change the polarization 
of macrophages a pro-tumor (M2) to an anti-tumor (M1) phenotype [361, 362].  This is 
one mechanism by which M1 macrophages may inhibit tumor growth.  Since tumors 
become reliant on the pro-tumor phenotype of macrophages, it is plausible that peripheral 
activation of monocytes and their subsequent macrophages may inhibit tumor growth 
[363, 364].  It has been previously shown that increased numbers of TAM is prognostic 
in certain cancers; however, the results are conflicting and tumor type dependent [365-
367].  Therefore, further classification of macrophages and their responses are required to 
differentiate these effects. 
 
Alternatively Activated Macrophages (M2) 
 There have been many classifications concerning the phenotype of the 
alternatively activated (M2) macrophage; however, many of differences focus on the anti-
inflammatory and repair roles of these cells.  Therefore, for the purpose of this review, 
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attention will be focused on the general classification of these cells as M2 macrophages, 
and not into individual subgroups.  However, it is important to remember that the 
differences between M1 and M2 macrophages are a continuum rather than a black-and-
white comparison [349]. 
 M2 macrophages are characterized by their propensity to promote tumor growth, 
and are involved in wound healing and tissue repair in other disorders [349].  These cells 
are thought to be derived from steady state monocytes, but the tumor microenvironment 
is the primary mechanism determining the phenotype of these cells [349].  M2 
macrophages create an environment of immune inhibition by promoting regulatory T 
cells and are themselves stimulated in the presence of TH2 responses [349, 368-372].  
This inhibition of immune responses helps protect the tumor from adaptive immune 
responses that may be activated against the tumor, and provide a basis for immune 
evasion.  Anti-inflammatory cytokines such as IL-4 and IL-10 help promote M2 
formation and activities [373-375].  Interleukin-10 also inhibits macrophage 
differentiation into DC, inhibiting future immune responses [372].  Furthermore, 
production of TGF-β promotes macrophage repair activities, and is also a potent inhibitor 
of immune responses [376, 377].  Up-regulation of the mannose receptor in these cells is 
thought to promote debris clearance and initiate repair of their environment [375]. 
 In order to help repair damaged areas, as suggested by Dvorak, macrophages 
break down the extracellular matrix; however, this leads to increased tumor invasion, and 
is supportive of tumor growth [378].  Hypoxia is also thought to induce an M2 phenotype 
in macrophages since this leads to the production of VEGF and other pro-angiogenic 
factors [111].  Macrophages produce an environment conducive to tumor growth by 
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limiting the intrusion of immune effectors, and promoting tumor growth by breaking 
down the extracellular matrix and providing oxygen and nutrients to tumor cells by 
stimulating angiogenesis and metastasis [379, 380].  Indeed, it is easy to see how some 
tumors can accumulate a large number of these cells, and how macrophage density can 
lead to a poor prognosis when macrophages are activated in this manner.  It has therefore 
been suggested that depletion of macrophages may be a viable method for the inhibition 
of tumor growth [303, 381]. 
 
Neutrophils 
 Neutrophils are one of the first-responders to damage within the body.  This 
damage leads to a release of inflammatory mediators which act as a chemoattractant for 
neutrophils.  One of the primary roles of neutrophils is to remove infectious organisms 
from a specific area [382, 383].  They are able to perform this role by entering tissues 
using IL-8 as a gradient and releasing a number of inflammatory compounds, which leads 
to a hostile environment in which invading organisms cannot survive [382-385].  
However, in this process, neutrophils typically die in their release of these compounds, 
requiring that more neutrophils invade the area.  The short lived but highly cytotoxic role 
neutrophils have makes them proficient at clearing infectious agents, but also leads to a 
large degree of collateral damage, although in a tumor these effects may be beneficial to 
control of the disease.  
 Neutrophils may have a multiple phenotypic characterizations much like 
macrophages [386-392].  Furthermore, it has been suggested that neutrophils may 
undergo a type of differentiation akin to macrophages that may lead to a type of duality in 
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their final function [393].  Indeed, there has been contrasting information in the literature 
suggesting antagonistic roles for neutrophils and their role in cancer disease progression 
[390, 394-396].  It has been suggested that one role for this change is the persistent 
hypoxic environment in the tumor that may lead to decreased apoptosis of neutrophils, in 
turn leading to pro-tumor phenotypic changes [120].  Therefore, our understanding of the 
role of neutrophils in cancer biology is still relatively unclear at this, time, but due to the 
large component that these cells compose of peripheral blood and indirect connections to 
disease outcome, it is plausible that neutrophils play a role in maintaining a pro-tumor 
environment in many patients and possibly mediate monocyte/macrophage function [397-
399].  It has recently been suggested that an immature subset of neutrophils, the myeloid 
derived suppressor cell, may be the effector portion of the neutrophil population [400]. 
 
Myeloid Derived Suppressor Cells 
 Myeloid derived suppressor cells (MDSC) are a recently discovered type of 
immune cell.  MDSC are thought to be similar to immature monocytes and neutrophils, 
and may be an immature circulating precursor of these cells [400-403].  They have risen 
to greater importance in cancer due to their increased numbers in human patients and 
murine models of cancer [400-402, 404-406].  It is believed that these cells accumulate in 
the spleen of tumor bearing human patients and mice leading to immunosuppression via 
T-cell inhibition by releasing arginase and nitric oxide which may lead to the formation 
of regulatory T-cells; an inhibitory type of T cell prior implicated in being pro-
tumorigenic [407-409].  Phenotypic differentiation of these cells is difficult and requires 
complex multi-color flow cytometry.  However, numerous studies describe these cells as 
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being CD11b+Gr-1+ cells in mice [400, 410] and CD11b+CD14-CD33+ and possibly 
CD15+ in humans [400, 411].  The concern is that both CD11b and Gr-1 are expressed 
ubiquitously on mature circulating leukocytes, specifically monocytes and neutrophils, 
and that more work is necessary to differentiate this specific cohort of cells from other 
cells in circulation.  Further characterization of these cells will allow for increased 
research into targeting these cells as a possible therapeutics and determining the role that 
the play in cancer biology. 
 
Natural Killer Cells 
 Natural killer (NK) cells are thought to be a mediator between innate and adaptive 
immunity.  The term NK cell was coined in 1975 when it was determined that these cells 
have the ability to kill tumor cells innately, and without pre-conditioning [412-414].  
However, the ability for NK cells to have memory, such as that of T or B cells, was only 
recently described, and only expressed in a very limited capacity [414-416].  The primary 
difference is that NK cells encode a number of receptors that do not undergo specific 
rearrangement like T and B cells [417].  However, the presence of cells that express 
markers of both NK and T cells have previously been described, and are thought to act as 
a mediator between the innate and adaptive branches of immunology; however, these 
cells are not classified as conventional NK cells, but as NKT cells [418]. 
 NK cells mediate their effects primarily through the release of large amounts of 
inflammatory cytokines, which help to elicit an immune response and attract other 
leukocytes to the area of inflammation.  For example, NK cells can express large amounts 
of IFN-γ, a potent inflammatory cytokine [419].  When NK cells are challenged with 
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foreign bodies, they release large amounts of perforin and granzyme that create pores in 
target cells membranes and induce apoptosis [420, 421].  It has been suggested that 
subsets of NK cells can undergo a more vigorous response to re-challenge with specific 
pathogens, akin to T and B cells, and become tolerant to specific stimuli [414].  These 
properties make NK cells important mediators in the priming of an immune response to a 
potential pathogen, as well as coordinating future responses to the possible recurrence of 
a given pathogen. 
 The role that NK cells play in cancer is also quite varied.  NK cells have been 
implicated in causing the direct lysis of tumor cells and activation of T cells, thus creating 
a bridge between the innate and adaptive immune systems [422].  The NK cell receptor 
NKG2D is believed to be expressed on almost all activated NK cells [417].  Cells 
expressing NKG2D are implicated in immune surveillance and are thought to be one of 
the defenses against cancer [423, 424].  It has even been shown that NK cells are able to 
respond to the presence of DNA damage and lyse these damaged cells [425].  Due to the 
inherent genetic instability present in many tumor cells and their metastatic variants, 
surveillance by NK cells is an important phase in detecting neoplastic cells by the 
immune system.  Finally, the stress response present in tumor cells leads to the up-
regulation of heat shock proteins (HSP).  NK cells are able to survey for these changes 
and lyse these stressed cells, therefore suggesting an additional method for NK cell 
control of cancer [417].  Indeed, it is easy to see the many facets involved in NK cell 







 A biomarker is a relevant biological marker that can be used as an indicator of a 
given biological state or process.  Biomarkers are of significant importance in cancer 
because they allow scientists and clinicians to help characterize a specific type of tumor, 
understand the processes occurring due to specific treatments, and even prognosticate the 
possible outcome of patients based on previously described data.  For example, CEC can 
act as a biomarker because they describe the current state of angiogenesis within a patient 
[170].  Since increased CEC are present in patients that have a poor prognosis, CEC may 
be associated with disease outcome [426, 427].  Furthermore, since CEC are an indicator 
of angiogenesis, they can be measured over time, and thus changes in CEC due to anti-
angiogneic therapies are used to understand the status of a patient’s disease.  Other 
groups have shown that circulating tumor cells may be prognostic in that they may be a 
surrogate for distant metastases and metastatic potential of tumors [428, 429].  Therefore, 
biomarkers are of absolute importance to understanding the underlying biology present in 
cancer patients and acting as a window into the disease process. 
 The possibilities associated with a field as wide as biomarkers have led to a 
number of approaches for the identification and characterization of biomarkers and their 
relative utility.  Both genomic and proteomic approaches have been used to identify 
individual genes and proteins which may be involved in specific types of cancer [430-
436].  One of the best understood biomarkers is HER2/neu on breast cancer cells.  
Expression of HER2 on breast cancer cells has been correlated with increased 
aggressiveness and consequentially decreased survival [437].  However, it is believed 
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that the combination of many of these markers may be cancer specific, and may be 
compounded so that a greater prognostic index can be made by combining a number of 
risk factors.  For example, it has been recently postulated that a unique 70-gene signature 
may be prognostic in breast cancer [438].  However, the problem with some of these 
approaches is that they are time consuming, require specialized resources and skill sets, 
and are not always economically feasible. 
 Diagnostic tests that are relatively inexpensive and straightforward are necessary 
to allow wide acceptance of specific biomarkers.  For example, circulating levels of 
serum alkaline phosphatase have been associated with decreased survival in humans and 
dogs with OSA [439-441].  This is a relatively simple test that can be taken from 
peripheral blood and analyzed in a cost and time efficient manner.  However, it should 
not be believed that simple tests are automatically superior to those that are more 
consuming.  Comparative analyses must be performed in large cohorts of patients to 
better understand the relative effectiveness of biomarkers.  These studies are typical in 
human patients, in which a number of factors can be analyzed to determine which 
provide significant prognostic information, and if a combination of these factors lends 
itself to a greater understanding of the disease state.  In the future, studies will have to be 
done to not only validate novel biomarkers discovered by a variety of approaches, but to 
determine the validity of biomarkers in a greater context.  These markers should not only 
be implemented to characterize disease, but would optimally be able to be used as a 







 Tumors are composed of a complex and dynamic mix of many components.  
Interactions between tumor cells and these other components, such as macrophages and 
endothelial cells, provide the foundation for numerous interactions that propagate tumor 
growth, invasion, and metastasis.  Therefore, there is intense interest in how these 
mechanisms interact, and how they can be disrupted in order to exploit the weaknesses of 
tumors, and possibly eradicate the disease.  The interaction of immunosuppressive cells 
and tumor cells provides a supportive environment for tumor growth by inhibiting 
immune responses and enhancing invasion and migration.  Endothelial cells form vessels 
deliver oxygen and nutrients to tissues while removing waste products.  Tumors exploit 
this process, not only for the reasons explained above, but to metastasize to distant 
organs.  The overall goal of this dissertation is to explore some of these mechanisms and 
better understand the clinical observations.  The other goal is to develop new models and 
techniques to better explore these observations and interactions, and further the 
development of novel methods to understand tumor biology and metastasis. 
 The first project presented in this dissertation was based upon a clinical 
observation made in dogs with OSA and later confirmed in human patients [442, 443].  
That observation was that dogs with OSA that were treated by a limb-spare and 
subsequently developed an infection at the surgical site lived significantly longer than 
patients not developing infections, owing to a significant delay in metastasis 
development.  Local recurrence of the disease was not impacted by the infection.  
Therefore, we hypothesized that we would be able to recapitulate these observations in a 
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mouse model of osteomyelitis where mice were challenged with OSA (Chapter 2: 
Chronic Bacterial Osteomyelitis Suppression of Tumor Growth Requires Innate 
Immune Responses).  We further hypothesized that the effects would be mediated by 
inhibition of angiogenesis as was suggested by contemporary literature in related models 
[227, 300].  However, there are a number of mechanisms that could induce the anti-tumor 
response, and thus we planned to also study the role that IFN-γ and immune cells play in 
this system. 
 Chapter 2 explains the development of a model of murine osteomyelitis based on 
a similar model previously developed.  Once a model of infection was developed, and 
was found to be chronic and localized, work was performed to determine if the infection 
could inhibit growth of a primary tumor located at a distant location. With a model that 
recapitulated the clinical observations, we sought to determine the mechanism of action 
behind the observed tumor growth inhibition.  Furthermore, to determine if the effect is 
tumor type specific, we investigated three different tumor types in three different mouse 
strains, and two different bacterial pathogens.  We first investigated the role of 
angiogenesis in the presence of infection, and the possible role that circulating 
endothelial cells play in angiogenic development.  Due to previous literature concerning 
the role of IFN-γ, and the ability of NK cells to produce large amounts of this cytokine, 
we depleted these cells to determine if they were required for tumor growth inhibition.  
We then sought to characterize changes in circulating monocyte populations and 
subsequent changes on tumor associated macrophages.  Thus, our goal was to better 
describe the mechanism of action associated with the inhibition of systemic tumor due to 
distant and localized infections. 
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 The process of infection leading to tumor growth inhibition is an inflammatory 
process, and thus we sought to study the counter-role that anti-inflammatory compounds 
play in tumor growth.  There have been numerous examples of how anti-inflammatory 
compounds (NSAIDs) can inhibit tumor growth [250, 274-278].  Even though many of 
these observations were made in colon cancer, it was hypothesized that other high COX-2 
expressing tumor cells could be similarly vulnerable to these compounds [249].  The 
ability to modulate inflammation reduces the supportive environment for the tumor thus 
leading to growth inhibition.  Therefore, we hypothesized that a dual COX-1/COX-2 and 
5-LOX inhibitor would inhibit tumor growth (Chapter 3: Induction of VEGF by 
Tepoxalin Does Not Lead to Increased Tumor Growth in a Canine Osteosarcoma 
Xenograft). 
We first performed in vitro assays to determine if tepoxalin inhibited cellular 
viability on a number of different canine tumor cell lines.  Further investigation into what 
appeared as a slight stimulation of growth lead us to investigate possible growth factors, 
such as VEGF.  We then observed that tepoxalin stimulated VEGF production from these 
cells.  We then hypothesized that this increase in VEGF is due to the unique structure of 
tepoxalin acting as an iron chelator, and investigated the stabilization of HIF-1α in 
response to tepoxalin treatment by western blot analysis.  These observations led us to 
hypothesize that tepoxalin would lead to increased tumor growth in a tumor xenograft 
model.  In order to test this hypothesis, we investigated the role that tepoxalin has in a 
canine xenograft model using pharmacologically achievable concentrations that are 
comparable to those found in dog, the target species of the drug.  Pharmacokinetic 
analysis was performed to determine an appropriate dose for these studies.  In vivo 
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experiments were then performed to investigate the effects of tepoxalin on tumor growth, 
and explore changes in systemic VEGF in response to tepoxalin.  Finally, we sought to 
determine the effects of short term tepoxalin administration on changes in systemic 
VEGF concentrations in normal dogs. 
 The first two studies performed thus far have investigated the role of 
inflammation on changes in tumor angiogenesis.  However, analysis of angiogenesis 
could only be performed by euthanizing mice, removing the tumor, cryosectioning, and 
immunostaining for the endothelial cell marker CD31.  This process is time consuming 
and requires the use of large numbers of mice.  Furthermore, there is no technique that 
could be used to investigate changes in angiogenesis in a single tumor over time [185].  
These experiments are typically performed by selecting an arbitrary time point at which 
mice are sacrificed and analyzed, or groups of mice are serially sacrificed to reveal trends 
associated with changes in angiogenesis.  However, both of these techniques are time 
consuming and require large numbers of mice.  Therefore, we sought to develop a novel 
technique to characterize angiogenesis in tumors over time that was minimally invasive.  
Clinical use of fine needle aspiration (FNA) allows for small samples of tumor to be 
obtained, and analyzed by microscopy.  In this process, there is typically a large amount 
of immune infiltrate and other tumor components present.  Therefore, we hypothesized 
that FNA could be used to obtain small samples of EC by a minimally invasive method.  
Characterization of these EC could then be performed by flow cytometry (Chapter 4: 
Minimally Invasive Assessment of Tumor Angiogenesis by Fine Needle Aspiration 
and Flow Cytometry). 
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In order to determine if FNA was a feasible method to identify EC, we first used a 
variety of techniques to determine the needle type that would provide a sufficient number 
of cells for analysis while not causing irreparable harm to a tumor bearing animal.  Once 
this was performed, we sought to identify EC in tumors and compare the results of an 
FNA to digest of the whole to tumor to determine if the FNA was representative of the 
overall tumor burden due to variations in angiogenesis.  In order to validate the 
technique, we compared the FNA technique to the current gold standard of IHC to 
determine if the two approaches gave similar results.  In order for this technique to be 
feasible we insured that repeated FNA did not induce an artifact and alter angiogenesis.  
This then allowed us to investigate if we could detect changes in angiogenesis as a 
function of time, and as a consequence of anti-angiogenic therapy.  These experiments 
provided evidence that FNA coupled with flow cytometry is a reliable technique to 
serially measure angiogenesis in tumor growth.  The creation of a technique to better 
monitor angiogenesis is beneficial because it allows for removing experimental bias 
through repeated measures, and helps decrease the animal burden required to investigate 
changes over time using in vivo tumor models.  
The development of a novel model of angiogenesis is important to investigating 
changes in tumor angiogenesis; however, there remains a need for more realistic tumor 
models that more closely approximate the clinical scenario.  The use of primary tumor 
models in heterotopic sites is common practice for in vivo tumor biology even though 
these conditions do not mimic the relationships of the tumor to its natural environment 
[42, 44, 55-57].  It has been previously shown that an orthotopic location can greatly alter 
tumor growth, metastasis, and response to therapy [52-54].  Therefore, we sought to 
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create a novel model of osteosarcoma that could be implanted orthotopically.  We also 
sought to luciferase transfect the tumor cells so the progression of systemic metastases 
could be non-invasively measured.  Furthermore, treatment in clinical patients typically 
includes surgical removal of the tumor prior to the initiation of systemic chemotherapy, 
and thus we created a model in which the primary tumor implanted orthotopically could 
spontaneously metastasize before amputation of the tumor bearing leg (Chapter 5: An 
Orthotopic, Postsurgical Model of Luciferase Transfected Murine Osteosarcoma 
with Spontaneous Metastasis).  We thus hypothesized that a novel murine model of 
OSA would allow us to investigate the role of novel therapeutics for OSA in a 
micrometastatic setting independent of the pressures of the primary tumor. 
We first utilized a plasmid system that would allow us to transfect the luciferase 
gene into the DLM8 murine osteosarcoma cell line and would be constitutively active.  
We then selected for luciferase positive cells that metastasized to the lung from an 
orthotopic site.  Characterization of the orthotopic tumor and its metastases was 
performed using micro computed tomography, luciferase imaging, and 
immunohistochemistry.  There are a number of orthotopic tumor models, but this is the 
first using this cell line and C3H mice.  Therefore, we sought to more closely resemble 
the clinical treatment paradigm by amputating the tumor bearing leg.  A surgical adjuvant 
model was created, and experiments were performed to determine when 100% of the 
mice developed micrometastatic disease.  Using this model, we were then able to 
investigate the role of conventional and novel chemotherapeutics for OSA.  The 
development of an orthotopic OSA tumor model in immunocompetent mice that 
spontaneously metastasizes in a postsurgical setting will allow for the screening of novel 
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compounds in a model system similar to that which human and canine cancer patients 
endure. 
After defining a more relevant model system for OSA, we sought to explore the 
role of circulating leukocytes as a prognostic in clinical disease.  Observations from the 
osteomyelitis study suggested that changes in circulating leukocytes may be mediators of 
tumor growth in OSA.  We also investigated changes in response to the anti-
inflammatory compound tepoxalin.  However, it would be beneficial to determine if 
circulating leukocytes could be prognostic in OSA.  The need exists to define simple tests 
that can cost-effectively prognosticate outcomes in OSA.  Therefore, we investigated the 
role that a pre-treatment complete blood count may play in determining OSA prognosis 
(Chapter 6: Increased Circulating Monocytes and Lymphocytes are Associated with 
Decreased Disease Free-Interval in Dogs with Osteosarcoma). 
In chapter 6 we determined that changes in circulating leukocytes were prognostic 
in OSA.  Changes in leukocytes may suggest more about the biology of the tumor and 
disease progression.  We hypothesized that differences in monocytes would be prognostic 
in OSA due to the observed role that these cells play in mediating tumor biology.  To 
answer this question, we screened 313 clinical OSA cases presenting to the Colorado 
State University Veterinary Teaching Hospital between 2003 and 2006.  Patients were 
selected based on surgery type received, lack of detectable metastases at presentation, and 
treatment with conventional chemotherapy.  We then performed statistical analyses on 
these dogs to determine if circulating leukocytes or other variables assessed were 
prognostic in OSA.  Conclusions from the first population of dogs were then tested and 
reproduced in a second independent population of dogs also treated at CSU.  Therefore, 
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we concluded that increased numbers of circulating monocytes and lymphocytes at the 
time of presentation were a prognostic factor for disease-free interval (time to clinical 
metastatic development).  
The goal of the work presented in this dissertation is to better describe the 
processes of angiogenesis and innate immunity in OSA.  This exploration begins with the 
observation that localized osteomyelitis can increase survival in patient dogs.  Thus we 
sought to develop a model of this process in mice to better define the mechanism by 
which this effect may occur.  We then explored the antithesis of this in determining what 
the role of an anti-inflammatory compound may have on OSA biology.  Interestingly, 
both of these techniques led to decreases in tumor growth, and thus the complex duality 
of inflammation in different forms was shown in this approach.  Exploration of methods 
to better characterize changes in angiogenesis, and development of models for which to 
investigate OSA biology and novel therapeutics were also undertaken to improve the 
understanding of OSA.  Lastly, we went back to the clinic to explore the role of 
circulating leukocytes in naïve OSA patients.  This dissertation concerns the interactions 
of the many factors implicated in tumor biology, and seeks to explain a few of these 
factors and add to the expansive field of tumor biology as a whole, and more specifically 
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Chronic Bacterial Osteomyelitis Suppression of Tumor 




Clinical studies over the past several years have reported that metastasis free 
survival times in humans and dogs with osteosarcoma are significantly increased in 
patients that develop chronic bacterial osteomyelitis at their surgical site.  However, the 
immunological mechanism by which osteomyelitis may suppress tumor growth has not 
been investigated.  Therefore, we used a mouse model of osteomyelitis to assess the 
effects of bone infection on innate immunity and tumor growth.  A chronic 
Staphylococcal osteomyelitis model was established in C3H-HeN mice and the effects of 
infection on tumor growth of syngeneic DLM8 osteosarcoma were assessed.  The effects 
of infection on tumor angiogenesis and innate immunity, including NK cell and 
monocyte responses, were assessed.  We found that osteomyelitis significantly inhibited 
the growth of tumors in mice, and that the effect was independent of the infecting 
98 
 
bacterial type, tumor type, or mouse strain.  Depletion of NK cells or monocytes reversed 
the antitumor activity elicited by infection.  Moreover, infected mice had a significant 
increase in circulating monocytes and numbers of tumor associated macrophages.  
Infection suppressed tumor angiogenesis but did not affect the numbers of circulating 
endothelial cells.  Therefore, we concluded that chronic localized bacterial infection can 







 The ability of bacterial infections to inhibit tumor growth was first described over 
a century ago by Dr. William Coley [1].  Coley suggested that the fever accompanying 
the infection led to a warming of the tumor which triggered tumor regression [2].  More 
recent studies have shown that systemic infection with non-bacterial pathogens is capable 
of inhibiting tumor growth.  For example, infection with Toxoplasma gondii has been 
shown to suppress tumor growth via induction of IFN-γ release, suppression of tumor 
angiogenesis, and leukocyte recruitment [3, 4].   
Models of tumor localized infection, where bacteria home directly to the tumor, 
have been used as one approach for tumor immunotherapy [5-8].  The homing of the 
pathogen to the tumor triggers leukocyte recruitment to tumor tissues, which is believed 
to stimulate non-specific antitumor immunity.  Genetically altered bacteria and viruses 
have also been used to deliver immunostimulatory cytokines and other anti-tumor 
molecules to the tumor microenvironment [6, 7, 9-13].  Studies in various tumor models 
have shown that these approaches elicit leukocyte recruitment to the tumor and promote 
anti-tumor activity.   
 Osteosarcoma is the most common primary bone tumor in humans and dogs, and 
the tumor in dogs is widely viewed as the most relevant animal model for human 
osteosarcoma [14, 15]. Tumor metastasis is the most common cause of death from 
osteosarcoma [16].  For this reason, both humans and dogs with osteosarcoma typically 
receive adjuvant chemotherapy [14, 17].  Despite the use of chemotherapy, the long term 
survival of dogs with osteosarcoma remains less than 20% [16].  In humans, the overall 
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5-year survival is 60% with surgery and adjuvant chemotherapy as the standard of care 
[17]. 
 It was recently reported that dogs with osteosarcoma developing localized 
osteomyelitis following limb-sparing surgery had significantly increased metastasis-free 
intervals and survival times compared to dogs that did not develop infections [18].  
Survival times were nearly doubled in dogs that developed osteomyelitis.  Even when 
adjusted for confounding variables, bone infection was significantly associated with 
inhibition of metastasis.  Furthermore, the authors noted that disease progression and 
survival effects were due to the delay in metastasis, rather than to local recurrence of 
disease [18].  Similar findings were reported in humans with osteosarcoma that 
developed osteomyelitis at the site of limb sparing surgery [19]; although, it should be 
noted that a second study in humans with osteosarcoma failed to find an association with 
bone infection and survival times [20].  These findings suggest that localized 
osteomyelitis may elicit an immune response that is associated with the inhibition of 
tumor growth and metastasis.   
 Therefore, we hypothesized that localized bacterial osteomyelitis was capable of 
eliciting systemic antitumor immunity.  To test this hypothesis, we developed a mouse 
model of chronic osteomyelitis and subcutaneously implanted syngeneic DLM8 
osteosarcoma cells [21].  Using this model, we found that localized bone infection could 
suppress tumor growth through sustained activation of innate immune responses.  These 
findings are important because they suggest that chronic, sustained, low level 




Materials and Methods 
 
Cell Lines 
The mouse osteosarcoma tumor cell line, DLM8, was generously provided by Dr. 
Eugenie Kleinerman (MD Anderson Cancer Center) and was maintained in C/10 
Dulbecco’s modified Eagle media [DMEM (Lonza, Walkersville, MD) supplemented 
with 1X MEM vitamin solution (Cellgro, Henderson, VA), 2 mM L-glutamine (Cellgro), 
1 mM sodium pyruvate (Cellgro), 1X non-essential amino acid solution (Cellgro), 1X 
antibiotic/antimycotic (Cellgro), and 10% heat inactivated fetal bovine serum (FBS, 
Atlas, Fort Collins, CO)].  The murine CT26 (colon carcinoma) and B16 (melanoma) cell 
lines were maintained in C/5/5 MEM media [MEM (Lonza) and supplemented as 
described above with 5% FBS and 5% heat inactivated newborn calf serum (Hyclone, 
Logan, UT)].  
 
Bacteria 
Staphylococcus aureus stably expressing both the luciferase and luciferin genes 
(XEN36) was purchased from Xenogen/Caliper Life Sciences (Hopkinton, MA).  
Pseudomonas aeruginosa engineered to stably express luciferase and luciferin was kindly 
provided by Dr. Herbert Schweizer (Colorado State University).  Bacteria were grown to 
log phase in LB Broth (USB Corporation, Cleveland, OH), then bacterial stocks were 






 All animal studies were performed in an AALAC-approved facility, with approval 
of the Colorado State University Institutional Animal Care and Use Committee.  Female 
mice 8-10 weeks of age were used for all experiments, and were purchased from Harlan 
Sprague Dawley (Indianapolis, IN).  C3H-HeN-Hsd mice were used for all experiments 
involving the DLM8 tumor cell line, BALB/c-Hsd mice were used for all studies 
involving the CT26 tumor cell line, and C57BL/6-Hsd mice were used for experiments 
involving the B16 tumor cell line.  Five mice per group were used for all in vivo 
experiments.   
 
Bacterial Osteomyelitis Model 
 Osteomyelitis was induced in mice, using a modification of a previously reported 
technique [22].  Briefly, bacteria were cultured in sterile LB broth at 37°C in a shaking 
incubator for 4-6 hours to log growth.  Bacteria were diluted to a concentration of 1x106 
CFU per mL in LB broth, and 3 mm segments of 3-0 braided silk suture (Syneture, 
Norwalk, CT) were incubated in the bacteria for 2 hours at 37°C on a shaking incubator.  
To induce biofilm formation on the suture material, suture segments were then 
transferred to sterile LB broth and incubated for an additional 36 hours in a shaking 
incubator, with the culture medium changed every 12 hours.  Control suture segments 
were prepared similarly, except without bacterial infection.   
 Mice were anesthetized using isoflurane (Minrad, Bethlehem, PA) for the 
procedure and the surgical site shaved and cleaned.  An incision was made over the 
proximal tibia, and a 25g needle (Becton Dickinson, Franklin Lakes, NJ) was used to drill 
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a perpendicular hole in the proximal tibia.  The hole was then enlarged through the use of 
a 23g needle (Becton Dickinson) to facilitate insertion of the suture segment.  Suture 
segments were placed into the medullary cavity of the tibia.  Mice receiving infected and 
sham treated suture material received buprenorphine (0.05 mg/kg) administered 
subcutaneously every 12 hours for 72 hours post-surgery. 
 
In Vivo Imaging of Infected Bone 
The bone site of infection was evaluated 2 to 3 times weekly to assess the 
intensity of bacterial infection by quantifying luciferase expression intensity.  Imaging 
was performed using an IVIS 100 imaging system and Living Image version 2.50.1 
software (Xenogen).  Mice were anesthetized with isoflurane and imaged.  A one minute 
exposure time with high sensitivity binning was used to enhance quantification of the 
infection.  The minimum intensity was set at 10% of the maximum, and a contour ROI 
plot with default parameters (ROI edge value of 5%) chosen to increase objectivity.  
Total flux of the ROI was recorded as photons/sec for each sample. 
   
Determination of Bacterial Burden in Tissues 
To determine whether bacterial infection had disseminated from the site of bone 
infection to other tissues, mice were sacrificed at the peak of bone infection, 10 days 
post-infection, and blood, spleen, liver, lung, infected tibia, opposite tibia, and tumor 
tissue were dissociated for determination of bacterial counts (colony forming units; 
CFU).  Tissues were subjected to collagenase digestion and trituration before serial 
dilutions of supernatants were plated on LB agar plates (Fisher, Fair Lawn, NJ) and 
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incubated overnight at 37°C.  Bacterial colonies were counted visually and CFU per 
organ were determined.  Plates were imaged using the IVIS system described above to 
identify luiferase-positive colonies and exclude contaminating organisms. 
 
Tumor Challenge and Growth Model 
 Three days after establishment of bone infection, mice were injected with 2x106 
DLM8 tumor cells subcutaneously (s.c.) on the contralateral flank to the bone infection.  
In other experiments, B16 and CT26 tumor cells were injected s.c. at a concentration of 
5x105 cells per mouse.  Mice were then imaged as previously described, and tumors 
measured two to three times a week using calipers.  Mice were tail bled weekly by lateral 
tail vein incision to assess changes in circulating cell populations by flow cytometry.  All 
mice were euthanized when the tumor of the first mouse in the control group reached a 
tumor diameter of 10 mm, except in survival experiments where each mouse was 
sacrificed when the individual tumor reached a size of 10 mm. 
 
NK Cell Depletion 
 NK depletion was performed by intraperitoneal (i.p.) injection of 50 μL rabbit 
anti-asialo GM1 antiserum (Wako Pure Chemical Industries, Inc., Osaka, Japan), as 
described previously [23].  Treatment was initiated three days post tumor challenge and 
continued weekly.  This treatment resulted in depletion of 73% of NKG2D+ cells in the 







 Monocytes and macrophages were depleted by intravenous (i.v.) injection of 
liposomal clodronate, as reported previously [24-27].  Liposomal clodronate was 
prepared as described previously [28].  Control liposomes were prepared similarly, 
except that phosphate-buffered saline (PBS) was used instead of clodronate.  Treatment 
with liposomal clodronate was initiated 3 days after tumor challenge and continued 
weekly.  The efficiency of monocyte depletion was assessed by flow cytometry; i.v. 
injection of liposomal clodronate was found to deplete 71% of circulating monocytes 
(Figure 2.11).  Injection of PBS liposomes did not deplete monocytes (Figure 2.11). 
 
Flow Cytometry 
 Leukocytes in the blood, tumor, spleen, and lymph node tissues were quantified 
using flow cytometry.  Blood was lysed in ACK lysis buffer (150 mM NH4Cl, 10 mM 
KHCO3, and 0.1 mM Na2EDTA) to remove red blood cells from analysis.  Cells were 
then washed in FACS buffer (1x PBS with 2% FBS and 0.1% sodium azide).  Tumors 
were prepared by collagenase digestion and the single cell suspensions were washed once 
in FACS buffer.  Spleen and lymph node samples were prepared by pushing sample 
through a 10 μm nylon cell strainer.  Spleen samples were then lysed with ACK lysis 
buffer while lymph node samples were not.  Spleen and lymph node samples were then 
washed in FACS buffer. 
 Single cell suspensions, at a concentration of 5x105 to 1x106 cells per well, were 
immunostained with the following antibodies:  anti-mouse CD3-APC-alexa fluor 750 
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(clone 17A2), anti-mouse NKG2D-APC (clone CX5), anti-mouse CD4-PB (clone RM4-
5), anti-mouse CD8-PE/Cy7 (clone 53-6.7), anti-mouse CD11b-biotin (clone M1/70), 
anti-mouse CD3-biotin (clone ebio500A2), anti-mouse CD31-FITC (clone 390), anti-
mouse CD11b-APC/Cy7 (clone M1/70), anti-mouse CD115-PE (clone AFS98), anti-
mouse F4/80-APC (clone BM8), and anti-mouse Gr-1-PE/Cy7 (clone RB6-8C5) were 
purchased from eBioscience (San Diego, CA); anti-human CD45-Pacific Orange (clone 
HI30) and nuclear stain (LDS-75) were purchased from Caltag/Invitrogen (Eugene, OR); 
and anti-mouse Ly6G-FITC (clone 1A8) and anti-mouse Ly6C (clone AL-21) were 
purchased from BD Pharmingen (San Jose, CA).  For biotinylated antibodies, streptavidin 
conjugates were used to provide flourophores for analysis (eBioscience and Invitrogen).   
 Neutrophils were defined as being Ly6G+CD11b+.  Monocytes were defined as 
being Ly6G-CD11b+CD115+Ly6C+ and were further subdivided into steady state 
(Ly6Clo) and inflammatory (Ly6Chi) monocytes.  Macrophages were defined as Ly6G-
CD11b+F4/80+.  NK cells were defined as CD3-CD4-CD8-NKG2D+.  Circulating 
endothelial cells were defined as CD45-CD11b-CD3-CD31+LDS-751+ events.  
Endothelial cells in tumor tissues were identified as CD45-CD11b-CD3-CD31+. 
Prior to immunostaining, cells were first blocked for non-specific staining using 
unlabelled anti-mouse Fcr III antibody (CD16/32; clone 93; eBioscience) diluted in 
normal mouse serum (Jackson Immunoresearch).  Immunostaining was performed at 
room temperature for 30 minutes, and then the samples were washed.  Spleen and lymph 
node samples were fixed in 1% paraformaldehyde prior to flow cytometric analysis; 
blood and tumor samples were not fixed but analyzed immediately.  Samples were 
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analyzed using a CyAn ADP flow cytometer (Beckman-Coulter, Fullerton, CA) and 
analysis performed using Summit software v4.3 (Beckman-Coulter). 
 
Immunohistochemistry 
 The following antibodies were used for immunohistochemistry: anti-mouse 
purified CD31 antibody (clone 390; eBioscience), anti-mouse purified CD68 antibody 
(clone FA-11; AbD Serotec, Raleigh, NC), biotinylated donkey anti-rat (Jackson 
ImmunoResearch).  Tumor tissues were embedded in OCT embedding medium (Sakura, 
Torrance, CA) and cryosectioned into 4 μm sections.  Slides were rehydrated, non-
specific binding blocked with appropriate serum, then incubated with appropriately 
diluted primary antibodies.  After washing, sections were incubated with appropriate 
biotinylated secondary antibody described above.  A Vectastain ABC kit (Vector) and 
subsequent AEC peroxidase substrate kit (Vector) were used according to manufacturer’s 
instructions.  Slides were then counterstained with hematoxylin and crystal mount 
(Biomeda, Foster City, CA) applied. 
Immunohistochemical staining was analyzed in a randomized and blinded 
fashion.  Microvessel density (MVD) was analyzed by manually counting the number of 
microvessels per 20X high power field, with five random fields counted per tumor 
section.  Macrophage density was determined using five random fields and Carl Zeiss 
AxioVision Software v4.6 (Zeiss, Thornwood, NY).  Computerized determination of 
positively staining cells was performed by blanking against sections stained with an 
irrelevant isotype control antibody.  The average number of vessels or macrophages per 




Assessment of Tumor Associated Macrophage Cytotoxicity 
 Tumor tissues from infected and control mice were removed and prepared by 
collagenase digestion.  Single cell suspensions were prepared in sort buffer (1x PBS with 
2% FBS) and TAM were immunostained using CD11b and F4/80, as described above.  
Cells were then sorted using a MoFlo Flow Cytometer (Beckman-Coulter).  The purity of 
the recovered cells was determined by flow cytometry to be 85%. 
 The sorted TAM were admixed with DLM8 tumor cells at macrophage to tumor 
ratios from 1:2 to 1:8.  The cells were incubated for 24 hours and cytotoxicity was 
assessed using an LDH release assay, according to manufacturer’s directions (Promega, 
Madison, WI).  As a positive control for macrophage cytotoxicity, thioglycolate-elicited 
peritoneal macrophages were used, following overnight activation with 20 ng/mL of 
recombinant murine IFNγ (Prepotech, Rocky Hill, NJ). 
 
Statistical Analysis 
Statistical analysis was performed using Prism 5 (GraphPad Software, La Jolla, 
CA).  Tumor growth experiments with two groups were compared using two-way 
repeated measures ANOVA, and those with three or more groups were analyzed using 
repeated measures one-way ANOVA and Bonferroni post-test.  For all tumor growth 
experiments, day zero was not included in the statistical analysis since this was the day of 
tumor challenge and no mice had measurable disease; this point is present for graphical 
depiction only.   Data from two groups were compared using a two-tailed Student’s t-test 
and data with three or more groups was compared using one-way ANOVA with 
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Bonferroni post-test.  Survival analysis, as described as time to a specific tumor diameter, 
was performed using Kaplan-Meier log-rank analysis.  Comparison of monocytes over 
time was performed using a two-way ANOVA with Bonferroni post-test.  For all 





Establishment of Mouse Model of Chronic Osteomyelitis 
 To study the effects of a localized bone infection on distant tumor growth, we first 
established a mouse model of chronic bacterial osteomyelitis, using a modification of an 
earlier protocol [22].  One of the primary modifications in our model was to establish 
bacterial biofilms on the suture prior to implantation in the marrow cavity of the tibia.  
This was done by prolonging the length of incubation in bacterial cultures, along with 
continuous shaking.  We found that biofilm sutures led to more reliable infections with 
greater sustained luciferase intensity over time than did sutures prepared using the 
original method (Figure 2.1).  We also observed a 4-fold increased mean infection 
intensity at the bone site in mice receiving biofilm infected suture, compared to mice 
implanted with non-biofilm suture at 49 days after suture implantation (Figure 2.1).   
 Luciferase expressing Staphylococcus aureus biofilms were established on 
silk suture and placed in the medullary cavity of C3H-HeN mice (n=5 per group).  
Following placement of the suture, the intensity of luciferase expression was determined 
in each infected mouse (Figure 2.2).  With this infection model, we observed that there 
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was a progressive increase in the intensity of bone infection, with the peak of infection 
developing 10 days post challenge (Figure 2.2).  The bone infection was also sustained, 
with live bacteria still detectable by luciferase imaging at the bone infection site over 50 
days post-challenge. 
 
We also determined whether the infection remained localized in the tibia or 
whether the Staphylococci became disseminated after bone infection; no signs of illness 
were noted during the infection.  By Xenogen imaging we did not detect a luciferase 
signal at any sites besides the bone inoculation site (Figure 2.2).  However, to increase 
the sensitivity of detection, we also performed quantitative cultures of various organs 
 
 
Figure 2.1: Biofilm suture provides a more robust infection than lyophilized suture.  
Biofilm and lyophilized suture segments were established as described in the 
Methods.  Sutures were implanted in C3H mice (n=5 per group) and serially imaged 
using the IVIS system described in the Methods.  Biofilm established osteomyelitis 
had a significantly (p<0.01) greater intensity over time as measured by repeated 
measures two-way ANOVA.  Data are representative of two independent experiments 
and mean (± SEM) are depicted. 
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from mice with infected limbs.  We did not detect bacterial colonization of any tissues 
other than the inoculated bone at any time during the infection studies.  Therefore, we 





Figure 2.2: Development of localized osteomyelitis in the mouse.  Mice (n=5 per 
group) were challenged with luciferase-transfected Staphylococcus biofilm-coated 
suture material introduced into the medullary cavity of the tibia, and imaged using a 
Xenogen In Vivo Imaging System to track the intensity and localization of the 
infection.  A) Time course analysis of infection intensity of osteomyelitis with means 
(± SEM) calculated.  B) Serial images of a representative mouse compared using a 




Tumor Growth is inhibited in Mice with Bacterial Osteomyelitis 
 To determine whether bacterial osteomyelitis could inhibit tumor growth, 
Staphylococcus aureus infected suture was placed in the tibia of C3H-HeN mice (n=5 per 
group).  Three days later, mice were injected with syngeneic DLM8 tumor cells on the 
contralateral rear flank.  Tumor growth was assessed every 2-3 days using calipers.  We 
found that mice with bacterial osteomyelitis had a significant decrease (p<0.02) in tumor 
growth compared to uninfected control mice (Figure 2.3).  However, in mice with tumors 
established 3 days before infection, we did not observe significant tumor growth 
inhibition (Figure 2.3).  Mice that were sham-infected with control suture did not have a 
significantly altered tumor growth compared to untreated mice with tumors only (Figure 
2.3).  In addition, survival times, using time to reach 10 mm as the event, were 
significantly increased (p<0.01) in mice with osteomyelitis compared to control mice 
(Figure 2.3).  These results indicated that localized bacterial infection significantly 
inhibited the growth of tumors at distant sites.  This finding was most consistent with the 
induction of a systemic antitumor response by the localized bone infection. 
 We next conducted experiments to determine whether the inhibition of tumor 
growth observed above was tumor type or mouse strain specific.  To address these 
questions, we assessed the effects of osteomyelitis on tumor growth using the CT26 
(colon carcinoma) model in BALB/c mice and the B16 (melanoma) model in C57BL/6 
mice.  In both of these models, we observed significant inhibition of tumor growth in 
animals with osteomyelitis compared to control animals (Figure 2.4).  Thus, we 
concluded that the tumor-inhibiting effects of localized osteomyelitis were not tumor type 




The preceding results indicated that chronic staphylococcal infection was capable 
of eliciting broad antitumor activity.  However, it was possible that the antitumor activity 
was specific to staphylococcal infection.  Therefore, osteomyelitis was induced in mice 
using Pseudomonas aeruginosa instead of Staphylococcus aureus and the effects on 
tumor growth were assessed.  As with the staphylococcal osteomyelitis model, we 
observed a significant (p<0.01) inhibition of tumor growth in mice infected with P. 
aeruginosa derived osteomyelitis (Figure 2.5).  These results suggested that inhibition of 
 
Figure 2.3: Osteomyelitis is associated with tumor growth inhibition.  Mice (n=5 per 
group) were infected with S. aureus containing biofilms three days before or after 
tumor implantation.  Growth kinetics were assessed by two-dimensional 
measurements and the longest diameter reported as the mean (± SEM) and statistically 
analyzed by repeated measures two-way ANOVA.  A) Mice receiving infections prior 
to tumor challenge with syngeneic DLM8 osteosarcoma cells have a significantly 
inhibited tumor growth (A, p<0.02; *p<0.001) and increased survival (B, p<0.01), as 
described as time for tumor to reach 10 mm longest diameter, compared to uninfected 
mice.  C)  Mice infected after tumor challenge did not have a significant growth 
inhibition (p>0.05).  D)  Mice challenged with a sham segment of suture did not have 
a significantly different (p>0.05) alteration in tumor growth compared to mice only 





tumor growth was not specific to staphylococcus, but could in fact be elicited by both 
gram-negative and gram-positive bacteria.  Furthermore, tumor growth inhibition was 
independent of the effects of bacterial lipopolysaccharide (LPS), since significant 
inhibition was observed following staphylococcal infection.  
 
Figure 2.4: Osteomyelitis inhibits tumor growth in multiple murine tumor models.  
Mice were infected with S. aureus containing biofilms three days before tumor 
challenge.  Growth kinetics were assessed by two-dimensional measurements and the 
longest diameter is reported as the mean (± SEM) calculated for each group.  A) 
Infected BALB/c mice (n=5 per group) challenged with syngeneic CT26 colon 
carcinoma cells have a significantly (p<0.001; *p<0.05) inhibited tumor growth 
compared to uninfected mice as assessed by repeated measures two-way ANOVA.  B) 
Infected C57BL/6 mice challenged with syngeneic B16 melanoma cells were followed 
as previously described.  Infected mice had a significantly (p<0.05; *p<0.05) inhibited 






Infection is Associated with Inhibition of Tumor Angiogenesis 
 Previous studies have shown that tumor angiogenesis was inhibited following 
infection with Toxoplasma gondii [29].  To determine whether localized bacterial 
osteomyelitis was capable of inhibiting tumor angiogenesis, we assessed tumor 
microvessel density (MVD) in tumors from infected and control mice.  Tumor sections 
from control and Staphylococcus infected mice (n=5 per group) were analyzed using 
CD31 immunohistochemistry (Figure 2.6).  We observed a significant decrease (p<0.01) 
in tumor MVD in infected mice compared to the uninfected mice.  A similar decrease in 
tumor CD31+ endothelial cells was also noted when collagenase-digested tumor tissues 
were analyzed by flow cytometry (data not shown).    
 
Figure 2.5: Osteomyelitis associated tumor growth inhibition is not pathogen specific.  
Pseudomonas aeruginosa biofilm-impregnated suture was implanted three days prior 
to challenge with DLM8 cells.  Tumor growth was assessed as previously described 
and is reported as mean ± SEM.  Infected mice had a significantly (p<0.01; *p<0.01) 
decreased tumor growth compared to uninfected mice as assessed by repeated 
measures two-way ANOVA. 
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 Recent studies indicate that tumor angiogenesis results from two independent 
processes; local sprouting of tumor vessels and the seeding of tumor tissues by 
circulating endothelial progenitor cells [30, 31].  Therefore, we used flow cytometry to 
assess the effects of osteomyelitis on circulating endothelial cells (CEC) in tumor-bearing 
mice.  Using multicolor flow cytometry, we evaluated CD45-CD11b-CD3-CD31+LDS-
751+ CEC in the blood of tumor bearing infected and control mice (Figure 2.6).  We 
found no significant difference (p>0.05) in CEC in infected mice with tumors compared 
to control mice with tumors.  These results suggested that the inhibition of angiogenesis 
elicited by localized osteomyelitis was not mediated by suppressing the number of CEC. 
 
Figure 2.6: Osteomyelitis inhibits tumor angiogenesis by a CEC independent 
mechanism.  A) Tumors from infected and uninfected mice were flash frozen in OCT 
and cut into 4 μm sections for CD31 immunohistochemistry.  Microvessel density was 
significantly (*p<0.01) decreased in the infected mice compared to the uninfected 
mice by t-test.  Results are representative of two independent experiments.  B) CECs 
were assessed by flow cytometry as described in the Methods.  The mean (± SEM) 
number of CEC per μL of blood was calculated and compared by one-way ANOVA 
with Bonferroni post-test.  CECs from infected-tumor-bearing mice were not 
significantly (p>0.05) different from those of tumor bearing mice.  An increase in 
CECs was observed in mice only challenged with infections (*p<0.05), but not 
significantly compared to tumor only or infected mice with tumors (p>0.05).   
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Suppression of Tumor Growth by Infection is Dependent in Part on NK Cells 
 Prior studies have shown that IFN-γ plays a prominent role in the control of tumor 
growth elicited by infectious agents [3, 4, 29, 32].  Since conventional NK cells are a 
major source of IFN-γ following bacterial and protozoal infection, we investigated the 
role that NK cells played in mediating tumor growth inhibition in the bacterial 
osteomyelitis model.  To address this question, we depleted NK cells in vivo using a 
depleting antibody (anti-asialo GM1), as previously reported [23].  Mice with chronic 
osteomyelitis were depleted of NK cells three days post injection of tumor cells and 
weekly thereafter.  This treatment resulted in 73% depletion of NKG2D+CD3- cells in the 
spleens of treated mice (Figure 2.7).  Tumor growth rates were compared to untreated 
mice with infection and uninfected tumor bearing mice (Figure 2.7).  NK cell depletion 
in infected mice with tumors led to a significant increase in tumor growth compared to 
untreated infected mice with tumors.  However, NK depletion did significantly alter the 
intensity of Staphyloccus infection at a single day (Figure 2.7).  Thus, NK depletion 
reversed the tumor inhibitory effects of chronic bone infection.  In contrast, NK depletion 
of uninfected mice did not significantly alter tumor growth (Figure 2.7).  These results 
indicated that NK cells were major mediators of the inhibition of tumor growth observed 
following bone infection.   
 
Chronic Osteomyelitis Increases Inflammatory Monocytes in Infected Mice 
 The preceding experiments indicated that chronic osteomyelitis activated innate 
immunity, as evidenced by the anti-tumor activity conferred by NK cells.  Therefore, we 




bearing mice.  Previous studies have reported conflicting results for the role of monocytes 
in tumor growth, suggesting that they may either suppress or promote tumor growth [33, 
34].  Therefore, we assessed the effects of bone infection on circulating steady state and 
inflammatory monocytes in the blood and spleen of mice [34-37].  Steady state 
monocytes were identified as Ly6G-CD11b+CD115+Ly6Clo, while inflammatory 
monocytes were identified as Ly6G-CD11b+CD115+Ly6Chi.  Inflammatory monocytes 
 
Figure 2.7: NK depletion reverses tumor growth inhibition conferred by osteomyelitis.  
Mice (n=5 per group) were challenged with infections and tumors as previously 
described.  Three days after tumor challenge, mice were treated with an anti-asialo 
GM1 antibody administered IP to deplete NK cells, and treatment was repeated 
weekly.  A) There was a significant decrease in NKG2D+ cells by flow cytometric 
analysis of spleens at sacrifice (p<0.05).  B) There was significant (*p<0.05) growth 
inhibition in the infected tumor bearing mice when compared to the uninfected mice 
and the NK-depleted infected mice as measure by repeated measures one-way 
ANOVA with Bonferroni post-test.  C) There was a significant difference in infection 
intensity between infected mice receiving the anti-asialo GM1 antibody and those not 
(p<0.05) at a single point as measured by repeated measures two-way ANOVA.  D) 
NK-depleted infected mice did not have a significantly (p>0.05) different tumor 




have been found to be more likely to differentiate into activated macrophages with an 
anti-tumor phenotype than steady state monocytes [38, 39].   
 Total monocytes were significantly (p<0.05) increased in the circulation of mice 
with osteomyelitis compared to uninfected mice (Figure 2.8).  The numbers of steady 
state monocytes in the blood were not increased, whereas there was a significant 
(p<0.001) increase in inflammatory monocytes in infected animals (Figure 2.8).  A 
significant (p<0.05) increase in the number of inflammatory monocytes in the spleen was 
also observed (Figure 2.8).  These data are most consistent with the idea that 
osteomyelitis induces an inflammatory response that results in the mobilization of 
circulating inflammatory monocytes.  This is important because these inflammatory 
monocytes may serve as a source of macrophages in tumor tissues. 
 
Tumor Associated Macrophages are increased in Mice with Chronic Osteomyelitis 
 Next, we examined numbers of tumor associated macrophages (TAM) and how 
chronic osteomyelitis affected their numbers.  Although TAM are generally thought to 
promote tumor growth, there are situations where activated TAM may suppress tumor 
growth [40-42].  We used both flow cytometry and immunohistochemistry to assess 
numbers of TAM in tumor tissues.  Mice (n=5 per group) with osteomyelitis had twice as 
many CD11b+F4/80+Gr-1- cells in tumor tissues as uninfected mice by multi-color flow 
cytometry (Figure 2.9).  By immunohistochemistry, there was a significant (p<0.02) 
increase in CD68+ TAM in mice with osteomyelitis compared to uninfected tumor-
bearing mice (Figure 2.9).  These findings suggested that accumulation of TAM in this 





Figure 2.8: Localized osteomyelitis induces monocytes in the blood and spleen.  Mice 
(n=5 per group) were challenged with S. aureus osteomyelitis and tumors as 
previously described.  A) Mice were tail bled on days 2, 9, and 17 post-tumor 
challenge.  Samples were processed and analyzed by multi-color flow cytometry as 
described in the Methods and means (± SEM) calculated for each group.  There were 
significant (***p<0.001, **p<0.01, *p<0.05) increases in total blood monocytes at the 
bracketed measures by two-way ANOVA with Bonferroni post-test.  B) Analyses 
from the day two bleed are further characterized showing a significant increase 
(***p<0.001) in Ly6Chi monocytes in infected mice with no difference (p>0.05) in 
Ly6Clo monocytes between groups.  C) Mice were euthanized on day 21 and spleens 
were analyzed by flow cytometry as described in the Methods.  There was a 
significant increase (*p<0.05) in the number of Ly6Chi monocytes present in the 
spleen measured by one-way ANOVA with Bonferroni post-test.  Results are 







Figure 2.9: Macrophages are induced in infected, tumor bearing mice.  Tumor-
bearing mice (n=5 per group) were sacrificed when the first control mouse reached a 
maximal tumor diameter of 10mm.  Tumors were removed and homogenized for 
analysis by flow cytometry or prepared for IHC as described in the Methods.  A) 
There was a significant increase (*p<0.05) in the number of CD11b+F4/80+ 
macrophages in the tumors of infected mice compared to uninfected mice.  B) There 
was a significant increase in the number of CD68+ cells per 20X high power field 
(hpf) in the tumor tissue of infected mice compared to the uninfected mice (*p<0.02).  
Results are representative of two independent experiments and two-tailed t-tests were 




Tumor Associated Macrophages Are Not Directly Cytolytic to Tumor Cells 
 To assess the cytotoxic capabilities of TAM, the TAM were sorted using flow 
cytometry from tumors of uninfected and infected mice (n=5 per group) and used in an in 
vitro cytotoxicity assay, with DLM8 tumor cells as targets.  We did not observe 
spontaneous cytotoxic activity from either population of TAM and there was no 
significant (p > 0.05) difference in cytotoxicity between the two groups of mice (Figure 
2.10).  As a positive control, we did note however that significant anti-tumor cytotoxic 
activity was exerted by IFN-γ stimulated peritoneal exudate macrophages (Figure 2.10).  
These results therefore indicate that infection induced cytotoxic activity of TAM was 
unlikely to account for the tumor growth inhibition observed in the infected mice with 
tumors.   
 
Monocyte and Macrophage Depletion Reverses Tumor Inhibition by Chronic 
Osteomyelitis 
 Finally, to specifically address the antitumor role of increased inflammatory 
monocytes and TAM in infected mice, we conducted monocyte/macrophage depletion 
experiments.  Depletion was accomplished by i.v. injection of liposomal clodronate (LC), 
which has been previously reported to efficiently deplete both monocytes and 
macrophages [24-26, 43].  Mice with established osteomyelitis and tumors were treated 
weekly with LC administered i.v.  Treatment with LC resulted in a 71% depletion of 






 We observed that treatment of infected mice (n=5 per group) with LC 
significantly increased tumor growth compared to tumors in infected mice not treated 
with LC (Figure 2.11).  Thus, monocyte/macrophage depletion by LC appeared to 
 
Figure 2.10: TAM from infected mice are not cytotoxic to tumor cells.  A) Mice were 
infected and challenged with tumors as previously described.  At sacrifice, tumors 
were digested and pooled within groups before TAM were sorted as described in the 
Methods.  Sorted TAM were mixed with DLM8 tumor cells at various ratios and 
analysis of LDH release was performed.  TAM from infected mice were not 
significantly (p>0.05) cytotoxic to tumor cells.  B) Thioglycolate elicted PEC 
activated with IFN-γ (20 mg/mL) were significantly (p<0.05) cytotoxic at identical 
ratios as that of TAM. 
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reverse the antitumor effects of bone infection.  In fact, tumor growth in infected mice 
treated with LC was similar to that of mice without infection.  As a control, we found that 
treatment of infected tumor-bearing mice with control PBS liposomes did not have a 
significant impact on tumor growth compared to untreated mice with infections (Figure 
2.11).  There was no significant alteration in infection intensity associated with LC 
treatment of infected mice (Figure 2.11).   
 These results suggested that monocytes and macrophages elicited by chronic bone 
infection were in fact responsible for a significant degree of tumor growth inhibition.  
However, in a number of tumor models, we and others have observed that treatment of 
uninfected tumor-bearing mice with LC significantly inhibits tumor growth (Guth, AM; 
manuscript in preparation, [44-46]).  Therefore, the results of LC depletion studies in our 
model suggested that substantial antitumor activity was elicited by activation of 





 The ability of bacterial infections to suppress tumor growth was noted over a 
century ago by Dr. William Coley and provided the basis for modern day immunotherapy 
[1].  However, the role that systemic inflammation elicited by chronic bacterial infection 
plays in controlling tumor growth has yet to be well defined.  Therefore, we developed a 
model of chronic bacterial osteomyelitis to investigate the reported ability of chronic 
bone infection to control the growth of osteosarcoma metastases in dogs and humans [18, 
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19].  Others have studied the role that localized tumor infection plays on tumor growth 
suppression; however, the role of systemic inflammation in mediating these tumor 




Figure 2.11: Monocyte depletion abolishes the inhibitory effects of osteomyelitis on 
tumor growth.  C3H mice (n=5 per groups) were infected and challenged with tumors 
as described in the methods.  Mice were administered liposomal clodronate (LC) or 
PBS control liposomes (PBS) IV 3 days after tumor challenge and then weekly 
thereafter.  A) Flow cytometry was performed to determine the number of monocytes 
in circulation as described in the Methods.  There was a significant (p<0.05) depletion 
of monocytes in the mice receiving LC compared to all other groups as determined by 
one-way ANOVA with Bonferroni post-test.  B) Infected mice had significantly 
decreased tumor growth (*p<0.05) when compared to uninfected mice and infected 
mice receiving LC by repeated measures one-way ANOVA with Bonferroni post-test.  
There was no statistical difference (p>0.05) between infected mice treated with LC 
and uninfected tumor bearing mice.  C) Infected mice receiving control PBS 
liposomes had a significant growth inhibition whereas uninfected mice did not.  D) 
Administration of PBS or clodronate liposomes did not have a significant (p>0.05) 




 In our infection model, we did not observe any bacterial dissemination from the 
site of infection, leading us to conclude that localized infection of the tumor tissues 
themselves did not occur.  We also noted significant tumor growth inhibition in 3 
different mouse strains, 3 different tumor types, and with 2 types of bacterial organisms, 
suggesting that the antitumor effect was non-specific and most likely due to systemic 
activation of innate immune responses.  However, significant growth inhibition was not 
observed when the tumor challenge preceded the infection.  This result might be 
explained by the rapid and aggressive growth of the tumor lines used in these studies and 
the amount of time required for infection to peak following initiation.  
A previous study has found that systemic infection with the protozoan 
Toxoplasma gondii was capable of inhibiting tumor angiogenesis [29].  In our studies, we 
observed tumor inhibition and decreased tumor microvessel density following the 
development of Staphylococcus osteomyelitis, the most prominent bacterial species 
identified in dogs developing osteomyelitis following limb salvage surgery [18].  To 
better understand the nature of the anti-angiogenic effects of bone infection, we 
investigated the impact of infection on CEC.   We observed that CEC were not decreased 
in tumor bearing mice with infections, leading us to conclude that CEC changes are not 
likely responsible for the inhibition of angiogenesis observed by conventional CD31 
staining of tumor tissues. 
 Previous studies have found that IFN-γ suppresses angiogenesis, and is 
responsible for inhibition of tumor growth in the presence of Toxoplasma infection [4, 
29, 32, 49, 50].  Since NK cells are the major innate immune source of IFN-γ production, 
we depleted NK cells to identify the role these cells play in tumor inhibition.  We found 
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that depletion of NK cells reversed the protection associated with infection, indicating 
that NK cells were critical for inhibition of tumor growth.  Others have shown that NK 
cell production of IFN-γ was the mechanism responsible for tumor growth control, rather 
than direct NK cell cytotoxicity [29].  We thus conclude that NK cells are important 
mediators of tumor growth control associated with osteomyelitis.   
 To better describe the systemic effects of infection, leukocyte changes in blood 
were assessed.  A significant increase in inflammatory monocytes was observed in both 
the blood and spleen of mice with osteomyelitis.  This result suggested a role for 
inflammatory monocytes in the inhibition of tumor growth, which the LC depletion 
studies confirmed.  However, we cannot exclude a role for other cell types depleted by 
LC treatment, including macrophages and dendritic cells.   
 The phenotypic plasticity of monocytes and their derivatives allows them to have 
both pro and anti-tumor phenotypes dependent on the stimuli present in the tumor 
microenvironment [40-42, 51].  We propose that increasing the number of inflammatory 
monocytes in circulation inhibits tumor growth by repopulating the tumor with activated 
TAM [24, 52, 53].  Thus, activated TAM are more likely to inhibit tumor growth than to 
stimulate.  Furthermore, we did not observe increased direct cytolysis of tumor cells by 
TAM sorted from tumors of infected mice, suggesting that tumor growth inhibition was 
likely mediated by other macrophage activities.  Other groups have shown that NK cells 
and monocytes can activate each other, thus leading to an activated state which may be 
responsible for tumor inhibition [54-56].   
 In conclusion, we have shown here that bacterial osteomyelitis induces significant 
non-specific tumor growth inhibition.  The tumor growth inhibition observed following 
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bone infection appeared to be mediated by NK cells, inflammatory monocytes, and TAM.  
Thus, systemic inflammation is a likely mechanism that explains the inhibition of tumor 
growth and metastasis observed in canine and human patients with osteosarcoma, and 
leads to the inhibition of metastasis and increased survival in this population.  It is also 
plausible that sustained low-level inflammation may be an important mediator of tumor 





 In this chapter we have explored the mechanism by which osteomyelitis can 
systemically inhibit tumor growth.  However, greater characterization of the 
monocyte/macrophage tumor infiltrate could be performed to greater understand the 
changes present in this environment.  I hypothesize that these macrophages will be found 
to have what is considered a classical, or M1 type activation.  We have shown that these 
macrophages are not cytotoxic, but were not able to further classify these cells.  
Preliminary experiments were performed to characterize these cells bys IHC, but the 
results of these tests were inconclusive.  It would be plausible to sort cells as was done in 
this chapter and try to characterize these cells using RT-PCR, microarray, or in vitro 
cytokine release by CBA assay.  These tests can investigate if the infiltrating 
macrophages have an anti-tumor disposition by being anti-angiogenic or 
immunostimulatory.  The PCR and microarray can be used to determine if changes in 
these specific cells take on these characteristics, while the CBA assay may provide 
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evidence for factors released by these cells that may inhibit tumor growth but are not 
directly cytotoxic.  These experiments will provide further description of the model and 
facilitate an understanding of the mechanism of action and provide information that may 
be duplicated in a therapeutic setting so as to illicit similar effects without an infectious 
agent. 
 The growth of literature concerning myeloid derived suppressor cells also 
provides ample evidence that these cells may have a modulatory effect in this model [57].  
We hypothesize that MDSC will be decreased in infected mice compared to untreated 
tumor bearing mice.  MDSC have been found to be increased in tumor bearing animals, 
and it is plausible that this effect may be reversed due to the systemic immune activation 
provided by the infection [57].  A decrease of MDSC may lead to decreased systemic and 
local immune inhibition and thus inhibited tumor growth.  Induction of osteomyelitis and 
determination of changes in circulating and resident MDSC (spleen) can be performed.  If 
differences are appreciated further characterization can be performed through cell sorting 
of these populations from the respective groups.  Sorting of these cells and in vitro 
characterization of elicited cytokines would be of importance.  Since MDSC are viewed 
as immature monocytes and neutrophils, it would be interesting to see if these cells 
preferentially differentiate based upon the presence of differing environment.  For 
example, MDSC may be sorted from a naïve mouse and placed in culture.  Serum from 
infected and non-infected tumor bearing mice could then be added to the isolated MDSC 
and characterization of the cells performed after incubation.  Differences in maturation 
and differentiation may suggest an in vivo mechanism that could then be investigated.  
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The importance of MDSC was not investigated in this chapter, but the interactions of 
these cells are plausible mediators for the inhibition of tumor growth observed. 
 This chapter primarily focused on the innate immune regulation afforded by the 
infection, and did not investigate the role of the adaptive immune system.  However, we 
hypothesize that T cells do not play a significant role in this model.  During this study, 
we did not observe differences in T cell numbers in the tumor itself or the tumor draining 
lymph node using flow cytometry and IHC; this does not speak to the activity of these 
cells, but only the relative number.  To test this hypothesis, nude mouse models could be 
used to better understand this phenomenon.  Infected and uninfected nude mice of an 
identical background could be compared to infected and uninfected wild-type immune 
competent mice.  If T cells play a role, then infected mice with tumors should have tumor 
growth similar to that of non-infected mice.  If this is the case, further description will 
need to be performed by selectively depleting CD4 and CD8 T-cells using antibody 
mediated depletion or genetically altered mice.  If T-cells are found to be involved, it 
would suggest that the infection could be a significant adjuvant in order to activate anti-
tumor T cells.  However, if T-cells are not found to play a role, it would suggest that the 
innate immune system and mechanism described herein is suitable to form an anti-tumor 
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Induction of VEGF by Tepoxalin Does Not Lead to Increased 




The purpose of this study was to determine the impact of the non-steroidal anti-
inflammatory drug tepoxalin on canine tumor cell growth and describe the changes 
associated with tepoxalin treatment.  In vitro experiments were performed to assess 
tepoxalin-associated alterations in tumor cell growth.  Vascular endothelial growth factor 
(VEGF) production and hypoxia-inducible factor-1α (HIF-1α) expression were studied 
in the presence of tepoxalin.  A canine osteosarcoma xenograft model was used to 
determine in vivo effects of tepoxalin on tumor growth and angiogenesis.  
Immunohistochemical analysis of the tumor infiltrate was performed to characterize 
changes in the tumor environment.  Normal dogs were administered tepoxalin to assess 
effects on systemic VEGF production.  Clinically achievable tepoxalin concentrations did 
not significantly alter tumor cell growth in vitro.  Tepoxalin dose-dependently increased 
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VEGF production in vitro through an increase in HIF-1α.  Despite increased VEGF in 
vitro, there was a significant growth delay associated with tepoxalin treatment of 
osteosarcoma xenografts.  Tepoxalin treated normal dogs had variable increases in 
circulating VEGF.  In conclusion, tepoxalin did not exacerbate tumor growth in a canine 
osteosarcoma xenograft, despite induction of VEGF in vitro by a HIF-1α dependent 






Cancer is one of the primary causes of death of companion animals.  The 
incidence of cancer in dogs increases with age, as do other illnesses such as osteoarthritis 
[1, 2].  Typically, older dogs may receive multiple medications, including non-steroidal 
anti-inflammatory drugs (NSAIDs).  The NSAID tepoxalin (Zubrin®, Schering-Plough 
Animal Health) is approved in dogs for the treatment of osteoarthritis. Tepoxalin acts 
through the dual inhibition of cyclooxygenase-1/2 (COX-1/COX-2) with inhibition of 5-
lipoxygenase (5-LOX) [3].  This multifocal block of leukotriene and prostanoid synthesis 
acts to inhibit inflammation and provide analgesia [3, 4].  Since many older dogs 
undergoing treatment for osteoarthritis are at risk for cancer, it was our goal to determine 
what the anti-inflammatory effects of tepoxalin were on tumor growth.    
Inflammation is a complex process encompassing a number of pathways and 
interactions, each of which varies based upon the local tissue environment, cytokine 
milieu, and infiltrating cells.  The cyclooxygenase (COX) enzymes, particularly COX-1 
and COX-2, are regulators of inflammation through the production of leukotrienes and 
prostaglandins which can promote inflammation [3].  The induction of COX-2 has been 
seen as a possible target for a range of diseases including Alzheimer’s disease, arthritis, 
and cancer [5-9].  Differential NSAID-associated side effects can occur due to the 
specific inhibition of COX-1 versus COX-2. [10, 11].  Leukotriene synthesis by 5-
lipoxygenase (5-LOX) has also been characterized as a potential target for cancer since 
the inhibition of inflammatory mediators and suppressed cellular proliferation can lead to 
tumor growth inhibition [12-14]. 
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Tepoxalin is an efficacious analgesic in dogs owing to its anti-inflammatory 
effects, and has a favorable gastrointestinal and renal toxicity profile when compared to 
other drugs [4, 15-20]. Tepoxalin’s anti-inflammatory activity is through non-selective 
inhibition of COX-1/COX-2 and 5-LOX activity leading to an inhibition of NF-κB 
activity via inhibited degradation of IκBα, resulting in a decrease in prostaglandin and 
leukotriene synthesis [5, 21].  Tepoxalin has also been observed to inhibit lymphocyte 
proliferation due to its ability to chelate iron, which may be the mechanism leading to the 
inhibition of NF-κB [22, 23].  It is this inhibition of NF-κB, in addition to its COX-1 and 
COX-2 inhibitory activity, which may promote tepoxalin as a unique anti-tumor 
compound. The pharmacologic inhibition of COX-2 may inhibit diverse oncogenic 
functions including proliferation, angiogenesis, inhibition of apoptosis, and immune 
suppression [14, 24].  These COX-2 dependent effects in combination with inhibition of 
NF-κB may lead to suppression of tumor growth. 
Folkman and others have described the necessity of functional vasculature as a 
requirement for tumor growth and progression [25-27].  The promotion of angiogenesis 
occurs due to the interactions of a variety of mediators, one of the most prominent and 
potent of which is vascular endothelial growth factor (VEGF) [28].  The production of 
VEGF is partially controlled by the transcription factor hypoxia inducible factor 1-alpha 
(HIF-1α), which is stabilized and thus more active in the presence of hypoxia [29, 30]. 
We show here that tepoxalin does not significantly alter canine tumor cell growth 
in vitro at clinically achievable concentrations.  However, tepoxalin’s unique structure, 
which allows it to chelate iron, leads to increased HIF-1α protein concentration and 
subsequent induction of VEGF in canine tumor cells and in normal dogs.  However, 
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tepoxalin inhibited tumor growth in a canine osteosarcoma xenograft suggesting that anti-
tumor effects not observed by in vitro growth inhibition dominate over potential pro-
tumorigenic effects from increased VEGF production. 
 
 
Materials and Methods 
 
Cell Lines and Drugs 
The canine cell lines utilized for these experiments are as follows: B cell 
lymphoma (1771), mast cell tumor (C2), melanoma (17CM98 and CML-6M), mammary 
carcinoma (CMT-12 and CMT-27), hemangiosarcoma (DEN-HSA and Fitz-HSA), 
bladder carcinoma (Bliley and K9TCC), and osteosarcoma (Abrams and D17).  The 
murine macrophage cell line AMJ was also used.  Cell lines were maintained in C/10 
[minimal essential medium (MEM) (Lonza, Walkersville, MD) supplemented with 1X 
MEM vitamin solution (Cellgro, Henderson, VA), 2 mM L-glutamine (Cellgro), 1 mM 
sodium pyruvate (Cellgro), 1X non-essential amino acid solution (Cellgro), 1X 
antibiotic/antimycotic (Cellgro), 5% heat inactivated fetal bovine serum (FBS) (Atlas, 
Fort Collins, CO), and 5% heat inactivated newborn calf serum (Hyclone, Logan, UT)].  
Once confluent, cells were washed with 1x phosphate-buffered saline and detached with 
0.25% trypsin (Cellgro) supplemented with 0.5 mM EDTA. 
Tepoxalin and its primary active metabolite, RWJ20142, were generously 




Cell Growth Inhibition 
Cell lines were plated in 96-well plates in C/10 at a density of 3,000 cells per well 
in triplicate and then incubated overnight at 37°C and 5% CO2.  Medium was aspirated 
and replaced with varying concentrations of tepoxalin and RWJ20142 spanning peak and 
trough plasma concentrations achievable in dogs following administration of 
pharmaceutical grade tepoxalin [31, 32]1.  For experiments evaluating the interactions of 
tepoxalin ± RWJ20142 and doxorubicin, all drugs were plated concurrently or 
doxorubicin was added 24 hours before or after treatment with tepoxalin ± RWJ20142.  
Doxorubicin was serially diluted by 4-fold dilutions in the presence of peak and trough 
concentrations of tepoxalin ± RWJ20142.  For drugs that could not be directly dissolved 
in media, they were first dissolved in dimethyl sulfoxide (DMSO, Sigma), and then 
dissolved in media.  For these experiments, DMSO at the highest concentration was used 
in the control wells.  Cells were then incubated at 37°C and 5% CO2 for 72 hours.  At the 
end of this incubation period, relative viable cell number was determined using a 
bioreductive colorimetric assay (CellTiter Blue, Promega, WI) according to manufacturer 
directions, and absorbance determined using a Synergy HT plate reader (Bio-TEK, 
Winooski, VT).  Relative viable cell number was then expressed as a percentage of 
control-treated cells.  Each experiment was repeated a minimum of three times and mean 
(± SEM) calculated. 
  
Western Blot Analysis 
Cells were grown to near confluence before being treated with clinically relevant 
peak (600 ng/mL) and trough (100 ng/mL) plasma concentrations of tepoxalin in C/10, 
                                                 
1 Further information available in package insert. 
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determined from prior pharmacokinetic experiments in normal dogs, or 100 μM 
desferrioxamine (DFO; Sigma-Aldrich, St. Louis, MO) as a positive control.  Cells were 
incubated for 12 hours followed by whole cell lysis using an SDS based lysis buffer; 2% 
SDS combined with 1 complete mini tab protease inhibitor (Roche, Indianapolis, IN), 1 
mM sodium orthovanadate, and 1 mM PMSF in 7 mL of M-PER (Thermo Scientific, 
Rockford, IL).  Protein quantification was performed using a CBA kit (Thermo 
Scientific) with a NanoDrop 1000 microspectrophotometer (Thermo Scientific).  Equal 
amounts of protein were loaded on a 10% TBE gel (Invitrogen, Eugene, OR) and 
electrophoresed in 1x MOPS/SDS running buffer (Teknova, Hollister, CA) for 1.25 hours 
at 100 mA.  Bands were then transferred to a PVDF membrane by electrophoresis at 170 
mA for 1 hour followed by 115 mA for 15 minutes. Blocking was performed using 5% 
instant milk in TBST (Tris-buffered saline, 1.37 M NaCl, 0.2 M Tris-base, and 8.96 mM 
Tween 20 in DI water) for one hour.  Primary antibodies used were a rabbit polyclonal 
antibody to HIF-1α (Novus Biologicals, Littleton, CO) at a dilution of 1:500, and a rabbit 
polyclonal anti-β-actin (AbCam, Cottonwood, AZ) at a dilution of 1:2000.  Primary 
antibodies were incubated overnight at 4°C.  The membrane was rinsed in 1x TBST three 
times.  A goat anti-rabbit secondary antibody (Thermo Scientific) was used against both 
primaries at a 1:1000 dilution, and incubated at room temperature for two hours.  
Detection was accomplished by exposing the membrane to ECL reagent (SuperSignal 
West Pico, Thermo Scientific) and development using radiographic film (Kodak, 





In Vitro VEGF Production 
Cells were plated in C/10 at a concentration of 250,000 per well in a 6-well plate 
and allowed to incubate overnight at 37°C and 5% CO2. The supernatants were removed, 
and the cells treated with 100 or 600 ng/mL of tepoxalin in complete MEM with 0.1% 
FBS; cells were then incubated overnight.  Supernatants were then collected from each of 
the treatment wells and stored at -20°C until measurement of VEGF using a canine-
specific ELISA (R&D systems, Minneapolis, MN).  
 
Pharmacokinetic Analysis 
All animal studies were performed in an AALAC-approved facility, with approval 
of the Colorado State University Institutional Animal Care and Use Committee.  6-8 
week old nu/nu mice were obtained from the National Cancer Institute (Bethesda, MD).  
After a 1-week acclimation period, tepoxalin was administered via oral gavage or 
subcutaneous injection at 40 mg/kg, and non-tumor bearing mice were terminally bled at 
specified time points following administration.  Plasma was prepared for LC/MS/MS, 
and analyzed similarly to Burinsky et al. with minor changes [33].  Briefly, 5 ng of 
internal standard (trazadone) was added to mouse plasma.  Tepoxalin and the active 
metabolite were isolated via organic extraction by the addition of 2 mL ethyl acetate.  
Samples were vortexed, centrifuged (3200 RCF for 10 min), and the organic layer 
collected and evaporated to dryness.  The samples were then reconstituted in 60% of 10 
mM ammonium acetate with 0.1% AcOH: 40% tetrahydrofuran (THF), transferred to 
HPLC vials and analyzed with an ABI-3200 triple quadrapole mass spectrometer 
(Applied Biosystems, Foster City, CA) with a TurboIonSpray source interfaced to an 
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Agilent 1200 Series Binary Pump SL (Agilent Technologies, Waldbronn, Germany). 
Samples were chromatographed using a 100 Å Phenomenex Luna C18 5 µm, 2 X 50 mm 
column maintained at 40°C with gradient elution at a flow rate of 200 µL/min as follows: 
40% THF for 0.5 min; a linear increase to 70% THF from 0.5 to 6 min; THF held at 70% 
for 0.5 min; linearly adjusted from 70% to 40% from 6.5 min to 7 min; with a final 
equilibration at 40% THF for 1 min.  Samples were quantified by internal standard 
reference in multiple reactions monitoring mode by monitoring the transitions m/z 386.0 
→ 339.0 for tepoxalin, 357.0 → 339.0 for RWJ20142 and 372.0 → 176.0 for the internal 
standard (trazodone). 
 
In Vivo Tumor Growth 
To determine the effects of tepoxalin on in vivo tumor growth, 6-8 week nu/nu 
mice (National Cancer Institute) were injected with Abrams osteosarcoma (OSA) cells 
(2x106) subcutaneously in the rear flank.  Three days post-tumor challenge, mice (n=5 
mice per group) were randomized to 1 of 3 treatment groups: tepoxalin dissolved in 
DMSO at a dose of 20 mg/kg subcutaneously, administered five consecutive days per 
week followed by a two-day drug holiday, continuously throughout the study; DMSO 
vehicle administered similarly; or no treatment.  Bi-dimensional tumor measurements 
were obtained at least twice weekly using calipers.  Tumor volume was calculated using 
the formula V = (S2∙L)/2, where 'L' is the longest dimension measured and 'S' is the 
perpendicular measurement.  Mice were sacrificed when the first mouse in the control 
group reached a maximal tumor diameter of 15 mm.  Throughout this time, peripheral 
blood was obtained via the lateral tail vein weekly to assess changes in neutrophils, 
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monocytes, and circulating endothelial cells (CEC).  Plasma was prepared from blood 
and VEGF concentration was measured using murine and canine VEGF ELISAs (R&D 
Systems).  At the time of sacrifice, tumors were placed into OCT embedding matrix 
(Sakura, Torrance, CA) for immunohistochemical analysis.  Terminal phlebotomy was 
performed and spleens were processed for analysis by flow cytometry. 
 
Flow Cytometry 
Flow cytometry of peripheral blood was performed by lysis of blood using ACK 
lysis buffer (150 mM NH4Cl, 10 mM KHCO3, and 0.1 mM Na2EDTA in 1x PBS).  Cells 
were then stained with primary antibodies in two panels to determine changes in CEC 
(CD31, CD45, and LDS-751, a nuclear stain) and neutrophils/monocytes (CD11b, 
CD115, F4/80, Ly6G, and Ly6C).  CD31-FITC, CD45-PE, CD11b-PB, CD115-PE, and 
F4/80-APC were purchased from eBioscience (San Diego, CA).  LDS-751 was purchased 
from Invitrogen.  Ly6G-FITC and Ly6C-biot were purchased from BD Pharmingen (San 
Jose, CA).  All primary antibodies were used at a 1:200 dilution from stock, and 
incubated with cells for 30 minutes at room temperature.  A streptavidin-PE/Cy7 
(eBioscience) was used to label the biotinylated antibody and was used at a 1:500 
dilution.  Relevant streptavidin conjugates were used to set instrument settings.  Samples 
were processed using a CyAn MLE flow cytometer (Dako-cytomation, Fort Collins, CO) 







Samples (n=5 per group) stored in OCT embedding media were cut into 4 μm 
sections and placed on glass slides.  Slides were air dried at room temperature before 
being fixed in acetone at -20°C and subsequently stored at -80°C prior to staining.  
Microvessel density assessment was performed by using a purified anti-mouse CD31 
antibody (eBioscience) at a 1:100 dilution.  To assess changes in infiltrating 
macrophages, a purified anti-mouse CD68 antibody (AbD Serotec, Raleigh, NC) was 
used.  To detect primary antibodies, immunostaining with a biotinylated donkey anti-rat 
(Jackson ImmunoResearch) was used at a 1:400 dilution.  Further detection was 
accomplished by use of a Vectastain ABC kit (Vector, PK-6100) and AEC peroxidase 
substrate (Vector, SK-4200).  Slides were then counterstained with hematoxylin and 
mounted with crystal mount (Biomeda, Foster City, CA).  Assessment of MVD was 
performed by manually counting the number microvessels per 20x high power field.  
Macrophage numbers were calculated using a Zeiss Axio 2 microscope and Carl Zeiss 
AxioVision Software v4.6 (Zeiss, Thornwood, NY).  Samples were blinded and 
randomized for both of these analyses.  Computerized determination of positively 
staining cells was performed using an isotype control antibody and characterizing 
positively staining cells in the formation of a protocol that was then applied to all of the 
slides.  Five random sections from each tumor were evaluated, and the average number of 






VEGF Induction in Normal Dogs 
Clinically normal dogs owned by faculty and staff of various ages and breeds 
were given commercial tepoxalin tablets at a dose of 10 mg/kg/day for seven days.  
EDTA-anti-coagulated blood was collected from each dog at 4 hours, 24 hours, and 7 
days post initial treatment.  Plasma was isolated from each sample and stored at -20°C 
until analysis using the anti-canine VEGF ELISA as described above.  All normal dog 
studies were performed with CSU-IACUC approval and informed consent. 
 
Statistical Analysis 
Statistical analysis was performed by using GraphPad Prism 5 (GraphPad 
Software, La Jolla, CA).  Results are representative of the mean (± SEM) calculated for 
each group.  Analysis was performed by using repeated measures one-way ANOVA in 
concordance with Tukey’s HSD post-test, one-way ANOVA with Tukey’s HSD post-test, 





Growth Inhibition by Tepoxalin and its Active Metabolite (RWJ20142) 
Given tepoxalin’s unique inhibition of NF-κB and pan-COX/LOX inhibition, we 
sought to determine the effect of clinically achievable concentrations of tepoxalin and its 
major active metabolite on the growth of canine tumor cell lines in vitro.  Twelve canine 
tumor cell lines of seven distinct histotypes were used to better understand the effects of 
150 
 
tepoxalin on a variety of tumor cell lines.  The AMJ cell line was utilized to determine 
the growth inhibitory effects of tepoxalin on murine macrophages, which can be a large 
component of tumor stroma [34].  RWJ20142 was used at 5x the given tepoxalin 
concentration to mimic pharmacokinetic relationships observed in tepoxalin-treated dogs 
[31].  Figure 3.1 depicts the relative viable cell number of all cell lines treated with 
tepoxalin, and a combination of tepoxalin with RWJ20142.  It was determined that 
tepoxalin ± RWJ20142 did not cause significant growth inhibition in canine tumor cell 
lines over the range of clinically achievable concentrations, from 100 to 600 ng/mL.  
Furthermore, only one of the cell lines, CML-6M, reached an IC50 at the maximum 
concentration of tepoxalin tested (6,400 ng/mL) (Figure 3.1).  When RWJ20142 was 
added, CML-6M, CMT12, K9TCC, Abrams, and D17 reached an IC50 at the highest dose 
(6,400 ng/mL of tepoxalin and 32,000 ng/mL of RWJ20142).  However, it is noteworthy 
that any IC50 reached only occurred at doses over ten times higher than the maximum 
plasma concentration achievable in the dog.  Given the frequency with which OSA 
occurs in dogs and the common use of NSAIDs as part of its therapy, we chose to better 
characterize the effects of tepoxalin on an OSA cell line. 
 
Synergism of Tepoxalin and Doxorubicin 
To determine if tepoxalin may reverse the cytotoxic effects of a commonly used 
cytotoxic drug, doxorubicin, in vitro cellular viability tests were performed with three 
representative cell lines (DEN-HSA, D17, and K9TCC).  Tepoxalin was used at its peak 
(T 600; 600 ng/mL) and trough (T 100; 100 ng/mL) concentrations and RWJ20142 was 
used at its peak (RWJ 1000; 1000 ng/mL) and trough (RWJ 500; 500 ng/mL) 
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concentrations.  Concentrations of tepoxalin and RWJ20142 were held constant and a 
doxorubicin was diluted serially by 4-fold dilutions (30,000 – 29.3 ng/mL).  Figure 3.2 
depicts the viable number of cells after 72-hour incubation with both compounds 
simultaneously.  There was no significant (p>0.05) difference in viability due to the 
presence of tepoxalin ± RWJ20142.  To determine if the timing of doxorubicin 
administration may play a role in altering cell viability, doxorubicin was incubated with 
cells for 24 hours before or after treatment with tepoxalin ± RWJ20142 before being 
washed out and tepoxalin ± RWJ20142 replaced as applicable.  There was no significant 
 
Figure 3.1: Growth of tumor cell lines treated with tepoxalin and RWJ20142.  Tumor 
cell lines [A: B-cell lymphoma (1771), mast cell tumor (C2), melanoma (17CM98 and 
CML-6M), and hemangiosarcoma (DEN-HSA and Fitz-HSA); B: mammary 
carcinoma (CMT12 and CMT27), bladder carcinoma (Bliley and K9TCC), and 
osteosarcoma (Abrams and D17)] were treated with a range of tepoxalin ± RWJ20142 
concentrations spanning the clinically achievable range of the drug for 72 hours.  
Analysis was performed by bioreductive colorimetric assay to determine relative 
viable cell number, and cell number expressed as a percentage of vehicle-treated cells 





(p>0.05) change in viability when the timing of doxorubicin administration was altered 
(data not shown).  Since there was no significant protection provided by tepoxalin ± 
RWJ20142 in vitro in the presence of a commonly used cytotoxic compound, we chose to 





Figure 3.2:  Growth of tumor cells treated with doxorubicin in the presence of 
tepoxalin and RWJ20142.  Tumor cell lines [A) D17-Osteosarcoma; B) DEN-HSA-
Hemangiosarcoma; and C) K9TCC-Transitional Cell Carcinoma] were treated with a 
range of doxorubicin concentrations in the presence of peak and trough concentrations 
of tepoxalin (T) and RWJ20142 (RWJ).  Analysis was performed by bioreductive 
colorimetric assay to determine relative viable cell number, and cell number expressed 
as a percentage of vehicle-treated cells.  There was no significant (p>0.05) growth 
inhibition potentiated by the addition of doxorubicin as measured by one-way 
ANOVA and Tukey’s HSD post-test. Results shown are the mean (± SEM) and a 




Induction of HIF-1α by Tepoxalin 
Owing to reports showing that tepoxalin can act as an iron chelator and the 
demonstrated ability of other iron-chelating agents such as desferrioxamine (DFO) to 
stabilize HIF-1α [22, 35], we sought to determine if clinically achievable tepoxalin 
concentrations were capable of increasing HIF-1α concentrations in canine OSA cells in 
vitro.  Tumor cells were exposed to tepoxalin concentrations corresponding to peak (600 
ng/mL) and trough (100 ng/mL) plasma concentrations observed in dogs before 
undergoing whole cell lysis and western analysis for HIF-1α.  Desferrioxamine was used 
as a positive control [35].  Figure 3.3 demonstrates an increase in HIF-1α by 600 ng/mL 
tepoxalin treatment.  Increased HIF-1α concentrations by physiologic processes, such as 
hypoxia, have been shown to alter a number of cellular processes, such as the production 





Figure 3.3: Effect of tepoxalin on HIF-1α induction.  Abrams osteosarcoma cells were 
treated with peak (T-600) and trough (T-100) concentrations of tepoxalin for 12 hours 
before whole cell lysis.  DFO served as a positive control for inducing HIF-1α.  
Western blot was used to detect HIF-1α and β-actin was used as a loading control. 
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In Vitro Induction of VEGF by Tepoxalin 
Induction of HIF-1α is known to induce VEGF in order to stimulate angiogenesis 
in hypoxic tissues. Abrams cells were treated with peak and trough plasma concentrations 
of tepoxalin followed by determination of supernatant VEGF concentrations.  Figure 3.4 
shows dose-dependent induction of VEGF from Abrams OSA cells by tepoxalin.  Since 
VEGF is normally produced by tumors to stimulate angiogenesis, potentially enhancing 
primary tumor growth and metastasis in vivo, we sought to determine the in vivo effects 
of tepoxalin on canine OSA tumor growth. 
 
Pharmacokinetic Analysis of Tepoxalin in Mice 
Pharmacokinetic experiments were performed to ensure that mice were exposed 
to clinically relevant concentrations of tepoxalin.  Mice were first treated with 40 mg/kg 
of tepoxalin by oral gavage to determine plasma levels of drug.  However, analysis 
showed that the peak tepoxalin concentration in mice was 0.71% of that observed in dogs 
 
Figure 3.4: In Vitro VEGF induction following tepoxalin treatment.  Abrams cells 
were incubated with peak and trough concentrations of tepoxalin overnight prior to 
determination of VEGF concentration by ELISA.  A significant (p=0.0268) increase 




(Figure 3.5), with significantly increased concentrations of RWJ20142.  We concluded 
that the rapid metabolism was occurring through first pass of the liver, leading to higher 
concentrations of the major metabolite in circulation rather than the parent drug, 
compared to those observed in dogs. 
To bypass first-pass hepatic metabolism, tepoxalin was administered 
subcutaneously at 40 mg/kg to determine if the dose and route of administration would 
better approximate the dog pharmacokinetics.  Peak tepoxalin concentrations in plasma 
(Figure 3.5) were approximately twice that observed in dogs.  Due to the linear and dose-
proportional pharmacokinetics of tepoxalin, we determined that 20 mg/kg would be 
sufficient to achieve peak tepoxalin concentrations approximating 600 ng/mL in mice. 
 
Figure 3.5: Pharmacokinetic analysis of tepoxalin in mice.  A) Non-tumor bearing 
mice were administered 20 mg/kg of tepoxalin dissolved in DMSO by oral gavage.  
Mice were sacrificed and terminally bled at various time points to determine the 
concentrations of tepoxalin and RWJ20142.  Due to the high levels of primary 
metabolite present and low levels of tepoxalin, it was concluded that first pass hepatic 
metabolism was rapidly degrading tepoxalin.  B) A second group of mice was then 
administered 40 mg/kg of tepoxalin dissolved in DMSO subcutaneously.  Due to the 
linear and dose-proportional pharmacokinetics of tepoxalin, we determined that 20 





In Vivo Effects of Tepoxalin on Canine Osteosarcoma-Bearing Mice 
Due to an absence of growth inhibitory effects and the stimulation of VEGF 
production in vitro by tepoxalin, we sought to determine if tepoxalin treatment would 
result in an increase in tumor growth in vivo by stimulating angiogenesis.  Athymic mice 
were challenged with Abrams canine OSA cells subcutaneously on the rear flank.  Three 
days post-tumor challenge, mice began receiving tepoxalin or DMSO vehicle 
subcutaneously at a site distant from the tumor at a dose of 20 mg/kg.  Mice were injected 
for five days and given two days as drug holidays, repeated weekly until sacrifice.  
Surprisingly, tumor growth was significantly decreased in mice receiving tepoxalin 
compared to all other groups, with no significant difference between vehicle-treated and 
untreated mice (Figure 3.6).  This suggests that, despite potential VEGF induction and a 
lack of growth inhibition in vitro, other mechanisms, potentially associated with 
modulation of the tumor microenvironment, contributed to tepoxalin’s observed growth 
inhibitory effects. 
Flow cytometry was performed on serially collected peripheral blood of treated 
mice to determine changes in circulating blood populations to better understand the 
inhibition of tumor growth by tepoxalin.  No changes in neutrophils, monocytes, or CEC 
were noted in these experiments (Figure 3.7).  Analysis of spleens at sacrifice showed no 
significant difference in neutrophils and monocytes (Figure 3.7).  Interestingly, there was 
also no significant increase in canine or murine plasma VEGF concentrations between the 
treatment groups (Figure 3.6); normalization by tumor volume did not alter these results 
(Figure 3.6).  The lack of systemic changes suggest that there was a mechanism present 
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in the tumor microenvironment leading to decreased tumor growth and inhibition of 
VEGF production that is contrary to the in vitro data and likely due to the presence of 
stromal components. 
 
Immunohistochemical Analysis of the Tumor Environment 
Immunohistochemistry was performed to determine if changes were induced in 
the tumor microenvironment following tepoxalin administration.  Mice were challenged 
with Abrams OSA cells and administered tepoxalin as described above.  All mice were 
euthanized when the first control mouse had a greatest tumor diameter of 15 mm to 
facilitate comparison between groups.  Microvessel density (MVD) was assessed by 
 
Figure 3.6: In vivo effects of tepoxalin on tumor growth and plasma VEGF.  Mice 
were challenged with Abrams osteosarcoma subcutaneously and treated with 
tepoxalin (20 mg/kg) or vehicle beginning three days post tumor challenge.  A) 
Growth kinetic measurements were performed using longest tumor diameter.  Growth 
curves where concluded once the first control mouse was sacrificed.  B) Plasma 
prepared from blood on day 24 was analyzed by ELISA for murine VEGF.  C) 
Volume was determined from tumor measurements and VEGF concentrations were 




CD31 immunostaining and manual counting of the vessels present (Figure 3.8).  There 
was no significant difference between the groups, suggesting that an increase in 
angiogenesis did not occur in the tepoxalin treated group.  Sections were also 
immunostained to determine changes in macrophage infiltrate by immunostaining with 
CD68 and computer aided analysis; no significant difference was observed (Figure 3.8). 
 
Tepoxalin Treatment of Normal Dogs to Assess Systemic Changes in VEGF 
Five clinically normal dogs were treated with 10 mg/kg/day of tepoxalin daily to 
determine if changes in plasma VEGF occurred.  There was a significant increase in 
plasma VEGF in three of five dogs at a single time point following tepoxalin 
administration when compared to pre-treatment concentrations.  However, there was no 
Figure 3.7: Flow cytometric analysis of tepoxalin’s effect on innate immune 
populations.  Mice were challenged with Abrams osteosarcoma subcutaneously and 
treated with tepoxalin (20 mg/kg) or vehicle control initiated three days after tumor 
challenge.  Mice were sacrificed when the first mouse reached a maximal tumor 
diameter of 15 mm.  Mice were terminally bled (A) and spleens (B) prepared as 
described in the Methods.  Flow cytometric analysis of monocytes, neutrophils, and 
CEC in the blood revealed that neither vehicle control nor tepoxalin significantly 
altered either of these populations.  Results are representative of two independent 
experiments and mean ±SEM are shown. 
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significant increase in plasma VEGF concentrations when the dogs were grouped for 
analysis (Figure 3.9).  The VEGF concentrations remained high while the dogs were 




Figure 3.8: Immunohistochemical characterization of the tumor environment.  Tumor 
sections were cryosectioned and immunostained for CD31 and CD68 to determine 
changes in microvessel density (A) and macrophages (B), respectively.  Five random 
fields were selected from each tumor, and these values averaged before comparison 
between groups of mice.  No significant difference was observed (p > 0.05). 
Figure 3.9: Induction of VEGF in normal dogs treated with tepoxalin.  Normal dogs 
were administered tepoxalin orally at a dose of 10 mg/kg/day for seven days.  Plasma 
VEGF was measured by ELISA.  Three of five dogs had a significant individual 
increase in VEGF at single time point post treatment, although there is no overall 





Due to the age related increase in cancer incidence, many animals with cancer 
may have a variety of chronic medical conditions requiring treatment.  A better 
understanding of potential effects of these non-oncologic medications is needed.  Thus, it 
was our goal to understand how an anti-inflammatory drug, tepoxalin, used in the 
management of osteoarthritis, would impact canine tumor growth.  A number of studies 
have suggested that NSAIDs and specific COX-2 inhibitors may inhibit tumor growth 
and metastasis in various mouse models [37-39] and in dogs with cancer [9, 40, 41]. 
Treatment with COX inhibitors may lead to decreased cancer risk in some human 
populations as well [42, 43].  New evidence suggests combination of COX and LOX 
inhibitors may be more efficacious against tumors than single agent therapy, and 
tepoxalin is a dual inhibitor of these enzymes [44, 45]. 
We observed that clinically achievable concentrations of tepoxalin, ± its major 
active metabolite RWJ20142, do not exert an anti-proliferative effect against canine 
tumor cells in vitro at clinically achievable concentrations.  Furthermore, treatment with 
doxorubicin, a common cytotoxic therapy for OSA, in the presence of tepoxalin ± 
RWJ20142 does not alter viability at therapeutic concentrations.  However, tepoxalin 
dose-dependently increased the concentration of HIF-1α in canine OSA cells, leading to a 
dose-dependent stimulation of VEGF production.  Increased VEGF production has been 
associated with a more aggressive tumor phenotype due to its initiation and activation of 
angiogenesis, and higher pre-treatment systemic VEGF concentrations have been 
associated with an inferior outcome in dogs and humans with OSA [46-48].  We believe 
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that tepoxalin’s effect on VEGF production is unique, owing to its ability to chelate iron, 
simulating a hypoxic phenotype in the tumor cells.  Modulation of HIF-1α has also been 
shown to modulate a number of genes besides VEGF, although a majority of these genes 
modulate the metabolism and activity of cells in a pro-tumorigenic manner [49].  
Furthermore, new evidence suggests that other NSAIDs can be used to inhibit the 
stabilization of HIF-1α, thus decreasing tumor cell adaptation to hypoxic environments 
[50].  Crokart et al. have used this information to show that NSAIDs can increase the 
oxygenation of tumors, and may act as powerful radiation sensitizers [51].  Given the 
absence of in vitro growth inhibition of canine tumors and significant stimulation of 
VEGF production by tepoxalin, we sought to determine if tepoxalin treatment would lead 
to the formation of a more aggressive tumor and increased angiogenesis due to the 
promotion of VEGF production in canine OSA tumors in vivo. 
 In vivo evaluation was performed to determine how treatment with tepoxalin 
would alter tumor growth in Abrams OSA subcutaneous xenografts.  Extensive effort 
was placed on attempting to achieve similar drug exposure in mice when compared to 
dogs dosed with tepoxalin, given the dose-dependent changes observed in vitro.  
Clinically relevant mouse dosing strengthens the relevance of the in vivo model and its 
conclusions, due to equivalent drug exposure in the experimental model and the clinical 
situation.  Surprisingly, mice receiving tepoxalin had a significantly slower tumor growth 
compared to control and vehicle treated mice, suggesting that tepoxalin was able to 
inhibit tumor growth despite the pro-tumorigenic effects of induced VEGF.  However, 
this effect is of questionable clinical significance, since mice still displayed progressive 
disease.  There were no observed changes to circulating populations of monocytes, 
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neutrophils or CEC following tepoxalin treatment.  It has been shown that tepoxalin 
inhibits extravasation of monocytes, but we did not note any significant changes in these 
populations [52-54].  Circulating endothelial cells were measured due to the induction of 
VEGF observed in vitro, which can lead to CEC outgrowth from the bone marrow and 
promotion of tumor angiogenesis [55, 56]. However, there was also no significant 
difference in plasma VEGF concentration between treatment groups.  These data suggest 
that tepoxalin-associated tumor growth inhibition is likely due to stromal interactions that 
were absent in the in vitro experiments.   
Due to the lack of changes identified in circulating cell populations, we sought to 
explain the decreased tumor growth by performing immunohistochemistry on tumor 
sections to characterize the tumor microenvironment.  Nevertheless, we were unable to 
detect a significant difference in microvessel density or the number of tumor associated 
macrophages.  Increasing evidence suggests that anti-tumor activity may be associated 
with the polarization of macrophages to a tumor suppressive phenotype rather than a 
change in their overall numbers [57, 58].  This effect is independent of T cells since our 
experiments were carried out in athymic mice. 
 To characterize the response of clinically normal dogs to tepoxalin, dogs were 
administered tepoxalin for one week and plasma collected for determination of VEGF 
concentration.  A variable increase in VEGF was observed, with 3 of 5 dogs 
demonstrating a significant increase in systemic VEGF at a single time point tested.  
However, on average, there was no significant increase in systemic VEGF over the 
course of treatment.  It is plausible that in a clinically relevant post-operative setting that 
an increase in systemic VEGF could lead to revascularization of the surgical site and 
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promote healing.  However, in order to definitively determine the relevance of observed 
changes in plasma VEGF and tumor growth in spontaneous canine OSA, a randomized, 
placebo-controlled clinical trial would be necessary. 
In conclusion, we have shown that, despite the presence of increased HIF-1α and 
subsequent stimulation of VEGF production by tumor cells in vitro, tepoxalin does not 
enhance the growth of OSA in mice as a single agent when given at a dose that 
recapitulates the pharmacokinetics observed in dogs.  Tepoxalin was able to control 
tumor growth despite the pro-tumor effect of increased VEGF production.  Therefore, 
tumor bearing animals may be administered tepoxalin for continued treatment of arthritis 





 In this study we have suggested that tepoxalin does not exacerbate tumor growth 
even though it elicits VEGF in vitro from a variety of tumor cell lines.  However, to 
properly test this observation, a clinical trial would need to be performed to ensure 
tepoxalin will not stimulate tumor growth in patients.  I hypothesize that tepoxalin will 
provide pain relief to tumor bearing dogs, but will not significantly prolong survival 
when combined with standard of care therapy.  We have performed the preliminary 
investigation that shows that combining tepoxalin with doxorubicin, a standard of care 
therapy in canine OSA, does not significantly alter cellular viability.  A double-blinded 
randomized trial will need to be performed with two-arms: patients receiving standard of 
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care (amputation and chemotherapy), and those receiving standard of care in addition to 
tepoxalin.  Long-term follow-up will need to be performed and information regarding 
DFI and OS gathered to determine if tepoxalin impacts either of these factors.  Due to the 
in vitro data, and progressive growth observed using in vivo mouse models, it possible 
that tepoxalin may numerically increase DFI and OS; however, the complexity of the 
clinical scenario (confounding factors) may not lead to a significant change in outcome. 
 It would also be interesting to investigate the combined effects of chemotherapy 
and NSAIDs in OSA.  In this chapter we presented data showing that there was no 
combined effect when doxorubicin and tepoxalin were compared.  However, it would be 
interesting to combine carboplatin or gemcitabine in combination with tepoxalin.  There 
has been previous work performed that shows both of these agents are efficacious in 
OSA, and the combination may lead to a synergistic and more effective treatment of OSA 
[59-62].  Therefore, I hypothesize that combination of tepoxalin with carboplatin or 
gemcitabine will be synergistic.  Investigation of these combinations will first need to be 
performed in in vitro as was previously performed with doxorubicin.  If the effect is seen 
as additive or synergistic, further study may be warranted.  Movement into a murine 
mouse model would be the most relevant model at this point, and use of the orthotopic 
model presented in chapter 5 would be an ideal method for testing these compounds.  
Using this model would also allow us to investigate the ability of tepoxalin to inhibit 
micrometastatic disease as a single agent, as this has not been previously described.  If 
these experiments show an efficacious increase in DFI or OS, it would be suitable to 




 Herein, we reported that treatment with tepoxalin leads to an inhibition of tumor 
growth, although we did not observe any changes in angiogenesis or macrophage 
infiltrate.  Therefore, further analysis of the phenotypic changes in the tumor 
microenvironment would be necessary to further describe the mechanism of inhibition.  I 
hypothesize that there are changes present in the TAM leading to an inhibition of tumor 
growth.  As in chapter 2, IHC was attempted to characterize the macrophages, but was 
inconclusive.  TAM are the most likely targets as they have previously been implicated in 
being modulated by COX-2 compounds, and provide a likely basis for controlling tumor 
growth [63].  As described in chapter 2, examination of these TAM by RT-PCR and CBA 
assay may be the best way to describe the phenotype of these cells.  Description of the 
phenotype is crucial since an anti-tumor response may be independent of cell number and 
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Minimally Invasive Assessment of Tumor Angiogenesis by Fine 




 The development of a new, less invasive, and more rapidly implemented method 
of quantifying endothelial cell density in tumors could facilitate experimental and clinical 
studies of angiogenesis.  Therefore, we evaluated the utility of tumor fine needle 
aspiration (FNA) coupled with flow cytometry for assessment of tumor angiogenesis.  
Samples were obtained from cutaneous tumors of mice using FNA, then immunostained 
and assessed by flow cytometry to determine the number of CD31+ endothelial cells.  
Results of the FNA/flow cytometry technique were compared with quantification of 
tumor microvessel density using immunohistochemistry.  The ability of the 
FNA/cytometry technique to quantify the effects of anti-angiogenic therapy and to 
monitor changes in tumor angiogenesis over time in individual tumors was also 
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determined.  We found that endothelial cell percentages determined in tumor tissue 
aspirates by flow cytometry correlated well with the percentages of endothelial cells 
determined in whole tumor digests by flow cytometry and with tumor microvessel 
density measurements by immunohistochemistry.  Moreover, we found that repeated 
FNA sampling of tumors did not induce endothelial cell changes.  Interestingly, by 
employing repeated FNA sampling of the same tumors we were able to observe a sudden 
and marked decline in tumor angiogenesis triggered when tumors reached a certain size.  
Thus, we conclude that the FNA/flow cytometry technique is an efficient, reproducible, 
and relatively non-invasive method of rapidly assessing tumor angiogenesis, which could 





 Angiogenesis is a critical process for tumor development, thus making 
measurement of tumor angiogenesis a valuable biomarker for evaluating tumor biology 
and assessing responses to anti-angiogenic therapy [1-3].  Currently, tumor angiogenesis 
is most often measured by CD31 immunostaining of tumor biopsies to quantify 
microvessel density (MVD) [4, 5].  However, determination of tumor MVD in mice 
requires that the animals be euthanized, while in humans, tissue biopsy is required.  Thus, 
other non-invasive approaches to measurement of tumor angiogenesis have been 
explored, including imaging techniques such as X-ray angiography, positron emission 
tomography, and doppler ultrasound [6-8].  However, these modalities are often 
expensive and labor intensive techniques that are not feasible for animal studies and are 
often not realistic for repeated measurements in humans or mice [4].   
 Therefore, we sought to determine whether an alternative, relatively non-invasive, 
but easily applied technique could be used for routine, direct assessment of tumor 
angiogenesis.  Previous studies have shown that flow cytometry could be used to assess 
angiogenesis when frozen and embedded tumor sections were used as the sample source 
[9].  However, this technique also requires relatively large amounts of tumor tissue for 
analysis.  Fine needle aspirates (FNA) of tumors are routinely used to identify tumors by 
cytologic criteria, based on staining of cell samples prepared on glass slides.  However, 
the FNA technique typically also collects infiltrating leukocytes and mesenchymal cells 
in addition to tumor cells in the sample.  Therefore, we hypothesized that sufficient 
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numbers of endothelial cells could be obtained in the FNA specimen to allow evaluation 
and quantification by flow cytometry.   
 To address this question, we developed an FNA approach to collect small samples 
of tumor tissue from cutaneous tumors.  The technique was optimized to allow 
reproducible samples to be collected from small tumors (i.e., tumors with a diameter of 5 
mm or greater).  Sample preparation was optimized to provide suitable single cell 
suspensions for immunostaining and analysis by flow cytometry.  We then conducted 
studies to determine whether the results of tumor endothelial cell analysis using 
FNA/flow cytometry were comparable to results obtained with conventional MVD 
analysis or whole tumor flow cytometry.  The FNA/flow cytometry technique was 
applied to evaluate the effects of anti-angiogenic drug treatment and to assess changes in 
tumor angiogenesis over time in individual tumors, using serial FNA samples.  Based on 
the results of these studies, we concluded that the FNA/flow cytometry technique could 
be used to accurately measure tumor angiogenesis in mice with cutaneous tumors.   
 
 
Materials and Methods 
 
Cell Lines 
The mouse tumor cell lines 4T1 (mammary carcinoma) and MCA-205 
(fibrosarcoma) were maintained in C/5/5 MEM medium [MEM (Lonza, Walkersville, 
MD) supplemented with 1X MEM vitamin solution (Cellgro, Henderson, VA), 2 mM L-
glutamine (Cellgro), 1 mM sodium pyruvate (Cellgro), 1X non-essential amino acid 
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solution (Cellgro), 1X antibiotic/antimycotic (Cellgro), 5% heat inactivated fetal bovine 
serum (FBS, Atlas, Fort Collins, CO), and 5% heat inactivated newborn calf serum 
(Hyclone, Logan, UT)].  Once confluent, cells were washed with 1x phosphate-buffered 
saline and detached with 0.25% trypsin (Cellgro) supplemented with 0.5 mM EDTA. 
 
Animals 
All animal studies were performed in an AALAC-approved facility and were 
approved by the Colorado State University Institutional Animal Care and Use 
Committee.  Female mice 6-8 weeks of age were used in all experiments and were 
purchased from Harlan Sprague Dawley (Indianapolis, IN) or Jackson Laboratories (Bar 
Harbor, ME).  The 4T1 tumor cell line was injected in the mammary fat pad of BALB/c 
mice using 5x105 cells in 100 μL of PBS.  MCA-205 tumor cells (2.5x105 cells per 
mouse) were injected subcutaneously into the rear flank of C57BL/6 mice.   
 
FNA Technique 
 Once tumors reached a minimal size of 5 mm in diameter, they were subjected to 
sampling using a 23 gauge needle.  Mice were anesthetized using isoflurane (Minrad, 
Bethlehem, PA) and a 23 gauge needle (Beckton Dickinson, Franklin Lakes, NJ) (without 
syringe attached) was inserted into the tumor using a rotating motion.  After insertion into 
the tumor, the needle was removed and the tissue sample was flushed from the needle by 
attaching a syringe filled with tissue culture medium and expelling the contents into a 
sterile eppendorf tube.  This process was repeated twice more, each time inserting the 
needle at roughly perpendicular angles to the previous insertion, for a total of 3 samples 
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collected from each tumor.  The 3 collected tumor samples were then pooled and 
processed using collagenase digestion [collagenase (5 mg/ml final concentration; Sigma-
Aldrich, St. Louis, MO) dissolved in MEM (Lonza) with 0.0125 mg/ml DNase (bovine 
deoxyribonuclease I; Sigma-Aldrich), and 0.25 mg/ml trypsin inhibitor (Sigma-Aldrich)] 
at 37°C for 20 min in a water bath.  The samples were then triturated using a 23 gauge 
needle and 1 ml syringe to assure that any tissue clumps were disaggregated.  Single cell 
suspensions obtained in this manner were washed once using FACS buffer (1x PBS with 
2% FBS and 0.1% sodium azide) and then counted and re-suspended in FACS buffer and 
kept on ice prior to immunostaining. 
 
Immunostaining and Flow Cytometry 
 Single cell suspensions from tumor aspirates were placed in individual wells of 
96-well round bottom plates at a concentration of 5x105 to 1x106 cells per well.  Prior to 
immunostaining, non-specific staining was blocked using 10 μL unlabelled anti-mouse 
Fcr III antibody (CD16/32; clone 93; eBioscience, San Diego, CA) diluted in normal 
mouse serum (Jackson Immunoresearch).  Immunostaining was performed at room 
temperature for 30 minutes using an anti-mouse CD31 antibody (FITC-conjugated; clone 
390; eBioscience), anti-mouse CD11b antibody (Pacific blue-conjugated; clone M1/70; 
eBioscience, anti-mouse VEGFR2 antibody (PE-conjugated; clone Avas 12α1; BD 
Pharmingen, Franklin Lakes, NJ), and anti-mouse CD133 (APC-conjugated; clone 13A4; 
eBioscience).  Samples were then washed twice and analyzed after addition of propidium 
iodide (5 μg/sample) for live-dead cell discrimination.  Samples were analyzed using a 
CyAn ADP flow cytometer (Beckman-Coulter, Fullerton, CA) and analysis was 
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performed using FlowJo software (Tree Star, Inc., Ashland, OR).  Endothelial cells were 
identified as CD31+CD11b-CD45-. 
 
Immunohistochemistry 
 Tumor tissues were embedded in OCT embedding medium (Sakura, Torrance, 
CA) and cryosectioned at a thickness of 4 μm onto Superfrost slides (VWR; West 
Chester, PA).  Slides were rehydrated, non-specific binding blocked with appropriate 
serum, then incubated with anti-mouse purified CD31 antibody (clone 390; eBioscience) 
appropriately diluted primary antibody.  After washing, sections were incubated with 
biotinylated donkey anti-rat (Jackson ImmunoResearch).  A Vectastain ABC kit (Vector) 
and subsequent AEC peroxidase substrate kit (Vector) were used according to 
manufacturer’s instructions.  Slides were then counterstained with hematoxalin and 
crystal mount (Biomeda, Foster City, CA) applied. 
Microvessel density (MVD) was determined by imaging five random 20x-high 
power CD31-stained fields using a Zeiss AxioVision 2 microscope and Carl Zeiss 
AxioVision Software v4.6 (Zeiss, Thornwood, NY).  Computerized determination of 
positively staining cells was performed by blanking against sections stained with an 
irrelevant isotype control antibody.  The average of positively stained areas for the 5 
fields was determined for each tumor.  
 
Tumor Growth Inhibition with ZD6474 
 The VEGF receptor-2 inhibitor ZD6474 was kindly provided by Dr. Dan 
Gustafson (Colorado State University) and AstraZeneca (Macclesfield, UK).  Three days 
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after tumor cell injection in mice (n = 5 per group), treatment was initiated.  One group of 
mice was treated with 25 mg/kg of ZD6474 dissolved in PBS with 1% Tween 80 vehicle, 
while a second group of mice was treated with diluent alone [10, 11].  Treatment was 
administered daily for the duration of the study.  Tumor aspirates were obtained from all 
mice 14 days post-tumor challenge as described above immediately before animals were 
euthanized.   
  
Statistical Analysis 
 Statistical analyses were performed using commercial software (Prism 5; 
GraphPad Software, La Jolla, CA).  Statistical comparisons between two groups were 
performed using the Mann-Whitney two-tailed t-test.  Comparisons between three groups 
were performed using one-way ANOVA, followed by the Bonferroni post-test.  Tumor 
growth analysis was performed using repeated measures two-way ANOVA.  Correlations 
were analyzed using a one-tailed Spearman correlation test.  For all statistical analyses, p-





Quantification of Endothelial Cells in Tumor Digests Using Flow Cytometry 
 In this study we identified tumor endothelial cells as CD31+ cells that did not 
express the integrin CD11b or the hematopoietic marker CD45, as described previously 
[12-15].  Cells that expressed CD11b were excluded from the endothelial cell population 
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because some monocytes and macrophages are known to also express CD31 [15-17].  
Propidium iodide staining was used to exclude dead cells from the analysis.  Cells were 
first gated by FSC and SSC to exclude debris.  Using this approach, we were able to 
routinely identify a distinct population of CD31+CD11b- cells in tumor aspirates and 
tumor digests (Figure 4.1).   
 
 We also assessed endothelial cell expression of other markers associated with 
tumor endothelium, such as CD133 and VEGFR2/Flk-1.  However, these determinants 
were expressed on only a very small subset of CD31+ cells and did not contribute 
substantially to endothelial cell identification and therefore not used further.   
 It should be noted that only tumors of a diameter of 5 mm or greater could be 
accurately aspirated using a 23 gauge needle.  We experimented with smaller and larger 
gauge needles, but found that use of 23 gauge needles gave superior results in terms of 
 
 
Figure 4.1: Flow cytometric analysis of tumor endothelial cells.  Fine needle aspirates 
(FNA) of tumors were processed for immunostaining and analyzed by flow cytometry 
as described in Methods.  Cells that were PI+ were first excluded to eliminate dead 
cells from analysis.  Then, live cells were gated using forward and side scatter 
characteristics to eliminate cell debris, and subsequent analysis of CD31 and CD11b 
stained cells.  Endothelial cells were classified as CD31+CD11b-. 
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cell yield from small tumors.  Moreover, it was possible to determine when only normal 
skin was aspirated, because FNA/flow cytometry of normal skin typically yielded fewer 






Figure 4.2: Comparison of FNA from skin and tumor.  FNA were taken from mice 
with established tumors as previously described.  At the same time, skin from the 
contralateral flank was also taken.  FNA were processed and analyzed identically.  
FNA from normal skin (A) have a much lower yield of cells for analysis (<1000) 
compared to FNA from established tumors (B).  Therefore, we can differentiate 
between FNA of tumors and that of normal skin. 
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Comparison of Endothelial Cell Percentages of FNA and Whole Tumor Digests by 
Flow Cytometry 
 Using the flow cytometry analysis scheme noted above, we first asked whether 
FNA/flow cytometry samples of tumors yielded similar results in terms of percentages of 
endothelial cells as samples obtained by whole tumor digestion and flow cytometry.  To 
address this question, FNA samples were collected from tumors of anesthetized mice (n = 
5 per group), then the mice were euthanized and whole tumor tissues were collected and 
digested enzymatically.  Single cell suspensions obtained by both techniques were then 
immunostained and analyzed by flow cytometry, using the protocol noted in the Methods.  
Endothelial cell populations from two different tumor types were compared.  We found 
that the percentages of endothelial cells obtained by FNA and whole tumor digests of 4T1 
breast carcinomas were significantly correlated (p<0.05), as determined by Spearman 
correlation (Figure 4.3).  In the case of the sarcoma cell line MCA-205, the two 
techniques also yielded results that were significantly correlated (p<0.05) (Figure 4.3).  
Thus, we concluded that flow cytometric analysis of endothelial cell populations in 
tumors using samples collected by FNA yielded results similar to those obtained using 
whole tumor digests.   
 
Correlation between FNA/Flow Cytometry and Tumor MVD Analysis 
 Next, we investigated the correlation between tumor angiogenesis assessed using 
FNA/flow cytometry and angiogenesis assessed using immunohistochemistry (IHC) and 
MVD analysis.  As noted above, FNA specimens were collected from tumors before the 




FNA/flow cytometry samples were compared with MVD results from the same tumor 
sample.  We observed a significant correlation (p<0.05) between endothelial cell 
percentages as determined by FNA/flow cytometry and tumor MVD for individual 
tumors in mice (Figure 4.4).  In addition, we observed a significant correlation (p<0.05) 
between the results of whole tumor digest by flow cytometry and tumor MVD results 
(Figure 4.4).  This latter result is in agreement with a previous report correlating 
angiogenesis determination by flow cytometry on archived frozen tissues and tumor 
MVD analysis [9].  Thus, the estimates of tumor angiogenesis provided by the FNA/flow 
cytometry technique correlated well with tumor angiogenesis measurements determined 




Figure 4.3:  Flow cytometric analysis of tumor FNA specimens and whole tumor 
digests yield similar estimates of tumor angiogenesis.  Tumor specimens were 
collected by FNA or tumor biopsy from mice with established 4T1 tumors (A) or 
MCA-205 tumors (B), and analyzed by flow cytometry to determine percentages of 
CD31+ endothelial cells, as described in Methods.  There was a significant (p = 
0.0402) correlation between the percentage of CD31+ cells in mice (n = 27) with 4T1 
tumors (A) and the percentage of CD31+ cells in mice (n = 15) with MCA-205 tumors 





Repeated FNA Sampling of Tumors Does Not Alter Tumor Angiogenesis 
Measurements 
 To determine whether repeated sampling of tumors by FNA introduced artifacts 
into the endothelial cell analysis, we compared endothelial cell percentages determined 
after a single tumor aspirate to values obtained after 3 repeated tumor aspirates in mice 
with tumors established for equal periods of time.  Mice (n = 5-6 per group) with 
 
Figure 4.4:   Tumor angiogenesis assessed by FNA/flow cytometry correlates with 
angiogenesis measured by immunohistochemistry.  Fine needle aspirate samples were 
collected from mice (n= 10 per group) with cutaneous 4T1 tumors and numbers of 
CD31+ endothelial cells were analyzed by flow cytometry (A), as described in 
Methods.  Mice were euthanized, and tumors isolated and analyzed for MVD by IHC 
(B) as described in Methods.  Correlation between MVD and percentage of CD31+ 
cells as determined by FNA (C) and whole tumor digest (WTD; D) was determined 
using Spearman correlation, which demonstrated a significant (p < 0.05) correlation 
between the values.  Results are representative of two independent experiments. 
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established 4T1 tumors were divided into two groups.  In group 1, the tumor was only 
aspirated once, 7 days after tumor challenge.  In group 2, tumors were aspirated on days 
7, 10, and 13.   Sixteen days after tumor implantation, FNA samples were collected from 
all mice in both groups and endothelial cell numbers compared by flow cytometry 
(Figure 4.5).  The mean percentage of CD31+ endothelial cells in tumors only aspirated 
once was 0.09%, while the percentage of endothelial cell in tumors aspirated 3 times was 
0.11%, and these percentages were not significantly different (p=0.35).  Therefore, we 
concluded that repeated sampling of tumors by FNA did not introduce significant 




Figure 4.5:  Repeated FNA sampling of tumors does not lead to endothelial cell 
artifacts.  BALB/c mice with established 4T1 tumors were divided into two groups (n 
= 5 per group).  In Group 1 mice, a single FNA was performed, while in Group 2 
mice, 3 separate FNAs were performed, each 3 days apart.  The percentage of CD31+ 
cells (mean ± SEM) was compared between the two groups by Mann-Whitney test.  
Significant differences in endothelial cell percentages were not observed (p < 0.05).  
Results are representative of two independent experiments with 5 mice per group. 
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FNA/Flow Cytometry for the Assessment of Tumor Angiogenic Responses to 
Angiogenesis Inhibitors 
 The FNA/flow cytometry technique would be particularly useful clinically if it 
could be used to assess tumor responses to anti-angiogenic agents.  Therefore, we 
assessed the ability of FNA/flow cytometry to detect changes in tumor angiogenesis in 
mice treated with the angiogenesis inhibitor ZD6474, a dual inhibitor of VEGFR2 and 
EGFR [18-20].  Mice with established 4T1 tumors were treated by daily oral gavage with 
ZD6474, which was initiated 3 days after tumor cells were injected.  Control mice were 
treated by daily oral gavage of dilution buffer.  Treatment with ZD6474 induced a 
significant (p<0.0001) delay in tumor growth compared to mice treated with dilution 
buffer (Figure 4.6).  In addition, the percentage of endothelial cells was significantly 
reduced in tumors of ZD6474-treated mice compared to control mice, as assessed by 
FNA/flow cytometry (Figure 4.6).  These results indicated that FNA/flow cytometry 
could realistically be used to monitor the efficacy of anti-angiogenic agents in vivo.   
 
Repeated FNA Sampling to Assess Changes in Tumor Angiogenesis Over Time 
 Finally, we evaluated the potential for repeated FNA/flow cytometry analysis of 
individual tumors over time to provide insights into how tumor angiogenesis may change 
over time.  Currently, to assess changes in tumor angiogenesis over time in mice, groups 
of mice with tumors must be serially sacrificed and tumor angiogenesis quantified by 
MVD analysis of each individual tumor tissue sample.  The entire process is therefore 
costly in terms of mouse usage and analysis time.  For clinical studies in humans, direct 




because of the need for repeated tumor biopsies.  Therefore, use of the FNA approach 
could offer substantial advantages over current technologies for repeated and relatively 
non-invasive assessment of tumor angiogenesis.   
 To address this question, we established cutaneous tumors (either 4T1 tumors in 
BALB/c mice or MCA-205 tumors in C57Bl/6 mice) in mice (n = 5 per group) and then 
serially evaluated tumor angiogenesis using tumor FNA samples collected from each 
individual tumor every 3 days using flow cytometry.  We correlated tumor angiogenesis 
measurements with changes in tumor size.  Results of the flow cytometric analysis 
showed that the percentage of CD31+ endothelial cells in 4T1 tumors increased steadily 
 
 
Figure 4.6:  FNA analysis can be used to assess the effects of anti-angiogenic therapy 
(ZD6474).   BALB/c mice (n=5 per group) with established mammary fat pad 4T1 
tumors were treated daily with ZD6474 (25 mg/kg) or with control buffer by oral 
gavage.  A) Tumor growth was assessed by measuring tumor diameter, and a 
significant (p<0.0001; *p<0.05) growth inhibition was observed in the presence of 
ZD6474 as assessed by repeated measures two-way ANOVA.  B) Percentages of 
CD31+ endothelial cells in treated and sham-treated tumors were determined (mean ± 
SEM) using FNA/flow cytometry, as described in Methods.  The percentage of CD31+ 
endothelial cells was significantly decreased (p < 0.05) in ZD6474-treated tumors, 
compared to control tumors, as assessed by Mann-Whitney test.  Results are 
representative of two independent experiments.   
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up until the point where the mean tumor diameter reached approximately 9 mm (Figure 
6).  At that point, the percentage of endothelial cells decreased dramatically, dropping 
from an average of 0.19% CD31+ cells to 0.05% CD31+ cells.  A very similar 
phenomenon was observed in mice with MCA-205 tumors (Figure 4.7).  For example, in 
the MCA-205 tumor model, the average number of CD31+ endothelial cells in tumors 
decreased from 0.83% to 0.21% once tumors reached a mean diameter of 7.6 mm.  These 
results suggested that reaching a critical tumor size was associated with a rapid and 
pronounced reduction in endothelial cell density.  It should be noted that these results 
were obtained using a total of 20 mice (groups of 5 mice for each tumor type, with one 
repeat each), whereas a similar experiment using serial sacrifice of groups of mice, with a 





 Most standard assays of tumor angiogenesis require sufficient amounts of tumor 
tissue to section in order to perform IHC analysis.  This generally requires obtaining 
tumor biopsies (humans) or removal of the entire tumor from euthanized animals (mice).  
Thus, techniques for quantifying tumor angiogenesis using much smaller specimens 
would greatly facilitate clinical and experimental studies.  In this report, we provide 
results to support the idea that FNA/flow cytometry, using very small tumor specimens, 
is an effective alternative to conventional tumor biopsy and IHC for assessing tumor 




cytometry technique could be adapted for use in mouse tumor studies, that the results of 
angiogenesis assays using FNA/flow cytometry correlated well with estimates of tumor 
angiogenesis provided by tumor MVD (analyzed by IHC) and whole tumor digest 
 
 
Figure 4.7:  Repeated measurement of tumors by FNA reveals angiogenic collapse of 
the tumor.  Syngeneic mice were challenged with 4T1 (A) or MCA-205 (B) tumors.  
Tumor measurements were initiated to coincide with the first FNA.  FNA were taken 
every three days after the initial FNA until the first mouse had a maximal tumor 
diameter of 10 mm, at which time all mice were sacrificed.  Tumors from mice 
challenged with 4T1 and MCA-205 tumors had a rapid decrease in the percentage of 
endothelial cells present suggestive of an angiogenic collapse.  Results depict the 
mean (±SEM) of endothelial cells as determined by FNA and tumor growth as 




samples (analyzed by flow cytometry), and that the FNA/flow cytometry approach could 
be used to repeatedly assess tumor angiogenesis over time. 
 The ability to assess angiogenesis relatively non-invasively and repeatedly using a 
technique such as FNA/flow cytometry represents an important advance, since it greatly 
reduces the number of mice required for animal experiments.  Equally important, it is 
reasonable to assume that the same approach could also be used to assess angiogenesis in 
solid tumors of humans, so long as the tumor was accessible by needle for aspiration.  
Thus, the approach could be used for tumor staging and as a readily obtained biomarker 
for evaluation of anti-angiogenic treatments and new drugs.   
 Key variables for performing the FNA/flow cytometry technique were identified 
in the current study.  Among these were tumor size, needle size, and sample digestion 
after procurement.  For example, we found that tumors < 5 mm in diameter could not be 
reliably sampled.  Thus, the technique could only be applied to analysis of more 
advanced tumors.  Several different needle sizes were evaluated for their ability to obtain 
reliable tumor FNA specimens and we found that a 23 gauge needle gave the most 
reliable results.  Larger needles were too large to use on mouse tumors, whereas smaller 
needles failed to yield sufficient cells for analysis.  In addition, pooling aspirated 
specimens from a single tumor obtained by inserting the needle in 3 different orientations 
also improved the cell yield and served to decrease sample-to-sample variability.  Finally, 
we found that a brief digestion step, using collagenase, increased the yield of cells overall 
and specifically endothelial cells from the FNA specimens. 
 A potential limitation to the FNA/flow cytometry technique was identified in the 
small number of events used for analysis.  For example, the overall number of endothelial 
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cells detected in each sample was relatively small, thus limiting the assessment of 
complex subpopulations of endothelial cells.  However, despite the small yield of 
endothelial cells, we still observed a relatively small and manageable variability in 
tumor-to-tumor endothelial cell numbers.  In the case of human tumor samples, this 
limitation might be partially overcome by simply performing more needle aspirates of a 
tumor, which is reasonable given the much larger overall size of tumors in humans 
relative to mice.  Regional variation in intra-tumoral angiogenesis did not appear to 
introduce significant problems with the FNA/flow cytometry technique, presumably 
because specimens were collected from several different regions of the tumor for each 
sample.  Moreover, repeated sampling of the same tumor at 3-day intervals also did not 
appear to introduce significant angiogenic artifacts. 
 Use of the FNA/flow cytometry approach to repeatedly measure angiogenesis in 
individual tumors also provided us with a unique tool to assess changes in angiogenesis 
over time.  Such information has not previously been reported in mouse or human tumor 
studies and generally can only be inferred by comparing levels of angiogenesis between 
tumors collected from carefully controlled groups of mice at different time points.  Thus, 
previous studies assessing tumor angiogenesis may overlook rapidly occurring changes in 
angiogenesis [4].  In the present study, we noted a precipitous drop in the percentage of 
endothelial cells within tumors as tumor size reached a critical level of approximately 8-9 
mm in diameter.  This critical threshold of tumor size was detected in repeated 
experiments involving different types of tumors.  Thus, the time and tumor size frame of 
such changes, such as this apparent vascular collapse phenomenon, can be documented 
using FNA/flow cytometry.   
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 In summary, we describe here a new technique for simple, repeated and relatively 
non-invasive assessment of tumor angiogenesis in mice, which is also readily applicable 
to study of human tumors.  Use of the FNA/flow cytometry technique should greatly 
reduce the number of mice required for experiments.  Repeated, closely spaced sampling 
of angiogenesis in individual tumors using the technique may also provide unique 





 Within this chapter we have created a technique to evaluate angiogenesis serially 
using a minimally invasive manner in mice.  In this process, we have observed a unique 
phenomenon in that the percentage of endothelial cells present in a tumor rapidly change 
once the tumor reaches a size of almost a centimeter.  This is an interesting observation 
that requires further study.  Since the analysis used within is based on the percentage of 
endothelial cells measured, it would be important to better understand the changes 
occurring in other cellular populations to see how they relate to that of endothelial cells.  
Therefore, I hypothesize that the change in endothelial cells will be due to a rapid 
increase in tumor cell growth.  It is plausible that a vascular network is developed in a 
growing tumor, and reaches a critical level at which time the tumor is able to rapidly 
increase in growth due to the presence of a richly oxygenated environment.  At this time, 
the tumor cells rapidly divide due to the presence of favorable factors, thereby 
outgrowing their blood supply.  The resulting decrease in endothelial cell percentage is 
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due as much to an increase in tumor cell growth as it is limited by the capacity of 
endothelial cells to sustain their own growth. 
 To determine if the above stated hypothesis is correct, serial sacrifice of mice will 
need to be performed and concurrent FNA taken.  This data will show if FNA are related 
to the overall tumor burden at each point established, and remove any bias associated by 
taking a small sample.  Samples can then be analyzed by IHC for Ki-67, CD31, CD11b, 
FSP (fibroblast surface protein) and measured for necrosis.  Flow cytometry analysis may 
be performed to investigate PI, CD45, CD11b, and CD31.  These analyses will allow for 
the study of the immune infiltrate, endothelial cells, necrotic tissue, and subtracted to 
analyze for tumor cells.  There are not good markers for fibroblasts by flow cytometry, so 
these conclusions may have to be made from the IHC.  Analysis of changes in each of 
these cellular types and how they relate to each other will be of importance in 
determining if and how endothelial cell numbers change in relation to the overall tumor 
burden.  Serial sacrifice of mice will also help determine if the same observation of 
decreased endothelial cells can be made using a separate modality.  These experiments 
should allow us to better understand the changes in angiogenesis observed by serial FNA, 
and better understanding of this underlying biology would be beneficial for investigating 
novel anti-angiogenic therapeutics. 
 Since FNA yields information about the dynamic nature of tumor vasculature, it 
would be beneficial if we could better characterize the endothelial cells within the tumor.  
I hypothesize that characterization of endothelial cells with markers such as CD133, 
CD34, CD117, and VEGFR1/2/3 may provide more information concerning the types of 
blood vessels formed during various points of tumor development.  In this manuscript, 
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we noted that CD133 and VEGFR2 did not yield viable results for subpopulation 
analysis.  However, pooling of FNA from multiple mice in a group may yield a sufficient 
number of cells for analysis, and thus allow us to make more concrete conclusions 
concerning the presence and phenotype of these cells.  Pooling of groups of mice is still 
superior to using separate groups of mice since the pooled mice can be tracked over a 
time course.  The pooling technique does not allow for extrapolation to individual mice; 
however, it does retain the repeated measures nature critical to the characterization of 
changes over time. 
CD34, CD117, and VEGFR1/3 are other markers expressed by endothelial cells 
to various degrees based upon the maturation of endothelial cells, and could provide 
evidence for the types of endothelial present in a tumor.  Many of these markers are 
developmental markers and characterization may be performed by multicolor flow 
cytometry.  Specifically, VEGFR3 expression is thought to be limited to lymphatic 
endothelium; however, this receptor is present on a subpopulation of immature vascular 
endothelium [21].  Use of the VEGFR3 marker may also suggest differences in metastatic 
route.  For example, an increase in VEGFR3 may allow for observation of differences in 
lymphatic infrastructure in tumors, and possibly suggest a bias towards lymphatic or 
hematogenous metastasis in cutaneous metastatic models.  These experiments may also 
better describe differences between tumor and normal vasculature, and define how these 
changes occur over time.  For example, if it is observed that tumors have predominantly 
immature endothelial cells whereas the other organs have more mature endothelium, this 
could act as a targeted site for anti-tumor therapy.  Hypotheses about the immaturity of 
tumor endothelial cells have previously been formed, but an observation made during this 
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work has shown that ZD6474 decreased the percentage of endothelial cells in normal 
liver and spleen, suggesting that ZD6474 may also target more mature endothelium 
which maybe a unique effect of this compound.  Endothelial cell markers such as CD31 
and CD146 are not specific enough in this manner to make conclusions concerning the 
maturity of resultant endothelial cells.  These experiments should not only provide more 
information as to the types of vasculature present in tumors, but the dynamic changes in 
tumor vasculature present. 
One final experiment that could be performed along a common vein as the 
previous objective would be the characterization of pericytes in the tumor.  Pericytes 
characterize mature vasculature, and are supportive cells of this vasculature.  I 
hypothesize that tumor associate pericytes may be evaluated using the FNA technique 
developed herein.  Since endothelial cells and immune infiltrate may be analyzed using 
the FNA technique described, it is also plausible that pericytes may be identified using 
this method.  Pericytes could be defined by a variety of markers, but are thought to be 
CD31-Ang-1+Thy-1+Stro-1+ [22-24].  It would be plausible to use other pericyte markers, 
but anti-mouse antibodies for those previously listed are already commercially available 
for flow cytometry.  By better characterizing the pericyte presence in tumors, it may alter 
the way in which tumor vasculature is viewed, and coalesce well with a better description 
of the maturity of the vasculature.  It is plausible that changes in pericytes and there 
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An Orthotopic, Postsurgical Model of Luciferase Transfected 




 Osteosarcoma (OSA) is the most common bone tumor in humans.  Newer, more 
clinically relevant models of OSA are required to investigate novel therapeutics.  The 
ability to study spontaneous micrometastases independent of the primary tumor is 
important.  Therefore, we have developed a novel model of murine OSA using the DLM8 
cell line, which is syngeneic to C3H mice.  We have engineered these cells to express 
firefly luciferase so the development of metastases can be followed serially and non-
invasively.  These cells form osteolytic/osteoproductive lesions and metastasize 
spontaneously after orthotopic implantation in the proximal tibia, and the development of 
soft-tissue metastasis can be followed serially following amputation.  We have 
demonstrated a significant prolongation of disease-free and overall survival in the 
surgical adjuvant setting following treatment with doxorubicin or carboplatin, drugs 
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which form the mainstays of treatment for human OSA.  In conclusion, we have 
developed a novel surgical adjuvant model of metastatic OSA in immunocompetent mice 
that closely recapitulates the clinical situation, allowing the evaluation of novel 






 Osteosarcoma (OSA) is the most common primary bone tumor in humans [1].  
Tumor metastases are the most common cause of death from OSA [2].  For this reason, 
OSA patients typically receive systemic chemotherapy for their disease [3].  Patients who 
develop OS typically undergo surgery to remove the primary tumor; however, death due 
to metastasis is the primary concern for these patients [1, 3].  Despite the use of adjuvant 
chemotherapy, the 5-year survival rate is only 60% illustrating that new therapeutics are 
needed to treat OSA [3].  Therefore, new model systems of OSA are required in which to 
evaluate new therapeutics so as to best recapitulate the clinical scenario.  Specifically, 
chemotherapy is typically employed in the surgical adjuvant setting for most highly 
metastatic human tumors but there are few models in existence that are useful for the 
study of therapy in this context.  Consequently, we have created a luciferase transfected 
murine OSA model that postoperatively metastasizes from an orthotopic location in 
syngeneic mice. 
 Novel murine models that recapitulate the clinical scenario are appropriate and 
necessary as a screening tool for potential therapeutics.  By not removing the primary 
tumor, treatment models aimed at treating metastatic disease will be influenced by the 
presence of the primary tumor, making it difficult to discern the effects of treating the 
metastases from that of solely treating the primary tumor.  However, amputation of the 
tumor bearing limb in a murine model removes this as a source of variability in 
laboratory studies.  Furthermore, the majority of OSA patients have micrometastases at 
the time of surgery.  Therefore, targeting of metastatic disease supersedes the importance 
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of treating the primary tumor with regard to medical therapy.  The development of a 
surgical adjuvant model, allowing for the direct treatment of micrometastatic disease will 
allow for trials of increased therapeutic efficacy.  
There have been numerous murine tumor models of OSA developed recently [4-
17].  These models include xenogeneic [4, 6-9, 13, 15] and syngeneic [10, 11, 14, 17] 
murine tumor models that have been used to better understand the biology of OSA.  
Syngeneic models are superior in that they retain immunocompetence and species 
dependent interactions between tumor and stromal cells [11, 17-19].  However, to our 
knowledge, none of these models allow for the study of metastatic disease in the 
orthotopic post-surgical model where the primary tumor can be removed to recapitulate 
the clinical scenario.  However, a post-surgical model of subcutaneous excision is present 
[20].    Typically, mice are euthanized and organs removed for histologic analysis of 
metastatic disease.  Serial sacrifice of mice requires large numbers of mice to be 
euthanized, and involves labor intensive analysis.  Therefore, it is of great importance to 
define novel tumor models that better approximate the clinical scenario and allow for 
minimally invasive serial tracking of metastasis. 
The evaluation of novel therapeutics in the metastatic setting is required since this 
is the primary cause of death in patients with OSA.  Evaluation needs to not only include 
classical cytotoxic chemotherapeutic agents, but could also include novel therapies.  
Receptor tyrosine kinase inhibitors are currently of much interest today, and it is 
necessary to determine the effectiveness of these compounds in the treatment of 
metastatic disease [21-23].  Immunotherapeutics have also been of great interest, and 
testing of novel agents in the metastatic testing would be of greater relevance than 
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treatment of heterotopic tumor in a heterotopic site [24-28].  The ability to utilize 
syngeneic mice and retain the core components of the immune system strengthens the 
conclusions of the investigation.  Maintaining the metastatic process is also of 
importance, as therapeutics that inhibit this process may be evaluated in a more relevant 
setting then that of heterotopic sites and intravenous injections as is the case in OSA. 
The creation of a better model in which to test novel treatments, specifically in 
relation to metastases, is crucial for the advancement of OSA therapy.  The ability to use 
immunocompetent mice and study a tumor that spontaneously metastasizes may therefore 
better approximate the clinical scenario.  Furthermore, luciferase transfection of the 
tumor allows for serial noninvasive tracking of the dissemination of disease, and allows 
for the study and inhibition of metastases.  Therefore, we have developed a murine model 




Materials and Methods 
 
Cell Lines 
 The DLM8 cell line was generously provided by Dr. E. Kleinerman (M.D. 
Anderson Cancer Center) and transfected (described below) to produce the DLM8-luc-
M1 cell line.  All cell lines were maintained in C/10 [Dulbecco’s minimal essential 
medium (DMEM, Lonza, Walkersville, MD) supplemented with 1X MEM vitamin 
solution (Cellgro, Henderson, VA), 2 mM L-glutamine (Cellgro), 1 mM sodium pyruvate 
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(Cellgro), 1X non-essential amino acid solution (Cellgro), 1X antibiotic/antimycotic 
(Cellgro), and 10% heat inactivated fetal bovine serum (FBS) (Atlas, Fort Collins, CO)].  
Once confluent, cells were washed with 1x phosphate-buffered saline and detached with 
0.25% trypsin (Cellgro) supplemented with 0.5 mM EDTA. 
 
Animals 
All animal studies were performed in an AALAC-approved facility, with approval 
of the Colorado State University Institutional Animal Care and Use Committee.  6-8 
week old female C3H mice were purchased from Harlan-Sprague-Dawley (Indianapolis, 
IN).  DLM8, DLM8-luc, and DLM8-luc-M1 were all injected into mice using 2x106 cells 
per tumor challenge.  Subcutaneous tumor challenge was accomplished by injecting cells 
subcutaneous into the rear flank.  For orthotopic injection, mice were first anesthetized 
with isoflurane.  The surgical site was prepared by first shaving and then cleaning with 
ethanol.  A 23G needle was then used to drill a hole into the proximal tibia.  Tumor cells 
(2x106) were re-suspended in PBS and injected into the proximal tibia in 50 µL to 
enhance focal tumor formation.  Mice received 0.05 mg/kg of buprenorphine every 12 
hours for 72 hours post-tumor challenge to manage pain associated with tumor challenge. 
 
Luciferase Transfection, Imaging, and Selection 
 The DLM8 cell line was transfected by electroporation with RSV-pGL4.17, a 
plasmid containing the firefly luciferase gene and a neomycin selection cassette. 
RSVpGL4.17 was constructed by subcloning a Hind III fragment containing the Rous 
Sarcoma Virus 5’ LTR (RSV) promoter into pGL4.17 (Promega Corporation, Madson, 
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WI).  The resulting transfected cells were named DLM8-luc.  Selection was 
accomplished by treating cells with G418 (500 μg/mL) for 2 weeks post transfection. 
Several luciferase positive clones were selected and mixed.  Populations of the positive 
clones were expanded and frozen to retain low passage numbers. 
To select for luciferase positive cells with metastatic potential to lung, DLM8-luc 
were passaged through mice a single time using a Fidler selection process [29, 30].  Mice 
were challenged orthotopically with DLM8-luc and followed by luciferase detection 
(described below) for luciferase positive metastases.  For imaging, mice were injected 
intraperitoneally with 100 µL of 30 mg/mL luciferin (Regis Technologies, Inc., Morton 
Grove, IL) 10 minutes before being anesthetized with isoflurane.  Imaging was performed 
using an IVIS 100 imaging system and Living Image 2.50.1 software (Xenogen).  A one 
minute exposure time with high sensitivity binning was used to enhance quantification of 
the tumor cells.  The minimum intensity was set at 10% of maximum and a contour ROI 
plot with default parameters (ROI edge value of 5%) chosen to increase objectivity of 
quantification.  Total flux of the ROI was recorded as photons/sec for each 
animal/sample.  Once luciferase positive clones were identified, mice were sacrificed and 
lung metastases were selected.  Lung metastases were isolated and collagenase digested 
before being placed back into in vitro culture for further selection with G418 to remove 
any tumor cells that may have lost luciferase expression.  This new line was named 






Characterization of Luciferase Expression 
 To characterize the luciferase expression of cells in vitro, 250,000 cells were 
plated in a 24-well plate format in quadruplicate and serially diluted by 2-fold dilutions.  
Plates were incubated at 37ºC and 5% CO2 for 24 hours.  Luciferin was then added to 
each of the wells before imaging with the IVIS system as previously described.  ROI 
were drawn around each well to measure the luciferase expression. 
 
Imaging Modalities 
 To further characterize the orthotopic tumors, multiple imaging modalities were 
used.  Mice were challenged orthotopically with DLM8-luc-M1 and primary tumors 
allowed to grow for two weeks.  Mice were then imaged for luciferase expression as 
described above immediately before being euthanized and tissues collected.  Tumor 
bearing and contralateral hind limbs were formalin fixed.  Both limbs were then 
compared using microCT (ScanCo USA Inc., Southeastern, PA).  After microCT, limbs 
were decalcified in dilute hydrochloric acid solution before paraffin embedding and 
sectioning for H&E staining. 
 
Surgical Adjuvant Model 
 To more closely recapitulate the clinical situation, a surgical adjuvant model of 
therapy was created.  Mice were orthotopically challenged with DLM8-luc-M1 tumors.  
At various times following injection, the tumor bearing limb was amputated by coxo-
femoral dislocation.  Briefly, mice were treated with 0.05 mg/kg of buprenorphine and 
anesthetized with isoflurane.  An incision was made and muscle bellies bisected and 
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major vessels cauterized before coxo-femoral dislocation.  The muscle and subcutaneous 
tissues were closed using 4-0 maxon suture (Syneture; Norwalk, CT) before closing the 
epidermis using surgical wound clips (Becton Dickinson; Sparks, MD).  Mice were 
recovered on room air and received 0.05 mg/kg of buprenorphine every 12 hours for 72 
hours post-surgery.  Mice also received 100 µL of saline IP every 12 hours for 24 hours 
post-surgery.  Weight was monitored as a surrogate for wellness, and mice with a greater 
than 10% weight loss postoperatively were euthanized. 
 To determine when metastases developed in the surgical adjuvant model, mice 
were challenged with DLM8-luc-M1 orthotopically.  Beginning 7 days post tumor 
challenge, mice were amputated every three days as described above.  Mice were then 
imaged for metastases twice a week to determine the time point at which 100% of mice 
developed luciferase positive metastases.  
 
Characterization of Metastases 
To further characterize the metastatic capabilities of DLM8-luc-M1, mice were 
challenged with orthotopic tumors and tumors allowed to grow for 16 days.  The 
orthotopic tumors were then surgically resected by amputation of the tumor-bearing limb 
as previously described.  Day 16 was selected as the time point after which 100% of mice 
developed metastases following tumor removal by amputation as evidenced from 
experiments above.  Mice (n=5 per group) were euthanized on day 16 and every three 
days following.  Following euthanasia, lungs, tumor draining lymph node, and ovaries 
were isolated, formalin fixed, and paraffin embedded.  Organs were sectioned into 3 
distinct and separate planes before undergoing H&E staining.  Each section was then 
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reviewed by a single trained pathologist (EJE) for the presence of metastases.  Images of 
representative metastases were taken at 100x. 
  
Chemotherapy and Treatment Experiments 
 To determine if treatment responses could be measured in the surgical adjuvant 
model, mice were orthotopically challenged with DLM8-luc-M1, and then amputated 16 
days post-tumor challenge as determined from previous experiments to ensure that all 
mice developed metastases.  Treatment was then initiated 24 hours post-amputation.  
Mice (n=5-8 per group) were treated with cationic liposome DNA complexes (CLDC; 
200 μL/mouse weekly IV), liposomal clodronate (LC; 200 μL/mouse weekly IV), 
metformin (250 mg/kg daily IP), carboplatin (60 mg/kg weekly IP), doxorubicin (5 
mg/kg weekly IV), or 2-deoxyglucose (2DG; 500 mg/kg thrice weekly IP) for one month 
postoperatively.  Mice were imaged twice a week after amputation to observe the 
formation of luciferase positive metastases.  Mice were euthanized immediately upon 
showing signs of distress due to metastatic disease. 
 
Statistical Analysis 
 Statistical analysis was performed using Prism 5 (GraphPad Software, La Jolla, 
CA).  Time to metastasis data was analyzed using Kaplan-Meier log-rank analysis.  For 








Characterization of Luciferase Transfected DLM8 Osteosarcoma Cells 
 DLM8 cells were transfected to incorporate the luciferase gene as described in the 
methods.  To enhance for the metastatic phenotype, in vitro selection was performed and 
followed by orthotopically challenging C3H mice.  Luciferase positive lung metastases 
were selected and underwent a single round of G418 treatment to further select for 
luciferase transfected DLM8 cells; resulting in the formation of the DLM8-luc-M1 cell 
line.  Quantification of luciferase intensity of the DLM8-luc-M1 cell line was described 
by serially diluting cells in vitro and imaging using the IVIS system as described in the 
Methods (Figure 5.1).  Chemiluminescence above background levels was clearly 
detectable in each of the wells and increases in chemiluminescent signal correlated 
linearly (r2=0.9639, p<0.0001) with increased cell number over this range.  A significant 
(r2=0.8060, p<0.01) correlation was also observed in vivo when luciferase intensity was 
compared to tumor size as measured by longest diameter (Figure 5.1), cross-sectional 
area, and volume. 
  
Characterization of the Orthotopic Tumor 
 To characterize tumor growth of the DLM8-luc-M1 cell line, cells were injected 
orthotopically into the tibias of syngeneic and immunocompetent mice as described in the 
Methods.  Tumors were allowed to grow and could be visualized after intraperitoneal 
injection of luciferin (Figure 5.2).  After two weeks of tumor growth, mice were 




formalin fixed before undergoing analysis by micro-computed tomography (microCT; 
Figure 5.2).  MicroCT revealed osteoproductive/osteolytic areas typical of OS growth 
when compared to normal bone.  After imaging, limbs were decalcified and sectioned for 
H&E staining.  Tumor invasion of the tibia was observed by histology compared to 
 
Figure 5.1: Luciferase expression by DLM8-luc-M1.  A) Luciferase transfected 
DLM8 cells (DLM8-luc-M1) were plated in two-fold serial dilutions and imaged 
using the IVIS system as described in the methods.  B) Quantification of the luciferase 
signal over this range of dilutions was observed to have a significant (p<0.0001) linear 
correlation.  C) Quantification of the luciferase signal from subcutaneous DLM8-luc-
M1 tumors was significantly correlated to tumor diameter (p<0.01). 
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normal bone (Figure 5.2).  Histopathology was characterized by sheets of plump 
neoplastic spindloid cells producing tumor-associated osteoid and causing significant 
effacement and osteolysis with residual embedded spicules of bone.  The tumor had 
multifocal areas of necrosis. The tumor extended through bone cortices with a significant 
paraosteal soft tissue component.   
 
Comparison of Orthotopic and Subcutaneous Tumor Metastasis 
 To compare the metastatic capabilities of the newly formed DLM8-luc-M1 cell 
line, groups of mice (n=7 mice per group) were challenged with the same number of cells 
orthotopically or subcutaneously.  Mice were then followed for the development of 
luciferase positive metastases (Figure 5.3).  Metastatic disease was first apparent by 
luciferase imaging at Day 20 post orthotopic challenge and 100% of the mice implanted  
 
Figure 5.2:  Characterization of orthotopic DLM8-luc-M1 tumors.  Mice were 
challenged orthotopically with DLM8-luc-M1 tumors as described in the methods.  
Mice were imaged for luciferase expression (A) from the primary tumor immediately 
before sacrifice.  Both the tumor bearing and contralateral hind limbs were formalin 
fixed and imaged using microCT (B) before being prepared for histology (C; 200x 
magnification).  Tumor associated osteoid with atypical cells within lacunar like 




orthotopically metastasized to visceral organs within 27 days after tumor challenge 
(Figure 5.4).  Surprisingly, none of the mice with DLM8-luc-M1 tumors implanted 
subcutaneously developed metastases before having to be euthanized due to the size 
(greatest diameter = 15 mm) of their primary tumors.  These data confirm previous 
observations that tumor growth in an orthotopic environment can significantly alter 
metastatic formation [31, 32]. 
 
Characterization of Metastatic Progression in Target Tissues 
 Having validated the metastatic potential of the DLM8-luc-M1 line, we next 
determined the metastatic potential of the tumors in a surgical treatment setting.  We 
asked how long the primary tumor needed to be in place prior to surgical treatment to 
guarantee that 100% of mice orthotopically challenged with DLM8-luc-M1 developed 
metastases.  To accomplish this, a surgical amputation model was used by coxo-femoral  
 
Figure 5.3:  Description of metastases to distant organs.  Mice were challenged 
orthotopically with DLM8-luc-M1 as previously described.  Mice were serially 
imaged using luciferase to determine the progression of metastases.  A) Mouse one 
week after tumor challenge with primary tumor.  B)  Mouse three weeks after tumor 




dislocation and amputation of the tumor bearing limb as described in the Methods.  Mice 
were challenged with orthotopic DLM8-luc-M1 tumors which were allowed to grow for 7 
days.  At this time, and every three days thereafter (days 7, 10, 13, and 16), groups of 
mice (n=5 per group) were amputated.  Mice were then followed for two months to 
determine if they developed metastases.  Mice amputated at 7 days did not develop 
metastases, suggesting that direct seeding of peripheral organs during tumor challenge 
did not occur, and that formation and maturation of the primary tumor is required.  
However, the earliest time point at which 100% of mice developed organ metastases was 
16 days post-tumor challenge (Figure 5.5).  In mice amputated 16 days post-tumor 
challenge, detectable metastasis occurred at a median of 24 days postoperatively, and 
median survival time was 33 days.  Gross metastatic disease after sacrifice was 
predominantly located in the lung, liver, and ovaries of mice succumbing to disease.  
 
Figure 5.4:  Determination of metastatic capabilities of DLM8-luc-M1 from an 
orthotopic location.  Mice (n = 7 per group) were challenged orthotopically or 
subcutaneously with equal numbers of DLM8-luc-M1 tumor cells.  Mice were then 
followed for the formation of luciferase positive metastases in visceral organs.  All 
orthotopic mice had developed distant metastases by 27 days after challenge.  
However, all mice challenged subcutaneously were euthanized due to the large size of 
their primary tumors (15 mm greatest diameter), and none were found to have grossly 
visible metastases post-mortem. 
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These data suggest that experiments can be performed in which all mice orthotopically 






Figure 5.5:  Determination of time to micro-metastatic disease in DLM8-luc-M1 
orthotopic model.  To determine the time at which 100% of mice whose primary 
tumor is amputated develop visceral metastases, mice (n = 5 per group) were 
orthotopically challenged with DLM8-luc-M1.  Beginning 7 days after challenge, and 
every 3 days thereafter, one group of mice were amputated.  Mice were followed to 
determine if metastases developed by luciferase imaging and gross inspection after 
sacrifice.  The earliest time point at which 100% of mice developed visceral 
metastases was 16 days post-tumor challenge (A). Representative bioluminescent 
images of mice before amputation are depicted on a standardized scale (C).  To 
determine the time at which 100% of mice develop histologic lung metastases in the 
post-surgical model, mice (n = 5 per group) were orthotopically challenged with 
DLM8-luc-M1, and tumor bearing limbs amputated 16 days after tumor challenge.  
Beginning 16 days after tumor challenge, and every 3 days thereafter, mice were 
sacrificed and lungs taken for histologic analysis of micro-metastatic disease.  The 
earliest day at which 100% of mice develop histologic lung metastases was 22 days 




Characterization of Metastases 
 Mice were challenged with orthotopic DLM8-luc-M1 as previously described and 
tumor-bearing limbs amputated 16 days post-challenge.  Mice were then euthanized on 
day 16 and every three days subsequently.  Lungs and ovaries were harvested, formalin 
fixed, and sectioned for characterization of micrometastatic disease.  A single board-
certified pathologist reviewed the sections for the presence of micrometastases. One 
hundred percent (n=5 per group) of mice had evidence of micrometastatic disease in the 
lung by day 22 post-tumor challenge (6 days post-amputation; Figure 5.5).  Tumor nests 
were present as early as 16 days post-tumor challenge (Figure 5.6).  The primary route of 
metastasis appeared to be hematogenous, owing to the presence of numerous 
intravascular tumor nests (Figure 5.7).  Tumor draining lymph nodes were also assessed, 
but there were no tumors present in these tissues.  However, it is of interest that none of 
the mice developed large/gross lung metastases within this time period.  Interestingly, a 
number of mice also developed metastases in the ovaries, and these organs became 
rapidly and completely effaced (Figure 5.6). 
 
Chemotherapy Delays Metastasis in the DLM8-luc-M1 Orthotopic Surgical Adjuvant 
Model 
 To determine if the presence of luciferase positive metastases could be used as an 
indicator of disease progression, we combined chemotherapy with the surgical adjuvant 
model previously described.  The goal was to recreate the clinical scenario that 
accompanies treatment of OSA patients. Mice were challenged with orthotopic DLM8-






Figure 5.6:  Characterization of lung and ovary metastases in the post-surgical 
setting.  Mice were challenged orthotopically with DLM8-Luc-M1 tumors.  Tumor 
bearing limbs were amputated 16 days post-challenge.  Beginning on day 16 and 
continuing every three days thereafter, mice were sacrificed and lungs and ovaries 
were formalin fixed.  All samples were evaluated for the progression of metastases 
and representative images shown at 100x magnification.  A) Normal Lung.  B) Small 
nest of cells in the lung.  C) Large nest of pulmonary metastasis.  D) Normal Ovary.  




Figure 5.7:  Hematogenous metastasis as evidenced by intravascular nest in the lung.  
Mice were challenged with DLM8-luc-M1 and amputated 16 days pos-tumor 
challenge as previously described.  Lungs were placed in formalin as previously 
described.  Presence of an intravascular nest with parenchymal invasion (arrow) is 
present suggesting the route of metastasis for lung metastases. 
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occurred (16 days post-tumor challenge) and mice were amputated as previously 
described.  Twenty-four hours post-amputation, chemotherapy or immunotherapy were 
initiated as described in the Methods.  Doxorubicin and carboplatin are considered 
standard of care in the adjuvant of OSA treatment, and were thus chosen for these 
experiments [33, 34].  2DG is a glycolytic inhibitor which exploits metabolic changes in 
cells addicting them to glycolysis [35, 36].  CLDC and LC are immunotherapies 
previously described [25, 26].  Metformin is a mitochondrial inhibitor and acts as an 
inhibitor of gluconeogenesis [37, 38].  We found that treatment with doxorubicin 
(p=0.007), carboplatin (p=0.004), 2DG (p=0.0246), and a combination of doxorubicin 
and 2DG (p=0.0029), led to a significant delay in time to detection of luciferase positive 
metastases (Figure 5.8).  There was also a significant (p<0.05) increase in survival time 
in the treated mice when compared to control except mice treated with 2DG had a 
significant increase in DFI, but not overall survival (p>0.05) (Figure 5.8).  Metformin, 
CLDC, and LC failed to significantly (p>0.05) increase DFI or overall survival (Figure 
5.8).  Therefore, we have shown that the orthotopic implantation of the DLM8-luc-M1 
cell line followed by amputation of the tumor bearing limb after the production of 
micrometastases can be used to investigate the therapeutic efficacy of novel compounds 
for the inhibition of metastases.  Thus, the surgical adjuvant model proposed herein in 
combination with chemotherapy may be used to further elucidate efficacious therapies 




Figure 5.8:  Osteosarcoma metastases are inhibited by chemotherapy.  Mice (n=5-8 mice per group) were challenged 
orthotopically challenged with DLM8-luc-M1.  16 days later, mice were amputated.  24 hours post-amputation, treatment 
was initiated and DFI, as determined by luciferase positive metastases, and survival measured.  A) Treatment with cationic 
liposome DNA complexes (CLDC) or liposomal clodronate (LC).  B) Treatment with carboplatin or metformin.  C) 
Treatment with doxorubicin, 2DG, or a combination thereof (combo).  All significant comparisons (p<0.05) are denoted by 






 Osteosarcoma is the most common primary bone tumor in humans and dogs [3, 
33].  The primary cause of death in osteosarcoma is the development of metastatic 
disease.  Consequentially, novel tumor models that are able to recapitulate the clinical 
scenario are required to screen new therapeutics for OSA.  Therefore, we created a 
luciferase transfected murine OSA cell line that can be implanted orthotopically in 
syngeneic immunocompetent mice and spontaneously metastasize after removal of the 
tumor bearing limb.  We have also identified a time point at which 100% of the mice 
develop micrometastases, further strengthening this model and decreasing inter-
experiment variability.  Furthermore, the ability to serially image these mice and define a 
time to luciferase positive metastases in a chemotherapy treatment model suggests that 
this model may be used to investigate novel therapeutics for the treatment of 
osteosarcoma metastases. 
 There are numerous models of OSA in mice currently, encompassing human 
xenografts [4, 6-9, 13, 15] and syngeneic murine tumors [10, 11, 14, 17].  These models 
can further be described by those that are luciferase transfected [14, 15], and those that 
may be implanted orthotopically [4, 6-8, 10, 11, 13-15].  However, to our knowledge, this 
is the first model that is luciferase transfected in immunocompetent mice that utilizes a 
surgical adjuvant approach. 
Our goal was to define a model that closely resembled the clinical experience in 
which patients undergo surgery for removal of their primary disease so as to provide a 




was based upon the DLM8 tumor model previously described [17].  The ability to 
transfect tumors with luciferase has allowed for the systemic tracking of metastasis 
formation [14, 15]; however, study of metastases independent of the primary tumor has 
not yet been evaluated.  It has been shown that orthotopic tumor models better 
approximate the tumor microenvironment of naturally occurring tumors in humans, and 
thus serve as better models of disease [31, 32, 39].  It has also been suggested that the use 
of syngeneic tumors in immunocompetent mice is superior to that of human xenografts in 
nude mice [18, 19].  By using immunocompetent mice, natural interactions between the 
tumor and host microenvironment and immune system are preserved.  The production of 
various factors from human tumor xenografts may not properly interact with their mouse 
counterparts as has been previously shown in various chemokines and cytokines [40].  
The use of nude mice disrupts these interactions, and leads to the murine stromal and 
immune components interacting with human tumor cells [18, 19, 41, 42].  Therefore, we 
sought to create a model in syngeneic mice that could be implanted orthotopically and 
would metastasize spontaneously. 
It has been shown that 20% of patients presenting with OSA will have clinically 
detectable metastases at diagnosis, although it is believed that a much higher percentage 
of patients have micrometastatic disease at this time [34, 43].  It is noted that 30-40% of 
patients with OSA will die from metastases, primarily to the lung, despite aggressive 
medical therapy [34, 43, 44].  Therefore, we defined a time at which 100% of mice 
challenged orthotopically with DLM8-luc-M1 have micrometastatic disease to decrease 
inter-experiment variability.  Much like the clinical scenario, we are able to amputate the 




The ability to track metastases using a non-invasive modality such as luciferase imaging 
is a powerful tool that can be used to assess time to metastasis of novel OSA therapeutics. 
We observed that a majority of mice developed histologically detectable 
micrometastatic lung disease within a week after amputation, with the presence of disease 
present in some mice on the day of amputation.  The observation that mice develop 
pulmonary micrometastatic disease, but rarely succumb to these metastases upon gross 
inspection, suggests that these tumor cells are not able to form large tumor masses in the 
lung environment.  It has been previously shown that numerous events are required for 
metastases to form in a peripheral organ [45-48].  For example, tumor cells must 
extravasate from circulation and colonize the foreign environment before expanding into 
larger metastases [45].  We have observed that metastasis of this model is by 
hematogenous spread, which mimics previous observations in human patients [49].  We 
have also demonstrated that tumor emboli that enter the lung invade into the vessel wall 
with extravasation into the adjacent parenchyma.  It has previously been suggested that 
the transfection with GFP may alter OSA biology, and the transfection with luciferase 
may imply a similar caveat here leading to the altered behavior of lung metastases [50].  
Furthermore, differences in the metastatic capabilities of various cell lines have been 
previously observed, and might be the cause for these observations [10, 12].  Even 
though mice do not succumb to gross lung metastases, these micrometastatic nodules 
may still be used to assess efficacy if novel treatments, since the lung can still be 





 Previous studies have investigated the effects of a variety of therapeutics on 
primary orthotopic tumors [51, 52].  Therefore, the ability to evaluate novel therapies in 
relevant tumor models is crucial to discovering new treatment modalities.  Interestingly, 
we observed that a novel agent (2DG) inhibited metastasis but did not significantly 
increase overall survival.  It is plausible that the inhibition of the glycolytic pathway led 
to a decrease in cellular ATP, a known co-factor of luciferase, and diminished the 
luciferase signal so that metastases could not be visualized by this imaging technique 
although present.  Further investigation into the phenomenon is currently being 
performed.  However, conventional chemotherapeutic agents, carboplatin and 
doxorubicin, delayed metastatic formation and significantly increased survival.  
Combination of 2DG and doxorubicin was performed based on prior evidence in the 
literature suggesting this as a synergistic combination for the treatment of other tumors, 
although this does not appear to be true within this model [53]. 
In diseases such as OSA, where treatment of metastasis is of critical importance, 
it is important to have models where the clinical scenario is closely recapitulated.  
Treatment of micrometastases may be very different than treatment of primary tumors.  
In mouse models, many primary tumors are induced with large numbers of cells injected 
into a small focus, and typically in heterotopic sites.  Our model allows the primary 
tumor to mature and metastasize, thus selecting for cells with a sufficient metastatic 
phenotype that must undergo intravasation, circulation, extravasation, and survival in 
distant tissues [45-48].  Indeed, study of these events and the role that various therapies 
may play in altering these pathways may be studied and targeted.  The treatment of 




many of the pressures associated with the process of metastasis which cannot be studied 
in vitro or in primary tumors [18, 19].  By using a model that retains the metastatic 
phenotype, it may be possible to study the mechanism of metastasis as well as develop 
novel therapeutics to inhibit not only the metastatic foci present, but the process of 
metastasis as a biologic endpoint. 
 We have created a model of murine OSA that allows for the development of 
spontaneous micrometastases.  The removal of the primary tumors is crucial because it 
differentiates treatment effects on the primary tumor from those indirect effects of tumor 
micrometastases.  This model may thus be used to study the processes associated with 
metastasis and investigate novel therapeutics for the treatment of OSA.  The transfection 
of luciferase into the DLM8 cell line allows for serial non-invasive imaging of metastases 
and acts as a positive indicator for the development of metastases in distant organs.  
Therefore, we believe that this model may allow for the study of novel OSA therapeutics 





 In this chapter, we have explored the development of a novel model of 
osteosarcoma that spontaneously metastasizes in the post-surgical setting.  The creation 
of this model will allow for the evaluation of the hypothesis made in chapter 2 that 
localized infection can systemically inhibit tumor growth.  I hypothesize that localized 




Preliminary data using a model in which mice are orthotopically challenged with tumors 
as described in this chapter and then infected with biofilms present on catheter segments 
(similarly to that presented in chapter 2) suggests that infection can inhibit systemic 
tumor growth and metastases (Figure 5.S1).  However, repeating these experiments is 
important to determine the validity of these findings, although preliminary observations 
are promising.  It would also be interesting to combine infection with chemotherapy to 
best mimic the clinical scenario.  Dogs developing infections also receive adjuvant 
chemotherapy, and incorporating this methodology into the mouse model would 
strengthen the conclusions made concerning inhibition of osteosarcoma by 
osteomyelitis/infection.  Combination of this work with the proposed studies in chapter 2 
investigating localized and systemic changes in infiltrating cells may better explain the 
phenomenon observed in the clinic. 
 
Figure 5.S1:  Infection increases survival in the post-surgical model.  Mice were 
challenged orthotopically with DLM8-luc-M1 and tumor bearing limb amputated 16 
days post-challenge as previously described.  Twenty-four hours after amputation, 
mice were challenged with infected catheter segments subcutaneously in the dorsum.  
Survival was significantly (p<0.05) increased for infected mice (n=4) compared to 




 In this chapter, the observation was made that 100% of mice develop lung 
metastases in this model.  However, few mice succumb to gross lung metastases, and 
rather succumb to disease localized to other organs.  It would be of interest to further 
characterize these lung metastases, and describe differences between metastases of 
different mice.  I hypothesize that mice that succumb to lung pathology have been 
selected for differently by the metastatic process and have a variant genetic expression 
profile compared to the primary tumor.  To investigate this hypothesis, a group of mice 
would be challenged orthotopically before undergoing amputation as previously 
described.  In order to circumvent death due to large ovarian metastases, male or 
ovectemized female mice may be used for study.  At the time which the first mouse 
succumbs to disease (pulmonary or otherwise) lungs from both groups of mice would be 
taken and analyzed by microarray after being histologically described and graded.  
Comparisons would then be made between mice with microscopic lung pathology, and 
those with more extensive pathology.  Genetic analysis would be performed to determine 
if clonal selection of tumor cells was a factor in enhancing the progression of lung 
metastases in a cohort of mice. 
 Analysis of the entire tumor burden is required since stromal and micro-
environmental factors are likely playing a role in this phenotype and need to be included 
in the analysis.  If genes of interest are discovered, analysis of the tumor cells themselves 
versus the stromal components in both the primary and metastatic lesions would be of 
interest.  Differences in angiogenic factors, immune inhibition factors, pro-metastatic 
factors, and survival factors would likely be the basis of this analysis.  PCR would then 




the lungs and tumor microenvironments could also be performed by IHC to better 
characterize the lung environment to determine if changes in this location may have 
altered the progression of these metastases.  For some reason there is a pre-disposition to 
some mice succumbing to lung metastases even though all mice develop small metastatic 
foci in the lungs.  Similarly, it would be interesting to determine why this tumor invades 
the ovaries since this is not typically a location of metastasis in clinical disease.  It is 
therefore important to understand these clonal variants and better describe them for they 
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Increased Circulating Monocytes and Lymphocytes are 





Identification of biomarkers that could better predict outcomes in dogs with 
osteosarcoma would be valuable to veterinarians and owners.  Recent studies suggest that 
leukocyte numbers in peripheral blood may be associated with outcomes in some types of 
cancer in humans.  We therefore examined whether pre-treatment numbers of monocytes 
and other leukocytes were associated with disease-free interval in dogs with appendicular 
osteosarcoma.  Medical data from 313 dogs with osteosarcoma evaluated at Colorado 
State University over a 4-year period, including 69 dogs with appendicular osteosarcoma 
treated with amputation and chemotherapy that were selected for additional study.  This 




leukogram values, tumor location, and serum alkaline phosphatase in osteosarcoma 
patients.  Statistical associations were assessed using univariate and multivariate analysis.  
Higher pre-treatment numbers of circulating monocytes and lymphocytes were 
significantly associated with shorter DFI in dogs with osteosarcoma.  Other parameters 
associated with poor outcomes were elevated alkaline phosphatase, primary tumor 
location, and age.  These results indicated that pre-treatment evaluation of monocyte and 
lymphocyte counts provided prognostic information for dogs with appendicular 
osteosarcoma.  Notably, most animals in this study had monocyte counts within the 
normal reference range, indicating that variations within the normal range of leukocyte 






 Osteosarcoma (OSA) is the most common primary bone tumor of dogs [1, 2].  
The median survival time in dogs with OSA is approximately 1-year following surgery 
and adjuvant chemotherapy, with fewer than 30% becoming long term survivors [3].  
Metastasis to the lungs is most common cause of death in dogs with OSA [3].  Given the 
fact that less than 50% of dogs with OSA will survive beyond a year, there is a need for 
biomarkers that might predict disease outcomes more effectively.   
 Many of the biomarker assays currently being investigated involve the use of gene 
expression profiling and proteomic approaches [4-6].  However, at this time, many of 
these techniques are time consuming and prohibitively expensive, particularly for 
veterinary patients [4].  Moreover, few of the gene profiling or proteomic approaches 
have been validated in dogs.  To date, the serum alkaline phosphatase (SAP) 
concentration is the only biomarker shown to be associated with disease free interval 
(DFI) and overall survival (OS) in dogs with OSA [7-9].  Thus, there remains a strong 
need for reliable, easy-to-use, and cost effective assays for determining prognostic 
information for dogs with OSA.   
Previous studies have shown that circulating monocytes can give rise to tumor 
promoting macrophages in mice, and are directed to the tumor by monocyte 
chemoattractant protein-1 (MCP-1) [10-14].  Recently, a great deal of attention has been 
focused on the role of macrophages in promoting tumor growth [14-16].  Moreover, 
several studies in human cancer have demonstrated a correlation between pre-treatment 




macrophages in tumors have been associated with reduced survival times in humans with 
a variety of tumor types [22-25].  Therefore, it is plausible that increased monocytes may 
be prognostic in canine OSA. 
 Other studies have found that numbers of circulating lymphocytes also have 
prognostic relevance for human cancer patients [19-21, 26].  For example, increased 
numbers of total lymphocytes has been associated with increased survival in pancreatic 
and renal tumor patients [27, 28].  More recently, lymphopenia was found to be a 
negative prognostic finding in humans with various cancers [29].  Therefore, it is 
plausible that pre-treatment numbers of circulating lymphocytes may also be prognostic 
in dogs with OSA. 
 In the current study, we evaluated whether numbers of circulating leukocytes 
were associated with outcome (DFI) in dogs with OSA.  The study retrospectively 
evaluated a relatively uniform population of dogs with appendicular OSA that underwent 
amputation followed by adjuvant chemotherapy.  Other factors potentially associated 
with outcome, including age, primary tumor location, and SAP concentration were also 
evaluated.  The results of these studies suggest that evaluation of pre-treatment 










Materials and Methods 
 
Patient Selection 
 The study included a total of 313 dogs evaluated for OSA at the Animal Cancer 
Center at Colorado State University (CSU) between 2003 and 2006.  Inclusion criteria 
included: 1) a diagnosis of appendicular OSA without metastases as determined by 3-
view thoracic radiographs +/- 99Tc scintigraphy; 2) treatment by amputation; 3) treatment 
with standard adjuvant doxorubicin (30 mg/m2), carboplatin (300 mg/m2), or an 
alternating combination of both therapies; 4) CBC and blood chemistry performed at 
CSU within one week prior to surgery.  From the original 313 dogs that were screened, 
69 were identified that met entry criteria. Disease free interval (DFI) was defined as the 
time between treatment initiation and detection of tumor metastases.  It was 
recommended that patients undergo 3-view thoracic radiographs every 2-3 months 
following diagnosis to determine metastatic progression and thus DFI. 
 A second population of dogs with OSA that were treated at the Animal Cancer 
Center at CSU was evaluated using identical criteria to assess the reproducibility of 
results obtained from the first population.  Dogs included in the original data set were 
excluded from this second population.  A total of 21 dogs were identified in the second 
population (Population 2) and were compared to the 69 dogs in the first population 
(Population 1) and the 244 dogs excluded from population 1.  Leukocyte values were also 







 To determine if MCP-1 levels were associated with monocyte counts or DFI, 
serum from 31 of the dogs in population 1 archived at the Colorado State University 
Animal Cancer Center was obtained.  Serum was analyzed using a commercially 
available ELISA for canine MCP-1 (R&D Systems, Minneapolis, MN).  Analysis was 
then performed to investigate the association between MCP-1 and pre-treatment 
monocyte number, as well as the prognostic significance of pre-treatment MCP-1. 
 
Statistical Analysis 
 Statistical analysis was performed using Prism 5 (GraphPad Software, La Jolla, 
CA) and SAS and PROC PHREG software (SAS v9.2, SAS Institute Incorporated, Cary, 
NC).  Variables assessed for association with DFI included age (years), sex 
(male/female), breed, primary tumor location (humerus versus all other locations), serum 
alkaline phosphatase (SAP, normal (30-142 IU/L) or elevated (>142 IU/L), and leukocyte 
values obtained by CBC (segmented neutrophils, lymphocytes, monocytes, and 
eosinophils).   
 Population parameters between dogs included and excluded from the study were 
compared statistically using a two-tailed Mann-Whitney t-test since the variables were 
not normally distributed, as determined by the D’Agostino and Pearson normality test.  
Population parameters between dogs in Population 1 and Population 2 were also 
compared using Mann-Whitney t-test.  Comparison of dichotomous variables (e.g. sex) 
between the groups was performed using a Fisher’s exact test.  Estimates of disease-free 




categorical variables (e.g. leukogram values and age) were divided into two groups based 
upon the median (≤median and >median) value of all patients included in the study.  
Comparisons were then made using a Mantel-Cox (log-rank) test to determine 
significance. 
 A multivariable Cox’s proportional hazard regression analysis was performed to 
determine the independent leukogram variables significantly associated with DFI. 
Variables and covariates such as: location, chemotherapy, SAP, age, sex, and breed were 
included in the model to account for their effect in the analysis.  The groups determined 
by division of the median were also used for this analysis.  PROC PHREG in SAS v9.2 
allows inclusion of a ‘CLASS’ statement with reference specified for each categorical 
variable.  Selection process of the significant variables was performed using a ‘Stepwise 
backward elimination method’ taking ‘p to enter=0.25’ and ‘p to stay=0.1’. The variables 
that would impact the outcome (CBC variables in question) were forced into the model 
and other variables moved in and out of the model as per the selection criteria through the 
model building process. 
 The median and the inter-quartile range are depicted throughout all tables.  All 












Patient Selection and Overview 
Sixty-nine of the 313 dogs with OSA evaluated met the inclusion criteria and 
were included in the study (Table 6.1).  None of the included dogs received cytotoxic 
chemotherapy or surgery for their tumor prior to the time blood was collected for CBC 
and serum biochemical analysis.  There were 244 dogs that did not meet inclusion criteria 
for the following reasons: presence of a second, unrelated tumor (n=3); incomplete 
evaluation for metastasis at the time of diagnosis (n=2); limb sparing surgery performed 
instead of amputation (n=69); axial tumor location (n=38); metastasis present at time of 
diagnosis (n=7); pre-treatment CBC result not in record (n=22); previous tumor 
diagnosed or treated (n=5); adjuvant chemotherapy not administered, or pursued at 
another institution and specifics of chemotherapy not detailed in the medical record 
(n=58); radiation therapy administered (n=10), surgery performed at a veterinary hospital 
other than CSU (n=11); or animal treated with non-standard chemotherapy (n=19).  The 
medical records of dogs in the study were evaluated to obtain information on sex, breed, 
weight, age, primary tumor location, SAP, and CBC results, and DFI.   
 The signalment parameters of the 69 dogs included in the study were compared to 
signalment information from the 244 dogs excluded.  We found no significant differences 








Univariate Analysis of 69 Dogs Included in the Study 
Next, we sought to determine if leukogram values in the 69 dogs in the primary 
study population correlated with disease-free interval (DFI).  In addition, we assessed 
whether primary tumor location, age, or SAP correlated with outcomes, based on results 
of previous studies [1, 7-9, 30, 31].  Twenty of the 69 dogs were censored in DFI analysis 
Table 6.1: Patient characteristics of 69 dogs in the primary population. 
 
Age (Yrs) Median (Range) 8 (2-14) 







Spayed Female 28 
 
Intact Female 1 
 
Castrated Male 38 
 






  Mix 16 
  Labrador retriever 11 
  Greyhound 7 
  Golden retriever 6 
  Rottweiler 6 
  Great Pyrenees 5 
  Doberman Pinscher 3 
  Mastiff 3 
  English Setter 2 
  Irish Setter 2 








  Tibia 12 
  Femur 11 
  Ulna 2 





because of loss to follow-up prior to an event (n=14) or euthanasia due to diseases other 
than cancer (n=6).  The median duration of follow-up for the 20 censored dogs was 179 
days.  The median DFI for the entire population was 194 days, with 29% and 9% of dogs 
metastasis-free at 1 and 2 years, respectively.  
 When associations between leukogram values and DFI were assessed using 
univariate analysis, monocyte count (above or below the median value, 0.4 x 103/µL) was 
the only leukogram variable significantly associated with DFI (p=0.015) (Table 6.2 and 
Figure 6.1).  Notably, 59 of the 69 dogs in this study had monocyte counts within the 
normal range (0.1-1.0x103 monocytes/µL).  This finding is important because prior 
studies in humans have only evaluated associations between increased monocyte counts 
(i.e., monocytosis) and outcomes and have not investigated outcome associations with 
monocyte counts in the normal range [17, 18, 20, 21].  In our study, only 5 dogs had 
increased monocyte counts (>1.0x103/µL) and 5 dogs had low monocyte counts 
(<0.1x103/µL).  Interestingly, in the 5 dogs with true monocytosis (>1.0x103 
monocytes/µL), the median DFI was significantly shorter (84 days) when compared with 
the overall DFI of the 59 dogs with normal monocyte counts (194 days; p<0.0001).   
The only other variable associated with DFI that was detected using univariate 
analysis was location of the primary tumor.  Dogs with primary tumors of the humerus 
had a significantly reduced DFI compared to dogs with primary tumors in other 
appendicular locations (p=0.002) (Table 6.2).  All other primary tumor locations were 
evaluated and the humerus location was the only location significantly associated 
(p<0.05) with decreased DFI.  There was no significant correlation between SAP 




there was no significant association between the type of chemotherapy administered 
(single agent doxorubicin, carboplatin, or a combination thereof) and DFI (p=0.6638).   
 
Multivariate Analysis of 69 Dogs Included in the Study 
Multivariate modeling was performed using the population of 69 dogs with OSA 
to identify variables that might be independently associated with DFI.  When all variables 
were subjected to multivariate analysis, it was determined that age (p=0.0156), SAP 
(p=0.0065), primary tumor location (p=0.0087), monocyte number (p=0.03) and 
lymphocyte number (p=0.04) were each significantly and independently associated with 
DFI (Table 6.3).  Specifically, higher monocyte and lymphocyte counts were associated 
with significantly reduced DFI, compared to dogs with lower monocyte and lymphocyte 
counts.  It is important to note that treatment with adjuvant doxorubicin and/or platinum 
based therapy did not significantly (p>0.05) or independently affect DFI. 
 
 
Figure 6.1: Kaplan-Meier analysis of the relationship between DFI and monocyte 
counts in dogs with OSA.  Increased monocyte counts (>0.4x103 monocytes/μL) were 
significantly (p=0.015) associated with decreased DFI when compared to dogs with 





Table 6.2:  Univariate analysis of population one associations between leukogram and clinical variables and DFI in 69 
dogs with appendicular osteosarcoma. 
 
 
Variable   Number of dogs Median DFI (d) p-value a) HR b) 1 Yr c) 2 Yr d) 
Monocyte Count 
(x103 cells/μL)               
  ≤0.4 35 466 0.015 2.09 54% 27% 
  >0.4 34 202     25% 11.03% 
Lymphocyte Count 
(x103 cells/μL)               
  ≤1 36 291 0.138 1.09 45% 15.63% 
  >1 33 267     35% 7.81% 
Location               
  Humerus 21 194 0.002 3.34 14% 0.00% 
  Other 48 383     51% 21.13% 
SAP               
  Normal 49 345 0.092 1.79 49% 21.64% 
  High 20 149     19% 12.86% 
Age               
  ≤8 39 204 0.188 0.59 35% 15.63% 
  >8 30 345     46% 23.70% 
 
 
a) p-values were calculated using Log-rank (Mantel-Cox) Test; significance defined as p < 0.05. 
b) HR = Hazard Ratio 
c) 1 Yr = One-year disease free percentage 






Evaluation of Pre-Treatment MCP-1 
 Serum from 31 dogs in population 1 was analyzed by ELISA for MCP-1.  We 
first sought to determine if there was an association between the circulating concentration 
of MCP-1 and pre-treatment monocytes since MCP-1 is one of the primary cytokines 
involved in eliciting monocytes from the bone marrow.  There was no significant 
(p>0.05) relationship between pre-treatment MCP-1 and monocyte counts in these 
patients (Figure 6.2).  Next, we wanted to determine if prognostic information could be 
obtained from MCP-1 concentrations.  Dogs were divided into two groups based upon the 
median MCP-1 value and compared by Kaplan-Meier log rank test.  There was no 
significant (p>0.05) difference in outcome as measured by DFI based upon MCP-1 
concentration (Figure 6.2).  
Table 6.3: Multivariate analysis of associations between leukogram and clinical 
variables and DFI in dogs appendicular osteosarcoma. 
 
Variable Comparison p-value HR a) 95% CI b) 
Lymphocytes High vs. Low 0.041 2.076 1.03 4.18 
Monocytes High vs. Low 0.0311 1.984 1.06 3.70 
Age group >8 vs. ≤ 8yrs 0.0156 0.421 0.21 0.85 
Location Humerus vs. Other 0.0087 2.791 1.30 6.01 
SAP Elevated vs. Normal 0.0065 2.605 1.31 5.19 
 
a) HR = Hazard Ratio 






Evaluation of Values in a Second Independent Population of Dogs 
 Finally, we studied a second population of dogs (Population 2) with appendicular 
OSA that met the same inclusion criteria used for the original population to determine 
whether the associations detected in the first study population were reproducible in a 
second independent population of dogs with OSA.  The second population of dogs was 
also treated at the Colorado State University Animal Cancer Center and 21 dogs met 
inclusion criteria; these dogs are described in Table 6.4. 
The signalment parameters of the 21 dogs in Population 2 were compared to those 
of the 69 dogs included in Population 1 and to the 244 dogs excluded from Population 1.  
There was no significant difference (p>0.05) in age, sex, or weight when these 
comparisons were made.  Furthermore, we also compared the leukocyte variables to those 
present in population 1 and also observed no significant difference (p>0.05) between the 
populations.  Therefore, this population of 21 dogs was comparable, in all important 
respects, to the 69 dogs included in Population 1. 
 
 
Figure 6.2:  MCP-1 concentration is not correlated with monocyte count or 
associated with DFI.  Serum from 31 dogs in population 1 were obtained from the 
CSU-ACC archive and analyzed by commercial ELISA.  A) Monocytes and MCP-1 
do not correlate by Spearman regression.  B) Pre-treatment MCP-1 is not associated 





Associations between monocyte and lymphocyte counts to DFI using identical 
values as the first population were evaluated by univariate analysis using Kaplan-Meier 
survival and Mantel-Cox (log-rank) test.  Dogs with monocyte counts below the median 
value (median DFI=595 days) had a significantly (p<0.002) increased disease free 
interval compared to dogs with monocyte counts above the median (median DFI=200 
days) (Figure 6.3).  Likewise, dogs with lymphocyte counts below the median value 
(median DFI=470) had a significantly increased (p<0.03) disease free interval compared 
to dogs with lymphocyte counts above the median (median DFI= 221 days) (Figure 6.3).  
Primary tumor location was significantly associated with DFI (p=0.0286), although age 
(p=0.6706) and SAP (p=0.1772) were not. 
Table 6.4:  Patient characteristics of 21 dogs in the second population. 
 
Age (Yrs) Median (Range) 9.2 (4.3-13.4) 
Weight (Kg) Median (Range) 37 (26-76) 
    
Sex    
 Spayed Female 10  
 Intact Female 0  
 Castrated Male 9  
 Intact Male 2  
    
Breed    
 Mix 9  
 Rottweiler 4  
 Greyhound 2  
 Other (1 each) 6  
    
Primary Tumor 
Location Radius 7  
 Humerus 5  
 Femur 4  
 Ulna 3  
 Tibia 1  









 Osteosarcoma is the most common bone tumor in dogs, yet the only biomarker 
that is currently used to assess prognosis is SAP [7-9].  Thus, one goal of the current 
study was to determine if information from a routine CBC could be used to help assess 
prognosis in dogs with appendicular OSA.  Notably, we found that the presence of 
increased numbers of monocytes and lymphocytes prior to treatment was significantly 
associated with decreased DFI in dogs with appendicular OSA.  Moreover, multivariate 
analysis demonstrated that finding increased numbers of monocytes pre-treatment had the 
highest hazard ratio for association with decreased DFI of any variable evaluated except 
location of the primary tumor.  This finding was also reproduced in a second, 
 
 
Figure 6.3:  Analysis of the association between monocyte and lymphocyte counts and 
DFI in a second population of dogs with OSA.  A second population of dogs with 
appendicular OSA, selected by identical methods, was analyzed to determine the 
reproducibility of the original analyses. Both monocyte (A) and lymphocyte (B) 




independent population of dogs with appendicular OSA.  However, MCP-1 concentration 
was not associated with monocyte counts or DFI. 
The type of adjuvant chemotherapy administered (i.e. doxorubicin or carboplatin 
alone versus alternating doxorubicin and carboplatin) did not have a significant influence 
on outcome.  The effectiveness of combined treatment with doxorubicin and carboplatin 
in dogs with osteosarcoma has been contradictory, and further study in a larger 
population of dogs would be necessary to conclusively determine whether combined 
treatment was more effective for preventing OSA metastasis [32, 33].   
 We also found that younger dogs (≤ 8yrs) had a shorter DFI compared to older 
dogs (> 8 yrs), which is in agreement with a previous report by Spodnick et al [1, 31].  
We also observed that dogs with tumors of the proximal humerus had a significantly 
decreased DFI compared to dogs with tumors in all other appendicular locations.  Others 
have suggested that tumors of the proximal humerus are relatively larger at the time of 
initial diagnosis, and this may be a plausible explanation for the decreased DFI observed 
within this study [1, 30, 34].  Interestingly, our univariate analysis did not find that SAP 
was significantly associated with DFI.  However, it is likely that there was a confounding 
relationship present in the univariate analysis, since the multivariate analysis determined 
that SAP had an independent and significant relationship to DFI. 
It is noteworthy that most dogs in the present study actually had monocyte counts 
that were within the normal range.  Thus, dogs with monocyte counts in the upper end of 
the normal range, specifically above the median value of 0.4x103 monocytes/μL, had a 
significantly decreased DFI when compared to dogs with monocyte values below the 




we evaluated.  This suggests that a value of 0.4x103 monocytes/μL may be clinically 
useful as a cut-off for assessing prognosis in dogs with appendicular OSA.  Furthermore, 
dogs (n=5) with overt monocytosis (i.e. >1.0x103 monocytes/µL) had a median DFI of 
only 84 days compared to an overall DFI of 194 days (p<0.0001).   
 One obvious question that arises from this study is why increased numbers of 
monocytes would be associated with decreased DFI, even in dogs with no obvious 
evidence of metastasis at the time of initial determination of monocyte count.  We 
speculate that at least some of the monocytes detected on routine CBC may in fact be 
myeloid derived suppressor cells (MDSC).  Recent studies have established that MDSC 
are comprised of a mixed population of immature monocytes and neutrophils [35-37].  
Myeloid derived suppressor cells suppress antitumor immune responses and increased 
numbers of MDSC are found in mice and humans with cancer [35-39].  Therefore, we 
propose that the small increase in numbers of circulating monocytes above the median 
value may reflect increased numbers of MDSC that in turn may account for the decreased 
DFI observed in these dogs.  This hypothesis would further suggest that tumor-specific 
factors could drive the expansion of MDSC.  Such factors could include tumor 
production of growth factors associated with generation of MDSC, including CSF-1, 
GM-CSF, MCP-1 and other cytokines and growth factors [35, 36, 40, 41].  Since MDSC 
are directly involved in the pathogenesis of cancer, this makes them prime biomarkers for 
the evaluation of cancer progression and metastasis risk.  However, confirmation of these 





 We also found that pre-treatment lymphocyte counts were associated with DFI in 
dogs with OSA in this study.  Dogs with lymphocyte counts above the median value of 
1.0x103 lymphocytes/μL had significantly shorter DFI than dogs with lymphocyte counts 
below the median.  In the present study, there were no dogs with lymphocytosis 
(>4.8x103 lymphocytes/μL), while there were 36 dogs with lymphopenia (<1.0x103 
lymphocytes/μL).  Dogs with lymphopenia had a significantly (p<0.05) longer DFI than 
dogs with normal lymphocyte counts.  Thus, lymphopenia was associated with better 
outcome in dogs with appendicular OSA.  This finding was unexpected and contrary to 
the results obtained in recent studies in human cancer patients, where lymphopenia was 
associated with poor prognosis [29, 42].  The explanations for this finding are unclear at 
present, but may be related to redistribution of lymphocytes from circulation and into 
tumor tissues in dogs with OSA micrometastases.   
 This study had several limitations.  For one, the study did not assess overall 
survival times (OST) as an endpoint.  Although survival time can be an important 
prognostic factor, the use of OST as an endpoint can be confounded by other medical 
problems that arise in older dogs with cancer.  It is also possible that the study population 
assessed here may not be representative of all dogs with OSA.  Since the CSU VTH is a 
referral institution, animals with OSA treated at CSU may represent a sub-group of the 
overall population of dogs with OSA.  However, the length of time over which study 
patients were collected (4 years for the first population) may help eliminate some 
potential bias here.  In addition, the CSU Animal Cancer Center receives patient referrals 





 We observed that MCP-1 was not associated with monocyte count or DFI in this 
population of dogs.  Recently, a study has shown that MCP-1 may be prognostic for 
colon cancer metastasis, although the authors did not investigate the role of moncytes in 
this study [43].  MCP-1 is an important mediator of release of monocytes from the bone 
marrow, and as a possible regulator of monocyte chemotaxis [13, 14].  It is plausible that 
concentrations of this cytokine in the local tumor microenvironment may have greater 
impact as a chemoattractant, and these associations were not observed due to sampling of 
systemic blood for analysis.  It is also plausible that other cytokines, such as CSF, are 
mediating and maintaining the relatively increased numbers of monocytes present in the 
tumor bearing dogs [44-46]. 
 In summary, we have shown here that routine evaluation of a pre-treatment CBC 
can provide important prognostic information for dogs with appendicular OSA. 
Investigations into the factors that regulate circulating monocyte and lymphocyte 
numbers in dogs with OSA, and how these factors may relate to tumor metastasis and 
response to chemotherapy will undoubtedly provide important insights into the immune 





 The ability to possibly prognosticate a disease such as OSA from a simple blood 
test is an exciting proposition.  However, the human literature suggests that these 




Therefore, it would be interesting to determine if a CBC could be used as a prognostic 
tool in other forms of cancer, human and canine.  I hypothesize that the effect would 
pertain across tumor types and not be directly related to any specific tumor type.  For 
example, a study could be performed in canine soft tissue sarcoma or melanoma with a 
standard of care therapy implemented for each tumor type.  I would also hypothesize that 
a similar effect would be observed in the study of human OSA due to the similarities 
present between canine and human disease.  As performed previously, it is important to 
limit the impact that various treatments would have on a tumor so that conclusions would 
be correlated to the disease state rather than the type of treatment received.  However, 
this conclusion could be controlled for in a multivariate analysis model so long as a 
sufficient number of patients are included in the study.  After selection of dogs and 
relevant risk factors, analysis of the data would be performed in a synonymous manner to 
that performed in this chapter.  It would be interesting to see what cell types are 
prognostic in these other tumors.  Furthermore, it would be interesting to see what the 
cut-offs for a positive prognosis would be in these tumors.  It is unlikely that the same 
cut-offs established above would be present, but if they were it may suggest larger 
ramifications to tumor biology in that there are finite divisions that are present across 
tumor types for these circulating leukocytes. 
 The first question may help provide prognostic information for other tumor types, 
but does not help define the biology of the interactions assessed in the above chapter.  
Therefore, it would be interesting to further characterize the phenotype of the circulating 
monocytes.  As presented within this dissertation, the role of monocytes in tumor biology 




cells may be of importance to understanding the differences in DFI observed herein.  I 
hypothesize that dogs with increased monocytes will also have a greater number of 
steady state monocytes in circulation.  Since steady state monocytes have been implicated 
in a pro-tumor phenotype, I suggest that they would compose a greater number of 
circulating leukocytes.  However, to fully address this question, an antibody for canine 
Ly6C would have to be created or identified, which is not a trivial task.  However, Ly6C 
is the murine homolog of human CD59, and thus commercially available anti-human 
CD59 antibodies might cross-react with canine cells [47].  If not, it would be plausible to 
prospectively follow dogs by a selection scheme similar to the one used in the study, and 
serially draw their blood to investigate changes in circulating monocyte populations. 
If an association was observed between pre-treatment numbers of steady state 
monocytes and outcome (DFI/OS), it may suggest a biological explanation for the 
observations made herein.  Preliminary evidence of this observation may be seen in the 
osteomyelitis model presented in this dissertation.  In Figure 2.8.a of this dissertation, 
there is a significant (p<0.05) increase in total monocytes in uninfected mice with 
osteosarcoma compared to normal mice; this figure has been reproduced in part here 
(Figure 6.S1).  Interestingly, when this difference is broken down to investigate 
differences in steady state (p<0.03) and inflammatory monocytes (p<0.01), there is a 
significant difference in both of these groups; with a slight but non-significant (p>0.05), 
bias towards steady state monocytes.  Indeed, this data suggests that changes in these 
subsets are present between tumor bearing mice and untreated controls.  Therefore, it is 
possible that a similar phenomena may be occurring in dogs with OSA, and that these 




analysis of circulating monocytes reveals changes in monocytes were associated with 
outcome.  For example, in the osteomyelitis model, an increase in overall monocytes 
(specifically Ly6C+ monocytes) lead to decreased tumor growth.  Therefore, it would be 
interesting to see if chemotherapy or some other intervention could recapitulate this 
response in the dog model, and if so could alter survival.  In other words, can a 
therapeutic intervention activate Ly6C+ monocytes to overcome a possible detriment 
established by high numbers of Ly6C- monocytes at diagnosis. 
  
A similar question I would be interested in asking is akin to the characterization 
of monocytes.  In the above chapter we propose that MDSC may be a component of the 
increased monocyte population observed, thereby leading to the decreased disease free-
 
Figure 6.S1:  Increased total monocytes, and subsets, are increased in tumor bearing 
mice.  Mice (n=5 per group) were challenged with subcutaneous DLM8 tumors or 
none at all.  Mice were tail bled and monocyte populations described by flow 
cytometry.  A) Total monocytes are significantly (p<0.05) increased in tumor bearing 
mice.  B)  Tumor bearing mice have significantly (p<0.05) greater numbers of steady 
state and inflammatory monocytes.  Results are representative of two independent 




interval observed.  I hypothesize that MDSC will be increased in naïve patients with 
OSA, and that an increase in these cells will be associated with an abbreviated DFI.  Flow 
cytometry and prospective analysis would need to be performed as suggested in the 
above experiment.  Once again, patient selection and treatment should be monitored and 
incorporated into analysis to adjust for any significant impact these factors may have on 
outcome. 
 The final question I would ask would be if treatment with liposomal clodronate 
(LC), which has been shown to deplete circulating monocytes, would be a beneficial 
therapeutic for OSA.  I hypothesize that LC treatment will be beneficial since it will 
deplete the inhibitory monocytes present in a naïve patient and allow for re-population 
with more activated monocytes in the presence of a stimulus, such as infection or 
possibly chemotherapy.  I would further propose combining LC and conventional 
chemotherapeutics like doxorubicin and carboplatin since both of these therapeutics have 
inflammatory properties.  Induction of tumor necrosis may be a potent inflammatory 
stimuli leading to activation of monocytes systemically leading to an activated phenotype 
of tumor infiltrating leukocytes.  Therefore, I believe LC may be a possible therapeutic 
for OSA due to its modulation of monocytes and ability to inhibit tumor growth in mouse 
models of cancer.  Even though the single agent LC results in the orthotopic model 
(chapter 5) suggest LC is not efficacious against OSA, it is plausible that combination 
therapy is required so as to repopulate the tumor with activated monocyte/macrophages 
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 The work presented within this dissertation is intended to further the knowledge 
base concerning innate immune responses and angiogenesis in osteosarcoma (OSA) 
biology and metastasis.  This research will help clarify novel mechanisms and models to 
study angiogenesis and OSA biology and metastasis.  Furthermore, we are able to use this 
information to study clinical observations and novel compounds, and hope to eventually 
translate relevant hypotheses to the clinical setting.  The purpose of this work is to 
expand the information available in the treatment of OSA, and identify novel therapeutics 
and mechanisms that can be exploited to increase survival. 
 Clinical observations in dogs and humans provided evidence that osteomyelitis 
may be a mechanism of increased survival in patients with OSA [1, 2].  We therefore 
sought to create a murine model of this phenomenon to more directly study the 
mechanism by which infection leads to systemic inhibition of metastases; and this 
information was presented in chapter 2.  By utilizing a luciferase transfected strain of S. 




growth at a distant site.  Furthermore, we were able to show that this effect was not 
model specific, and was retained when multiple tumor types, mouse strains, and bacterial 
pathogens were studied.  Depletion of NK cells and monocytes/macrophages was then 
performed, leading us to conclude that both of these cell types are required as mediators 
of the tumor inhibition in the presence of infection.  Characterization of circulating 
monocytes also revealed that a differential stimulation of inflammatory monocytes was 
associated with decreased tumor growth in infected mice.  Further examination of this 
mechanism may be performed by further characterization of the tumor associated 
macrophages and investigation of MDSC as a component of the systemic immune effect.  
These observations herein provide evidence for the mechanism of tumor inhibition, and 
provide insight into processes that may be exploited for therapeutic gain in OSA patients. 
 The duality of inflammation is of great interest, and creates a paradox for cancer 
research.  How can inflammation be a promoter of tumor growth and progression, while 
also acting as a possible therapeutic as evidenced by the presence of infection?  It is 
possible that the different environments under which these two forces come to bear may 
lead to differences in tumor growth.  Interestingly, the effect may also be tumor type 
specific, as Coley had once postulated [3, 4].  Initiation of colon/gastric tumors due to an 
inflammatory stimulus is likely different from that concerning systemic activation of the 
immune system in response to a foreign pathogen [5].  Moreover, the initial acute phase 
inherent to the infection may provide priming and reorganization of the immune system 
which may then be prolonged by the chronic phase of inflammation.  However, chronic 
infection after an acute phase reaction may in turn lead to prolonged effects of the acute 




to have a large stimulus to change the status quo adopted by the tumor, and a chronic 
phase of stimulation to maintain this altered anti-tumor phenotype.  However, 
observations presented within this dissertation show the effect is not specific only to 
sarcomas, as growth inhibition was observed when mice challenged with melanoma or a 
colon carcinoma were infected with S. aureus.  Further investigation into these questions 
is required to fully understand the complex processes of inflammation. 
 The duality of inflammation may also make it a possible target for therapy.  The 
inhibition of inflammation that led to tumor promotion may lead to resolving tumor 
progression.  This has been extensively demonstrated in the study of H. pylori and gastric 
tumors and that of the mucosal associated lymphoid tissue (MALT) [5-9].  Instead of 
providing a large acute inflammatory signal to reorganize the immune system, it is 
plausible that inhibition of the inflammation may be beneficial, and thus explains the 
efficacy associated with NSAID therapy for some tumors. 
We sought to investigate the role of the NSAID tepoxalin on tumor growth using 
in vitro and in vivo analyses (chapter 3).  Furthermore, we sought to understand these 
relationships using therapeutically achievable concentrations, as investigation outside of 
this range would not be clinically applicable.  Interestingly, we observed that tepoxalin 
has a unique structure allowing it to chelate iron, thus leading to the simulation of a 
hypoxic phenotype in tumor cells.  This hypoxic environment led to dose-dependent 
increases in HIF-1α and VEGF.  We next investigated the role that tepoxalin therapy 
would play in a murine model utilizing a dose relevant to dogs, the target species for this 
drug.  We observed an inhibition of tumor growth, but were unable to precisely describe 




experiments to better describe the tumor microenvironment and investigate tepoxalin as 
an anti-metastatic compound in addition to standard of care chemotherapy in murine 
experiments culminating in canine clinical trials if promising results are observed.   
 In each of the first two chapters, we have investigated the role of various 
phenomena concerning the endpoint of angiogenesis.  However, we were unable to 
investigate the changes in angiogenesis over time in single animals so as to determine a 
real-time assessment of these changes.  Angiogenesis is a critical component of tumor 
development, but analysis of this component is time consuming and requires large 
numbers of animals [10].  Therefore, we proposed that fine needle aspiration (FNA) of 
tumors would provide a sufficient number of endothelial cells for analysis by flow 
cytometry (chapter 4). 
Herein, we have provided evidence to show that FNA of tumor are representative 
of the overall tumor burden as compared by flow cytometry.  Moreover, we are able to 
show that FNA/flow cytometry is comparable to the gold standard method of 
immunohistochemistry (IHC) for assessing angiogenesis.  IHC is time consuming and 
requires large amounts of primary tissue, typically resulting in sacrifice of tumor bearing 
mice and invasive biopsies in humans.  However, FNA is minimally invasive and allows 
for repeated analysis of single tumors over time without production of an artifact in 
relation to endothelial cells.  Surprisingly, we observed a novel mechanism concerning 
the dynamic changes present in tumor angiogenesis, in which it appears that the 
percentage of endothelial cells rapidly declines once the tumor reaches a size of 
approximately 1 cm.  This observation could only have been made by serially sampling 




investigate changes in angiogenesis in response to anti-angiogeneic compounds further 
suggests that this technique may be used in investigational and clinical use.  More work is 
required to characterize the dynamic changes of angiogenesis described herein, along 
with exploration of vascular supporting cells in the tumor and their role in angiogenesis 
and tumor biology. 
Murine models are the primary means of in vivo testing of therapeutics and 
understanding mechanisms of action of metastasis.  However, many murine models 
utilize tumor cells injected at heterotopic sites or intravenously, and thus do not 
recapitulate the full process of metastasis with integration of the tumor microenvironment 
in an orthotopic environment [11-15].  Further, no model currently exists that fully 
recapitulates the surgical options for patients with OSA.  The use of a post-surgical 
model is important, because this is the arena in which many therapeutics will be utilized 
in the clinical setting, and provides the most appropriate testing site for these novel 
compounds.  We therefore designed an orthotopic murine model of osteosarcoma in 
syngeneic mice that is luciferase transfected to allow for non-invasive analysis of 
metastatic progression (chapter 5). 
The DLM8 tumor cell line is syngeneic to C3H mice and has been previously 
described.  We luciferase transfected the DLM8 cell line and selected cells that retained 
the metastatic capabilities of the parental cell line so metastases could be non-invasively 
monitored.  Characterization of the primary tumor and metastatic variation from 
orthotopic and heterotopic sites was also performed.  A surgical model of amputation was 
created to recapitulate the clinical scenario in which the primary tumor burden is 




setting to define a model where metastases reproducibly developed in 100% of the mice 
challenged with tumors.  Investigation into the characterization of these metastases was 
also performed.  Lastly, we tested conventional and novel therapeutics for OSA in this 
model, and found that we could detect a significant inhibition in time to metastasis.  It 
would be interesting to revisit and further define the characteristics of the metastatic 
process, especially the observation that all mice apparently develop micro-metastatic lung 
lesions, although few mice succumb to gross lung pathology.  The overall purpose of 
development of this model was to create a more clinically relevant platform to test novel 
OSA therapeutics. 
One of the focuses of this work has been the description of monocytes and other 
leukocytes in OSA.  Monocytes have been implicated in murine tumor progression, and 
resultant macrophages can make up a significant proportion of the tumor burden [16-18].  
Therefore, we hypothesized that pre-treatment monocytes may be prognostic in canine 
OSA.  There is limited information in the human literature concerning monocytes as a 
prognostic marker, but OSA is not one of the tumors previously identified, possibly due 
to the relatively small number of cases in humans [19-23].  However, analysis of pre-
treatment leukocytes as a predictor of outcome has not been performed in canine tumors 
to date.  Therefore, we sought to determine if a pre-treatment CBC could be used as a 
prognostic in canine OSA (chapter 6).  The need for cost-effective and easy-to-interpret 
diagnostics and biomarkers is of obvious importance to veterinary medicine, and the use 
of the ubiquitous CBC has met these criteria. 
To decrease selection bias in the population, 313 dogs treated for OSA at the 




evaluated.  Dogs were then selected for study inclusion if they had appendicular disease, 
were treated with amputation and conventional chemotherapy, and did not have 
metastases present at diagnosis.  Lack of metastases at diagnosis was necessary since we 
used disease-free interval as our measure of disease progression.  Statistical analysis was 
performed on the 69 dogs included in the study for leukocyte and historical variables of 
importance in dogs with OSA.  We observed that dogs with relatively higher monocytes 
and lymphocytes had a significantly decreased DFI compared to dogs with lower 
monocytes and lymphocytes.  Interestingly, a majority of the dogs in the study had 
leukocyte counts within the normal reference range, and thus we discovered that 
significant prognostic information could still be obtained even though the leukocyte 
numbers were clinically normal.  Furthermore, these observations were reproduced in a 
second and independent population of dogs.  Further investigation is necessary to further 
phenotype the leukocyte populations in dogs to determine what the biological 
significance of these findings may be.  For example, is there a population of expanded 
MDSC in patients with poor outcome?  We concluded from these data that defined cut-
offs can be applied to a CBC for prognostication of DFI in dogs with appendicular OSA. 
Osteosarcoma is the most common primary bone tumor of humans and dogs, with 
a long term survival approximating 60% in humans and 20% in dogs.  Understanding the 
metastatic biology of OSA is required to develop novel treatments for this disease since it 
is the primary cause of death from this disease.  The work presented herein aims to better 
understand the role of immune responses and angiogenesis as they relate to OSA growth 
and metastasis.  The development of novel models and techniques to study metastasis and 




required to understand observations made in the clinic that may provide a basis for future 
therapies, and as a platform for testing these therapies.  Therefore, these findings suggest 
novel mechanisms by which to study OSA biology, and therapies for its treatment.  We 
believe that the addition of these techniques and findings will add to the canon of 
knowledge concerning OSA biology; and the hope that therapeutic benefit will be gained 
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